IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene ERBB2 Ensembl ENSG00000141736 Chromosome 17 Start 35104766 End 35138441
Description Receptor tyrosine-protein kinase erbB-2 Precursor (EC 2.7.10.1)(p185erbB2)(C-erbB-2)(NEU proto-oncogene)(Tyrosine kinase-type cell surface receptor HER2)(MLN 19)(CD340 antigen) [Source:UniProtKB/Swiss-Prot;Acc:P04626]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :
     HGNC : 3430
     Entrez Gene : 2064
     UCSC : uc002hso.2
     GeneCards : 3430
     RefSeq : NM_001005862
     CCDS : CCDS32642.1
     Uniprot : P04626
     Interpro : P04626
     OMIM : 164870
     GeneTests : ERBB2
     CGAP : ERBB2

< Top >


Somatic Mutaions        (help)
Lung cancer Adenocarcinoma Squamous Cell Carcinoma
Unique Mutated Samples % Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
69 1.44 4777 45 2.13 2114 2 0.31 652
Sample datas
Sample Name Histology Subtype DNA Mutation Protein Mutation Mutation Description Zygosity Genomic Co-ordinates NCBI36 Pubmed
1000823 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452016988931
1000827 AD c.2329G>T p.V777L Substitution - Missense Heterozygous 17:35134526-3513452616988931
1005423 AD c.2326_2326G>TTAT p.G776>LC Complex - insertion inframe Unknown 17:35134523-3513452316775247
1007223 AD c.? p.P780_Y781insGSP Insertion - In frame Unknown 16638863
1007224 AD c.? p.G804S Substitution - Missense Unknown 16638863
1007225 AD c.? p.I829T Substitution - Missense Unknown 16638863
1010426 AD c.? p.M774_A775insAYVM Insertion - In frame Unknown 17001163
1040050 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Unknown 17:35134521-3513452216003726
1044290 AD c.2326_2327insTTT p.G776>VC Complex - insertion inframe Heterozygous 17:35134523-3513452417321325
11 AD c.2326_2327insTTT p.G776>VC Complex - insertion inframe Heterozygous 17:35134523-3513452415753357
1107277 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452018334834
1107278 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452018334834
1107279 AD c.2340_2341ins9 p.P780_Y781insGSP Insertion - In frame Unknown 17:35134537-3513453818334834
1107280 AD c.2333_2334insGGG p.G778_S779insG Insertion - In frame Unknown 17:35134530-3513453118334834
1107281 AD c.2333_2334insGGG p.G778_S779insG Insertion - In frame Unknown 17:35134530-3513453118334834
135 AD c.2326_2327insTTT p.G776>VC Complex - insertion inframe Homozygous 17:35134523-3513452415753357
1489264 AD c.2326_2327insTCT p.G776>VC Complex - insertion inframe Unknown 17:35134523-3513452420881644
1489265 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452020881644
153 AD c.2326_2326G>CTTT p.G776>LC Complex - insertion inframe Heterozygous 17:35134523-3513452315753357
154 AD c.2339_2340ins9 p.P780_Y781insGSP Insertion - In frame Heterozygous 17:35134536-3513453715753357
16660 AD c.929C>T p.S310F Substitution - Missense Heterozygous 17:35121734-3512173418948947
16668 AD c.2718G>A p.W906* Substitution - Nonsense Heterozygous 17:35135174-3513517418948947
16668 AD c.760-1G>A p.? Unknown Heterozygous 17:35120118-3512011818948947
16937 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Heterozygous 17:35134521-3513452218948947
189 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015753357
254 AD c.2340_2341ins9 p.P780_Y781insGSP Insertion - In frame Heterozygous 17:35134537-3513453815753357
276 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015753357
438 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015753357
478 AD c.2325_2326ins12 p.A775_G776insYVMA Insertion - In frame Heterozygous 17:35134522-3513452315753357
60 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015753357
79 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015753357
998906 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452016825508
998907 AD c.2326_2326G>TTGT p.G776>LC Complex - insertion inframe Unknown 17:35134523-3513452316825508
998908 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452016825508
998909 AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Unknown 17:35134519-3513452016825508
KD1007 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Unknown 17:35134521-3513452216863509
KD1024 AD c.2326_2327insTGT p.G776>VC Complex - insertion inframe Unknown 17:35134523-3513452416863509
KD1027 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Unknown 17:35134521-3513452216863509
KD318 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Unknown 17:35134521-3513452216863509
KD583 AD c.2326_2327insTGT p.G776>VC Complex - insertion inframe Unknown 17:35134523-3513452416863509
KD617 AD c.2324_2325ins12 p.A775_G776insYVMA Insertion - In frame Unknown 17:35134521-3513452216863509
NCI-H1781 AD c.2326_2327insTGT p.G776>VC Complex - insertion inframe Homozygous 17:35134523-3513452415753357
PD0258a AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015457249
PD0317a AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015457249
PD0319a AD c.2335_2336ins9 p.S779_P780insVGS Insertion - In frame Heterozygous 17:35134532-3513453315457249
PD1353a AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452015457249
PD1353a AD c.2322_2323ins12 p.M774_A775insAYVM Insertion - In frame Heterozygous 17:35134519-3513452016140923
1039736 SCC c.2305G>C p.D769H Substitution - Missense Unknown 17:35133787-3513378716029927
915507 SCC c.2305G>C p.D769H Substitution - Missense Unknown 17:35133787-3513378716029927

< Top >


Experimental Evidence        (help)
Expression Sample Number Method Clinical information PubMed Reference
up 39/238(16%) IHC- 11986780 Br J Cancer 2002, 86(9): 1449-56
up 83/410(20%) IHC- 14614004 Clin Cancer Res. 2003 Nov 1;9(14):5238-43.
up 26/115(23%) IHC- 14506153 Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3645-52.
up 33/89(37%) IHC- 11378338 Eur J Cancer. 2001 Jun;37(9):1089-95.
up 25/85(29%) IHCTumor type(P=0.03)//Survival analyses(P=0.004) 11823980 Hum Pathol. 2002 Jan;33(1):105-10.
up 100/238(42%) IHC- 10048471 Lung Cancer. 1998 Dec;22(3):181-90.

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1802_s_at  0.55  2.90e-3  8.03e-3  -0.79  2.66e-4  9.54e-4
 HG_U95  1901_s_at  0.12  3.84e-1  4.90e-1  -0.47  4.75e-4  1.60e-3
 HG_U95  33218_at  0.47  7.52e-5  3.17e-4  -0.49  8.01e-6  4.13e-5
 HG_U133A  210930_s_at  0.57  4.18e-6  1.01e-5  1.26  3.19e-17  4.46e-17
 HG_U133A  216836_s_at  0.81  2.47e-17  1.59e-16  -1.85  1.33e-60  3.63e-60
 HG_U133_Plus2  210930_s_at  0.97  6.40e-6  2.53e-5  0.51  3.89e-2  5.68e-2
 HG_U133_Plus2  216836_s_at  0.81  9.89e-11  7.89e-10  0.13  3.34e-1  3.94e-1
 HG_U133_Plus2  234354_x_at  0.88  8.24e-7  3.78e-6  0.30  1.50e-1  1.94e-1
 Stanford  962  0.92  5.90e-3  4.53e-2  -0.42  2.01e-1  4.27e-1
 Stanford  6028  0.00  0.00e+0  0.00e+0  0.00  0.00e+0  0.00e+0
 Stanford  11379  0.84  5.95e-3  4.56e-2  -0.49  1.82e-1  4.01e-1
 Stanford  22509  1.25  6.57e-4  1.10e-2  0.39  5.52e-1  7.53e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  210930_s_at  0.32  4.85e-1  9.26e-1  -0.04  8.47e-1  1.00e+0
 HG_U133A  216836_s_at  -0.43  1.90e-1  8.25e-1  0.06  6.58e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1802_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 1901_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U95 - 33218_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 210930_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 216836_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 210930_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 216836_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 234354_x_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 962    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 6028    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 11379    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 22509    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
her-2 chronic myelogenous leukemia The current success of molecular targeting therapy is shown by: imatinib mesylate (STI571, Gleevec), targeted to the Bcr/Abl fusion protein derived from a translocation between chromosomes 9 and 22 in chronic myelogenous leukemia; rituximab (Rituxan), a m 15052442 Human
her-2 non-hodgkins lymphoma The current success of molecular targeting therapy is shown by: imatinib mesylate (STI571, Gleevec), targeted to the Bcr/Abl fusion protein derived from a translocation between chromosomes 9 and 22 in chronic myelogenous leukemia; rituximab (Rituxan), a m 15052442 Human
her-2 cyst Apart from HER-2, all onco-proteins were more strongly expressed in epithelial cells of the adenocarcinoma than of the endometriotic cyst. 15015590 Human
neu mucoepidermoid carcinoma of the salivary glands OBJECTIVE: This preliminary study will attempt to evaluate the use of immunohistochemical markers HER2/neu and Ki-67 as prognostic markers of biologic aggressiveness for mucoepidermoid carcinoma of the salivary glands. 14974865 Human
her2 mucoepidermoid carcinoma of the salivary glands OBJECTIVE: This preliminary study will attempt to evaluate the use of immunohistochemical markers HER2/neu and Ki-67 as prognostic markers of biologic aggressiveness for mucoepidermoid carcinoma of the salivary glands. 14974865 Human
neu salivary gland mucoepidermoid carcinoma CONCLUSION: These preliminary results indicate that, overall, the overexpression of both the HER2/neu and the Ki-67 oncoproteins may serve as prognostic markers for poor outcome in salivary gland mucoepidermoid carcinoma. 14974865 Human
her2 salivary gland mucoepidermoid carcinoma CONCLUSION: These preliminary results indicate that, overall, the overexpression of both the HER2/neu and the Ki-67 oncoproteins may serve as prognostic markers for poor outcome in salivary gland mucoepidermoid carcinoma. 14974865 Human
neu bone metastases In conclusion, we show that MCF-7 cells cause osteosclerotic bone metastases and that Neu enhances this capacity of MCF-7 cells. 11830552 Mouse
her2 nasopharyngeal carcinoma Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. 11850071 Human
erbb-2 squamous-cell cancers PURPOSE: This study was conducted to evaluate the clinical significance of the localization of epidermal growth factor receptor (EGF-r), transforming growth factor (TGF)-alpha, and erbB-2 in the development, progression and prognosis of squamous cell canc 11895903 Human
her-2 cutaneous malignant melanoma In this study we evaluated the overexpression status of HER-2 and its prognostic significance on survival in patients with thick cutaneous malignant melanoma. 11930110 Human
erbb2 non-small cell carcinomas To test this hypothesis, we examined four cell lines derived from human non-small cell carcinomas for: (1) ErbB2 and ErbB3 expression and endogenous activation; (2) NRG-1 expression and secretion/shedding; and (3) the effect of receptor blockade on autocr 14739033 Human
erbb-2 rectal cancer PATIENTS AND METHODS: We investigated the relationship between the CaSR A986S polymorphism and the expression of erbB-2, EGFR, p53, and ras as well as the UICC stage in 56 patients with rectal cancer. 12018449 Human
her2 secondary tumor In two patients who had low levels of HER2 overexpression in their primary tumors, no staining was observed in the secondary tumor (one pulmonary tumor and one liver tumor). 12001113 Human
her2 liver tumor In two patients who had low levels of HER2 overexpression in their primary tumors, no staining was observed in the secondary tumor (one pulmonary tumor and one liver tumor). 12001113 Human
her2 secondary tumors In a few patients, a diminution in the level of HER2 expression was observed after CT or in secondary tumors. 12001113 Human
her2 stage-ii breast cancer The National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-31 is designed to test the advantage of adding Herceptin to the adjuvant chemotherapeutic regimen of doxorubicin and cyclophosphamide followed by paclitaxel (Taxol) in the treatmen 12048273 Human
neu serous carcinoma In serous carcinoma, p53 mutation is the most frequent genetic alteration, followed by inactivation of p16 and e-cadherin and amplification of her2/neu. p53 mutation occurs in endometrial intraepithelial carcinoma, the putative precursor of serous carcino 14747944 Human
her2 serous carcinoma In serous carcinoma, p53 mutation is the most frequent genetic alteration, followed by inactivation of p16 and e-cadherin and amplification of her2/neu. p53 mutation occurs in endometrial intraepithelial carcinoma, the putative precursor of serous carcino 14747944 Human
erbb2 squamous-cell lung carcinomas The expression of the proteins ERBB2, JUN, RAS and tissue factor was significantly higher in adenocarcinomas compared to squamous cell lung carcinomas. 12174921 Human
her2 chronic leukemia Three examples of inhibitors of protein kinases are reviewed, including low-molecular weight compounds targeting the cell cycle kinases; a potent and selective inhibitor of the HER1/HER2 receptor tyrosine kinase, the pyrollopyrimidine PKI166; and the 2-ph 12191602 Human
her2 apocrine carcinoma There was no correlation between the three types of apocrine carcinoma and the positivity rate of p53, HER2, bcl-2, MIB-1 and hormone receptor status. 12196721 Human
neu inflammatory breast cancer We report that copper deficiency induced by tetrathiomolybdate (TM) significantly impairs tumor growth and angiogenesis in two animal models of breast cancer: an inflammatory breast cancer xenograft in nude mice and Her2/neu cancer-prone transgenic mice. 12208730 Human
her2 inflammatory breast cancer We report that copper deficiency induced by tetrathiomolybdate (TM) significantly impairs tumor growth and angiogenesis in two animal models of breast cancer: an inflammatory breast cancer xenograft in nude mice and Her2/neu cancer-prone transgenic mice. 12208730 Human
her2 hepatocellular carcinoma Neither overexpression nor amplification of c-erb B2 (Her2/ ) can be regarded as a useful prognostic factor in hepatocellular carcinoma. 12373150 Human
erbb2 childhood ependymoma PURPOSE: This study was designed to investigate the biological and therapeutic significance of ERBB1, ERBB2, ERBB3, and ERBB4 in childhood ependymoma. 12374672 Human
erbb2 ependymoma Ligand-dependent activation of ERBB receptor-signaling in cultured ependymoma cells resulted in AKT phosphorylation and cellular proliferation that was significantly blocked in a dose-dependent manner using WAY-177820, a novel inhibitor of ERBB2 tyrosine 12374672 Human
erbb2 synovial sarcoma Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. 12414507 Human
erbb2 soft-tissue sarcomas Statistical analysis showed a distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue sarcomas, which included variably high expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas. 12414507 Human
erbb2 synovial sarcomas Immunohistochemical analysis of protein expression in tissue microarrays of 37 synovial sarcomas demonstrated strong expression of ERBB2 and IGFBP2 in the glandular epithelial component of biphasic tumors and in solid epithelioid areas of some monophasic 12414507 Human
her2 tumors HER2 gene amplification and receptor overexpression by tumors seems to be associated with poorer prognosis and may be predictive of response to certain anticancer therapies. 12422052 Human
her2 breast cancer HER2 overexpression/amplification, which is an early event in breast cancer development, is associated with a poor prognosis and may predict response to therapy. 12422056 Human
her2 urothelial carcinoma HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. 12432555 Human
her2 urothelial cell carcinomas The aim of this retrospective study was to evaluate immunohistochemic HER2 expression in a large cohort of muscle-invasive urothelial cell carcinomas of the urinary bladder and to compare the results to pathologic characteristics and survival. 12432555 Human
neu epithelial neoplasms Of particular interest was the frequent expression of Her2/neu, an oncogenic protein more commonly observed in epithelial neoplasms. 12458341 Human
her2 epithelial neoplasms Of particular interest was the frequent expression of Her2/neu, an oncogenic protein more commonly observed in epithelial neoplasms. 12458341 Human
her2 ovarian serous adenocarcinoma Thus, we investigated the expression level of HER2 in surgically resected CCA and ovarian serous adenocarcinoma, endometrioid adenocarcinoma, and mucinous adenocarcinoma specimens, as well as CCA cell lines, by an immunohistochemical method. 12460467 Human
her2 mucinous adenocarcinoma Thus, we investigated the expression level of HER2 in surgically resected CCA and ovarian serous adenocarcinoma, endometrioid adenocarcinoma, and mucinous adenocarcinoma specimens, as well as CCA cell lines, by an immunohistochemical method. 12460467 Human
her2 ovarian serous adenocarcinoma HER2 was over-expressed in 42.9% of CCA (P=0.026, vs. ovarian serous adenocarcinoma), 20.8% of ovarian serous adenocarcinoma, 23.1% of ovarian endometrioid adenocarcinoma, and 30.0% of mucinous adenocarcinoma specimens. 12460467 Human
her2 ovarian endometrioid adenocarcinoma HER2 was over-expressed in 42.9% of CCA (P=0.026, vs. ovarian serous adenocarcinoma), 20.8% of ovarian serous adenocarcinoma, 23.1% of ovarian endometrioid adenocarcinoma, and 30.0% of mucinous adenocarcinoma specimens. 12460467 Human
her2 mucinous adenocarcinoma HER2 was over-expressed in 42.9% of CCA (P=0.026, vs. ovarian serous adenocarcinoma), 20.8% of ovarian serous adenocarcinoma, 23.1% of ovarian endometrioid adenocarcinoma, and 30.0% of mucinous adenocarcinoma specimens. 12460467 Human
her2 non-melanoma skin cancer Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. 11166154 Human
her2 epithelial neoplasms CONCLUSIONS: Overexpression of HER2 is detected immunohistochemically in a proportion of epithelial neoplasms of diverse histogenesis in addition to ductal breast cancer. 11207822 Human
erbb2 endometrioid tumors Tumors of serous histology were more likely to express a higher level of erbB4 than endometrioid tumors, and for stage III serous tumors, long-term survival was associated with moderate to high coexpression of erbB4 and erbB2. 11280782 Human
erbb2 thyroid tumors Overexpression of the CCND1 gene was observed in both the benign and malignant thyroid tumors, whereas the ERBB2 gene was mainly overexpressed in malignant thyroid tumors. 11288983 Human
erbb2 peritumoral vessel invasion The analysis of concomitant P14ARF and TP73 overexpression and clinicopathologic parameters of the tumors showed a statistically significant difference with respect to peritumoral vessel invasion (P = 0.01), lymph node metastasis (P = 0.03), negative ERBB 11319797 Human
her2 bilateral breast carcinoma Differences in estrogen receptor status, HER2, and p53 comparing metachronous bilateral breast carcinoma. 11344480 Human
her2 bilateral breast carcinoma BACKGROUND AND OBJECTIVES: We analyzed the clinicopathologic characteristics and tumor biology of metachronous bilateral breast carcinoma with regard to p53, HER2 and hormone receptor status. 11344480 Human
her2 bilateral breast carcinoma CONCLUSIONS: Our findings indicate that p53 and HER2 expression levels in the second tumors might be the same as those of the first tumors in metachronous bilateral breast carcinoma; however, loss of ER was more frequently observed in the second primary t 11344480 Human
erbb2 benign ovarian tumors Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 an 11351242 Human
erbb2 mucinous carcinomas Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. 11351242 Human
erbb2 serous carcinomas Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. 11351242 Human
neu intestinal cancers We focussed on the oncogenes MYC and HER2/neu, since they are frequently involved in intestinal cancers. 11368094 Human
her2 intestinal cancers We focussed on the oncogenes MYC and HER2/neu, since they are frequently involved in intestinal cancers. 11368094 Human
erbb2 myelodysplastic syndrome Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. 11425459 Human
erbb2 acute myeloid leukemia Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. 11425459 Human
neu bile duct cancers The results suggest overexpression of bFGF, PDGF, and HER2/Neu and the presence of K-ras mutation are important for carcinogenesis of bile duct cancers, and detection of the above abnormalities in bile is helpful for early diagnosis. 11478488 Human
her2 bile duct cancers The results suggest overexpression of bFGF, PDGF, and HER2/Neu and the presence of K-ras mutation are important for carcinogenesis of bile duct cancers, and detection of the above abnormalities in bile is helpful for early diagnosis. 11478488 Human
erbb-2 rectal cancers Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. 11506951 Human
her2 stage iii non-small cell lung cancer Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 11551406 Human
neu breast cancer Overexpression and/or amplification of proto-oncogene Her2/neu has been shown to influence both prognosis and treatment of breast cancer. 11569926 Human
her2 breast cancer Overexpression and/or amplification of proto-oncogene Her2/neu has been shown to influence both prognosis and treatment of breast cancer. 11569926 Human
erbb2 skin carcinoma Human skin, cultured normal keratinocytes, and A431 skin carcinoma cells expressed ErbB1, ErbB2, and ErbB3, but not ErbB4. 11571634 Human
erbb-2 gallbladder adenocarcinoma Overexpression of ErbB-2 in the basal layer of biliary tract epithelium led to the development of gallbladder adenocarcinoma in 100% of transgenic mice by 3 months of age. 11585718 Mouse
neu peripheral nerve sheath tumors Point mutation of neu oncogene in animal peripheral nerve sheath tumors. 11732802 others
neu peripheral nerve sheath tumors Thirty-four peripheral nerve sheath tumors of four domesticated animal species were characterized and assayed for point mutation of the neu oncogene. 11732802 Human
neu malignant schwannomas Four malignant schwannomas and two MPNSTs expressed a point mutation of the neu oncogene by the polymerase chain reaction-restriction fragment length polymorphism method. 11732802 others
neu peripheral nerve sheath tumors The finding of neu oncogene mutation could be a useful diagnostic genetic marker in the malignant form of peripheral nerve sheath tumors in animals. 11732802 others
her2 thymic carcinomas Nine thymic carcinomas revealed membranous positivity for HER-2/neu, but no HER2 gene amplification could be demonstrated by FISH in any of the cases. 12877732 Human
her-2 adenocarcinoma of unknown primary CONCLUSION: Her-2 overexpression occurs in a minority of patients with poorly differentiated carcinoma/adenocarcinoma of unknown primary site. 10653878 Human
her-2 adenocarcinoma of unknown primary Because most overexpressors had poorly differentiated adenocarcinoma, further evaluation of patients with adenocarcinoma of unknown primary site is necessary to determine the frequency of Her-2 overexpression in this common subgroup. 10653878 Human
her-2 carcinoma of unknown primary Evaluation of the efficacy of trastuzumab in Her-2 overexpressors with carcinoma of unknown primary site is indicated. 10653878 Human
neu squamous cell carcinoma of the urinary bladder Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). 14991535 Human
her2 squamous cell carcinoma of the urinary bladder Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). 14991535 Human
neu breast and ovarian cancer In patients, neu amplification or overexpression in breast and ovarian cancer correlates with poor prognosis and tumor resistance to chemotherapy. neu-induced transformation can be reversed by the suppression of neu gene transcription. 10692468 Human
neu tumor In patients, neu amplification or overexpression in breast and ovarian cancer correlates with poor prognosis and tumor resistance to chemotherapy. neu-induced transformation can be reversed by the suppression of neu gene transcription. 10692468 Human
erbb-2 small-cell carcinoma Only seven of 23 (30. 4%) patients with small cell carcinoma had elevated ErbB-2 levels. 10754210 Human
erbb-2 rectal cancer In conclusion, VDR gene BsmI polymorphism might affect the development and prognosis of rectal cancer by influencing erbB-2 oncogene expression. 10765127 Human
her-2 clear-cell carcinomas As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%). 14751152 Human
neu clear-cell carcinomas As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%). 14751152 Human
erbb-2 malignant mesotheliomas Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. 10849094 Human
erbb-2 malignant mesotheliomas AIMS: To assess the immunoreactivity of malignant mesotheliomas for N- and E-cadherins, hepatocyte growth factor/scatter factor (HGF/SF) and the tyrosine kinase receptors, met and erbB-2. 10849094 Human
erbb-2 malignant mesotheliomas Malignant mesotheliomas were immunoreactive for N-cadherin (26/29; 90%), met (29/29; 100%) and erbB-2 (28/29; 97%). 10849094 Human
erbb-2 malignant mesotheliomas Signalling pathways mediated via met and erbB-2 may play a role in the growth and spread of malignant mesotheliomas. 10849094 Human
erbb2 papillary carcinomas In 55 papillary carcinomas, increased cytoplasmic immunostaining of the ErbB2 and ErbB3 receptors was significantly associated with each other and with cytoplasmic epidermal growth factor receptor (EGFR) immunoreactivity, indicating a common regulatory me 10956383 Human
erbb2 papillomas Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with >90% incidence by 6 months. 10980598 Mouse
her2 adult t-cell leukemia These effects were not caused by release of 17-APA-GA from the immunoconjugate because immunoconjugates containing [(3)H]GA were stable in serum at 37 degrees C. Furthermore, e21 : GA did not significantly inhibit proliferation of the adult T-cell leukemi 11018093 Human
her2 breast cancer Recently there has been a resurgence in interest in the use of HER2 protein overexpression or gene amplification to refine prognostic estimates of breast cancer patient outcomes and to predict which therapies might be most appropriate for individual breas 11049055 Human
erbb-2 gastric polyps The aim of the current study was to address this issue, taking into consideration the 2 main types of gastric polyps, the coexistence of foci of malignant transformation, and the expression of p53 and ERBB-2. 10547536 Human
neu acute myelogenous leukemia Conjugates composed of anti-CD33 antibodies and the chemotherapy agent, calicheamicin, show promising activity in patients with relapsed or refractory acute myelogenous leukemia Treatment of patients with advanced breast cancer using the anti-HER2/neu ant 10561017 Human
her2 acute myelogenous leukemia Conjugates composed of anti-CD33 antibodies and the chemotherapy agent, calicheamicin, show promising activity in patients with relapsed or refractory acute myelogenous leukemia Treatment of patients with advanced breast cancer using the anti-HER2/neu ant 10561017 Human
her-2 gastrointestinal stromal tumours We studied the expression of TGF-alpha and two EGFRs (HER-1 and HER-2) in gastrointestinal stromal tumours (GISTs) of the stomach (n = 9) and small intestine (n = 6) using standard immunostaining techniques in paraffin-embedded sections. 10599309 Human
neu b-cell lymphomas This progress is manifested by new cytotoxic drugs which have recently entered clinical practice (taxanes, topoisomerase I inhibitors, gemcitabine, vinorelbine, new purines), as well as the efficacy of monoclonal antibody therapies against the CD-20 antig 10676567 Human
her2 b-cell lymphomas This progress is manifested by new cytotoxic drugs which have recently entered clinical practice (taxanes, topoisomerase I inhibitors, gemcitabine, vinorelbine, new purines), as well as the efficacy of monoclonal antibody therapies against the CD-20 antig 10676567 Human
erbb-2 leukoplakia The mean gene copy numbers of erbB-1 and erbB-2 were calculated from the formula to compare the absolute quantities of reference gene and oncogene from 24 patients who did not have leukoplakia. 10687911 Human
erbb-2 gallbladder adenocarcinoma To confirm a direct relationship between erbB-2 expression and CDDP resistance, we examined the role of erbB-2 in the cellular sensitivity to cisplatin using erbB-2 transfected HAG-1 human gallbladder adenocarcinoma cell lines. 10697535 Human
erbb2 laryngeal carcinomas RESULTS: CyclinD1 and c-myc were overexpressed at higher frequencies in primary pharyngeal and laryngeal carcinomas compared with primary oral carcinomas (p < 0.001 and p < 0.001), while erbb1 and erbb2 overexpression was associated with oral site (p < 0. 14666705 Human
her-2 cancer The overexpression and/or mutation of the epidermal growth factor receptor family of tyrosine kinases, namely EGFR and HER-2, have been implicated in poor prognosis of human solid tumors and are under investigation as molecular targets for cancer therapy. 14561085 Human
neu colon tumors In two colon tumors, in addition to the amplification, DNA rearrangement of HER2/neu gene was also observed. 3345525 Human
her2 colon tumors In two colon tumors, in addition to the amplification, DNA rearrangement of HER2/neu gene was also observed. 3345525 Human
neu papilloma While the ras-transformed papilloma cells formed aggressive carcinomas, p53 and neu transformation yielded an intermediate phenotype, with formation of large exophytic tumors, not yet invasive but with highly dysplastic features remarkably similar to thos 2471536 Mouse
erbb-2 esophageal tumor We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. 10389922 Human
neu oral leukoplakia Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. 10428197 Human
erbb-2 endometrial adenocarcinoma Expression of keratinocyte growth factor receptor compared with that of epidermal growth factor receptor and erbB-2 in endometrial adenocarcinoma. 10427121 Human
neu papilloma Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. 9473766 Mouse
erbb-2 tumor angiogenesis We have determined the expression of transforming growth factor alpha (TGF alpha), amphiregulin (AR), CRIPTO, the epidermal growth factor receptor (EGFR), erbB-2, erbB-3, and tumor angiogenesis in a series of 195 patients with stage I-IIIA non-small cell 9516978 Human
her2 thyroid tumors HER2 expression in thyroid tumors. 14700299 Human
her2 thyroid tumors HER2 oncogene expression is known to be present in breast and prostate tumors, but conflicting data have been published about its presence in thyroid tumors. 14700299 Human
her2 thyroid carcinomas Two of 6 thyroid carcinomas from male patients showed 1+ reactivity for HER2 expression on immunohistochemistry assay, but remained negative on fluorescene in sito hybridization confirmatory testing. 14700299 Human
her2 thyroid cancer These results cast doubt on the value of HER2 as a prognostic factor or possible target for specific antitumor therapy for thyroid cancer. 14700299 Human
her-2 lobular carcinomas All tumors with Her-2/neu:EGFR ratios greater than 2 contained an infiltrating ductal carcinoma component, whereas all infiltrating pure lobular carcinomas had Her-2/ neu:EGFR ratios that were less than 2. 9563885 Human
erbb2 epithelial ovarian cancer Amplification and/or overexpression of the ERBB genes are a feature of many cancer types, and overexpression of erbB2 correlates with poor prognosis in epithelial ovarian cancer. 9581810 Human
erbb-2 renal carcinoma Murine renal carcinoma cells genetically modified with human erbB-2 receptor and bacterial beta-galactosidase genes form large pulmonary metastases when injected into the tail vein of BALB/c mice. 9635594 Mouse
her-2 recurrent tumor Interestingly, HER-2 remained below the detection limit in recurrent tumor tissue, suggesting that initially HER-2-dependent tumors switched to HER-2 independence. 14612517 Mouse
neu adult soft tissue sarcoma The purpose of this study was to investigate the clinical significance of HER2/neu in adult soft tissue sarcoma (STS). 12845212 Human
her2 adult soft tissue sarcoma The purpose of this study was to investigate the clinical significance of HER2/neu in adult soft tissue sarcoma (STS). 12845212 Human
neu lcis DCIS cribriform and LCIS displayed a higher positivity for ER (92.6 and 93.8% of cases); DCIS cribriform and DCIS non comedo a higher for PR (89 and 75.3%); DCIS comedo presented the highest values for PI (65.4%), NEU (72.8%), and p53 expression (37.3%). 9674874 Human
erbb2 colonic cancers In contrast, in 31 of 35 (89%) and in 29 of 35 (83%) colonic cancers, moderate to strong immunoreactivity for erbB3 and erbB2, respectively, was present in most epithelial cancer cells. 9712416 Human
erbb-2 childhood medulloblastoma We have previously reported the frequent coexpression, heterodimerzation, and prognostic significance of ErbB-2 and ErbB-4 in childhood medulloblastoma, an embryonal tumor of the cerebellar external granule cell layer (EGL). 9731505 Human
erbb2 traumatic neuromas In the present study we investigated the expression of the ERBB2 protein and neurofibromin in human benign and malignant Schwann cell tumors, traumatic neuromas and peripheral nerves without pathological findings. 9824645 Human
erbb2 traumatic neuromas By immunohistochemistry and Western analysis ERBB2 expression was not detectable in normal nerves but in proliferating Schwann cells of traumatic neuromas. 9824645 Human
erbb2 malignant schwannomas While none of the malignant schwannomas exhibited ERBB2 expression, weak expression was seen in a small proportion of the benign schwannomas. 9824645 Human
her2 stage iiia non-small cell lung cancer Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. 9857998 Human
erbb-2 carcinomas OBJECTIVE: Amplification and overexpression of the erbB-2 proto-oncogene in human carcinomas may have prognostic significance. 10197079 Human
neu ovarian cancer In recent years, some reports have described the prognostic significance of the amplification and overexpression of the oncogene c-erbB-2 (HER2/neu) in various human cancers, including ovarian cancer. 9138962 Human
her2 ovarian cancer In recent years, some reports have described the prognostic significance of the amplification and overexpression of the oncogene c-erbB-2 (HER2/neu) in various human cancers, including ovarian cancer. 9138962 Human
neu malignant glioma In addition, these studies provide a rationale for the application of the Neu ectodomain in gene therapy approaches to human malignant glioma and, potentially, to other systemic epithelial malignancies expressing erbB family receptors. 9096379 Human
her2 childhood medulloblastoma Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. 9242460 Human
her2 childhood medulloblastoma In a series of 70 patients with childhood medulloblastoma, we have used immunohistochemistry and Western blotting analysis to investigate the expression patterns of all four EGFR family members (EGFR, HER2, HER3, and HER4) and heregulin-alpha, a ligand fo 9242460 Human
neu gastrointestinal carcinomas The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. 8576278 Human
neu gastrointestinal carcinomas We report on our experience investigating the serum levels of the soluble domain of p185 and the neu protein expression in the corresponding tumour tissue in patients with advanced gastrointestinal carcinomas. 8576278 Human
neu adenocarcinoma of unknown primary Increased serum neu protein levels were found in 8 of 22 (36%) patients with colorectal carcinomas and in 2 patients with advanced abdominal adenocarcinoma of unknown primary. 8576278 Human
erbb-2 stage i lung cancer Multivariate survival analysis using angiogenesis, protooncogene erbB-2, tumor suppressor gene p53, and the proliferation marker KI-67 defined angiogenesis as the most significant prognostic factor in stage I lung cancer. 8633961 Human
neu small-cell lung cancer Mutations in the ras family of oncogenes, overexpression of the myc and neu families of oncogenes, and mutations of p53, the recessive tumor suppressor gene, occur with differing frequencies in small cell lung cancer and non-small cell lung cancer, and ar 8635391 Human
neu small-cell carcinomas DESIGN--Using immunohistochemical analysis of small cell carcinomas, the tissue expression of corticotropin, bcl-2, p-glycoprotein, cathepsin B, cathepsin D, CD44, carcinoembryonic antigen, collagenase IV, Leu-7, neu oncoprotein, p53, S100, and synaptophy 8639050 Human
erbb-2 conventional osteosarcoma METHODS. Expression of ErbB-2 in the tumors of 26 patients with conventional osteosarcoma was evaluated by immunoblotting. 8630943 Human
erbb-2 atypical meningiomas For erbB-2 immunoreactivity, typical meningiomas had a median staining score of 5.0 compared to 1.0 for atypical meningiomas (P < 0.0001, Mann-Whitney U test). 8699233 Human
erbb2 breast tumors The relationships of INT2 and ERBB2 amplification and of ERBB2 overexpression in primary breast tumors to prognostic factors, recurrence, and survival have generated considerable controversy. 8750529 Human
erbb2 breast tumors We examined the association of recurrence with INT2 and ERBB2 amplification and ERBB2 expression by comparing primary breast tumors from patients surviving without recurrence for > or = 8.5 years after diagnosis, the LTS group, to tumors from patients rec 8750529 Human
erbb2 ovarian malignancies Recently, immunohistochemical and Southern blot studies have suggested that overexpression/amplification of the oncogene ERBB2 (HER2/neu) is associated with aggressive ovarian malignancies; however, some studies have not supported this conclusion. 8818660 Human
neu ovarian malignancies Recently, immunohistochemical and Southern blot studies have suggested that overexpression/amplification of the oncogene ERBB2 (HER2/neu) is associated with aggressive ovarian malignancies; however, some studies have not supported this conclusion. 8818660 Human
her2 ovarian malignancies Recently, immunohistochemical and Southern blot studies have suggested that overexpression/amplification of the oncogene ERBB2 (HER2/neu) is associated with aggressive ovarian malignancies; however, some studies have not supported this conclusion. 8818660 Human
her2 pancreatic ductal adenocarcinoma METHODOLOGY: We studied 410 patients (166 African Americans and 244 Caucasians) with a histologic diagnosis of pancreatic ductal adenocarcinoma of the usual type and analyzed (a) the clinicopathologic characteristics of the tumors, (b) the immunohistochem 12499914 Human
neu malignant astrocytomas Neu receptor protein showed increased expression in malignant astrocytomas (including glioblastomas) and severe reactive gliosis. 8826951 Human
erbb-2 gastric adenocarcinoma To investigate the molecular mechanism of gastric carcinogenesis, we examined simultaneously the frequency of microsatellite instability and the immunoreactivities to ras, erbB-2, and p53 in 42 gastric adenocarcinoma tissues. 7882346 Human
her-2 ovarian adenocarcinomas Tumorigenic roles were variably suggested for HER-2 and INT-2 oncogene amplifications and the "atypical" aspartate to glycine mutability in the butyrylcholinesterase (BCHE) gene in ovarian adenocarcinomas. 7896186 Human
erbb2 colorectal tumor Overexpression of Src, EGF-R, and/or ErbB2 in breast and colorectal tumor cells suggests the potential that such interactions may contribute to the transformed phenotype of these carcinomas. 7797556 Human
her-2 primary carcinoma HER-2 oncogene is not amplified in primary carcinoma of the fallopian tube. 7637958 Human
her-2 fallopian-tube carcinomas Data suggest that the HER-2 oncogene does not play a role in tumor transformation and progression in fallopian tube carcinomas. 7637958 Human
erbb2 mouse plasmacytoma Using a mouse plasmacytoma cell line (MOPC315) which produces high levels of IgA heavy chain mRNA, a control mouse pre B cell line (7OZ/3B), a human mammary cell line (MCF7) which expresses the erbB2 or neu oncogene, MOPC315 cells as neu-negative controls 7556292 Human
neu mouse plasmacytoma Using a mouse plasmacytoma cell line (MOPC315) which produces high levels of IgA heavy chain mRNA, a control mouse pre B cell line (7OZ/3B), a human mammary cell line (MCF7) which expresses the erbB2 or neu oncogene, MOPC315 cells as neu-negative controls 7556292 Human
neu ampullary cancers For the purpose of determining the prognostic significance of HER2/neu oncogene in pancreatic and ampullary cancers, 21 pancreatic cancers of ductal origin and six cancers of the ampulla of Vater were studied immunohistochemically using the monoclonal ant 8568330 Human
her2 ampullary cancers For the purpose of determining the prognostic significance of HER2/neu oncogene in pancreatic and ampullary cancers, 21 pancreatic cancers of ductal origin and six cancers of the ampulla of Vater were studied immunohistochemically using the monoclonal ant 8568330 Human
neu neuroblastic tumors Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. 12594575 Human
her2 neuroblastic tumors Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. 12594575 Human
neu murine neuroblastoma Here, we have investigated HER2/neu expression in 14 human and 2 murine neuroblastoma (NB) cell lines by flow cytometric analysis and in 93 NT by means of a certified immunohistochemical system. 12594575 Human
her2 murine neuroblastoma Here, we have investigated HER2/neu expression in 14 human and 2 murine neuroblastoma (NB) cell lines by flow cytometric analysis and in 93 NT by means of a certified immunohistochemical system. 12594575 Human
erbb-2 nude mouse tumorigenicity Infection with erbB-2 (E) of Ha-ras (H) oncogene-transfected cells has been previously shown to cooperatively induce anchorage-independent growth of the MCF10A human mammary epithelial cell line in vitro, but not to induce nude mouse tumorigenicity. 8847140 Mouse
neu neuroectodermal tumors The neu oncogene was originally identified in cell lines derived from rat neuroectodermal tumors. neu is related to but distinct from the c-erbB gene, which encodes the epidermal growth factor (EGF) receptor. neu encodes a protein, designated p185, that i 2878363 Rat
neu c-cell hyperplasia In our series of 6 patients with MTC, including 5 patients with adjacent C-cell hyperplasia, Her2/neu levels were immunohistochemically evaluated on formalin-fixed, paraffin-embedded tissues using c-erbB-2/Her-2/neu Oncoprotein Ab-17 monoclonal antibody(m 12894498 Human
her2 c-cell hyperplasia In our series of 6 patients with MTC, including 5 patients with adjacent C-cell hyperplasia, Her2/neu levels were immunohistochemically evaluated on formalin-fixed, paraffin-embedded tissues using c-erbB-2/Her-2/neu Oncoprotein Ab-17 monoclonal antibody(m 12894498 Human
neu thyroid carcinomas The Her2/neu expression in poorly-differentiated thyroid carcinomas (PDTC) and in anaplastic thyroid cancer (ATC) was investigated retrospectively. 12894514 Human
her2 thyroid carcinomas The Her2/neu expression in poorly-differentiated thyroid carcinomas (PDTC) and in anaplastic thyroid cancer (ATC) was investigated retrospectively. 12894514 Human
erbb-2 endometrial hyperplasia Seventy specimens of normal endometrium (n = 13) and cervix (n = 12), endometrial hyperplasia (n = 4), cervical dysplasia (n = 20), endometrial (n = 11) and cervical carcinoma (n = 8) and uterine metastases of mammary carcinomas (n = 2) have been analysed 1980167 Human
erbb2 primary carcinomas The amplification of ERBB2 gene in metastatic gastric carcinomas is detected more frequently than in primary carcinomas. 2098274 Human
neu cholangioma The transforming gene from one cholangioma showed no sequence homology to the ras genes, neu, or c-raf. 2645046 Human
neu oral leukoplakia The purposes of the study were to summarize the preclinical and clinical development of Bowman-Birk Inhibitor and a Bowman-Birk Inhibitor concentrate against oral premalignant lesions and to evaluate Neu immunohistochemical staining intensity for lesions 14520092 Human
neu oral leukoplakia Bowman-Birk Inhibitor concentrate has dose-related clinical activity against oral leukoplakia and modulates levels of Neu and protease activity. 14520092 Human
her-2 renal cancers Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. 2572319 Human
erbb-2 renal cancers Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. 2572319 Human
her-2 wilms tumor In contrast, expression of the EGFR-related protooncogene HER-2 (erbB-2) was found to be decreased in 11 RCCs and one Wilms' tumor; HER-2 gene structure, however, appeared normal in all specimens. 2572319 Human
erbb-2 wilms tumor In contrast, expression of the EGFR-related protooncogene HER-2 (erbB-2) was found to be decreased in 11 RCCs and one Wilms' tumor; HER-2 gene structure, however, appeared normal in all specimens. 2572319 Human
erbb2 adenoid-cystic carcinomas These results suggested that overexpression of ERBB2 and ERBB3 is related to tumor differentiation and invasion in adenoid cystic carcinomas. 8669836 Human
neu neurofibromatosis neu proto-oncogene mutation is specific for the neurofibromas in a N-nitroso-N-ethylurea-induced hamster neurofibromatosis model but not for hamster melanomas and human Schwann cell tumors. 7906199 others
neu malignant schwannoma Moreover, any human Schwann cell tumors including neurofibroma, schwannoma, and malignant schwannoma did not show the mutation of c-erbB-2 gene (0 of 34), which is homologous to the hamster neu. 7906199 Human
neu neurofibroma Moreover, any human Schwann cell tumors including neurofibroma, schwannoma, and malignant schwannoma did not show the mutation of c-erbB-2 gene (0 of 34), which is homologous to the hamster neu. 7906199 Human
her2 desmoplastic small-round-cell tumors Desmoplastic small round cell tumors showed reactivity with calretinin in 4/21, desmin in 21/23, myoglobin in 5/17, placental alkaline phosphatase in 17/21, HER2/neu in 7/18 (3+ in 1 and 1+ in 6), c-kit in 2/14, MIC2 in 13/23, WT1 in 16/23, CAM5.2 in 21/2 12640103 Human
neu desmoplastic small-round-cell tumors Desmoplastic small round cell tumors showed reactivity with calretinin in 4/21, desmin in 21/23, myoglobin in 5/17, placental alkaline phosphatase in 17/21, HER2/neu in 7/18 (3+ in 1 and 1+ in 6), c-kit in 2/14, MIC2 in 13/23, WT1 in 16/23, CAM5.2 in 21/2 12640103 Human
erbb-2 pituitary tumors Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. 7956924 Human
erbb2 primary carcinomas The erbB2 and erbB3 were more strongly expressed than the epidermal growth factor receptor in the primary carcinomas. 7847801 Human
erbb2 pancreatic neoplasms Molecular genetic changes often present in ductal pancreatic neoplasms were not found by immunohistochemistry for DPC4, p53, and ERBB2 and by sequence analysis of KRAS codon 12. 15166675 Human
erbb-2 gallbladder cancer The expression of oncogene products and growth factors (epidermal growth factor, transforming growth factor-beta, erbB-2, ras p 21, and c-myc) in gallbladder cancer and chronic cholecystitis was measured by immunohistochemical staining on paraffin-embedde 8093356 Human
erbb-2 cancer Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. 8095411 Human
erbb-2 tumor Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. 8095411 Human
erbb-2 human tumors Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. 8095411 Human
erbb-2 bladder cancer Heterogeneity of erbB-2 gene amplification in bladder cancer. erbB-2 amplification and overexpression have been suggested as potentially useful prognostic markers in bladder cancer. 8097962 Human
erbb-2 barretts esophagus We examined 13 cases with esophageal adenocarcinomas and 5 cases with Barrett's esophagus for amplification of the EGFR and erbB-2 genes. 8098013 Human
erbb2 epidermoid carcinoma Cytosol from EGF-treated A-431 human epidermoid carcinoma cells was used as a source of PTPase activity, and tyrosine-phosphorylated ErbB2, EGF receptor, phospholipase C-gamma 1, and the Ras GTPase-activating protein were used as substrates to monitor PTP 8102801 Human
erbb2 low-grade tumor Cluster analysis revealed the markers fell into three independent groups: (i) G-actin and EGFR; (ii) ploidy, cytology, and p185 (HER-2/neu oncoprotein) (ERBB2); and (iii) p300, a low-grade tumor antigen. 8367495 Human
erbb2 pancreatic tumor Recombinant human tumor necrosis factor (TNF) alpha decreased the expression of ERBB2 mRNA by stimulating p55 TNF receptors of pancreatic tumor cells. 8105469 Human
erbb2 pancreatic tumor In our study we show that the TNF-mediated down-regulation of ERBB2 in pancreatic tumor cells is accompanied by an increase in growth inhibition at low doses of TNF. 8105469 Human
her2 differentiated thyroid carcinomas To investigate the prognostic value of Her2/neu expression in differentiated thyroid carcinomas 103 patients were retrospectively investigated. 12715168 Human
neu differentiated thyroid carcinomas To investigate the prognostic value of Her2/neu expression in differentiated thyroid carcinomas 103 patients were retrospectively investigated. 12715168 Human
her2 differentiated thyroid carcinomas Concerning the clinical outcome, Her2/neu overexpression may be regarded as a prognostic factor in differentiated thyroid carcinomas. 12715168 Human
neu differentiated thyroid carcinomas Concerning the clinical outcome, Her2/neu overexpression may be regarded as a prognostic factor in differentiated thyroid carcinomas. 12715168 Human
erbb-2 fibrocystic change The levels of c-erbB-2 oncoprotein (ErbB-2 protein) in nipple discharge were evaluated together with those of carcinoembryonic antigen (CEA) in 9 patients with breast cancer, 2 patients with borderline lesions, 8 patients with intraductal papilloma, and 1 7901888 Human
erbb-2 intraductal papilloma The levels of c-erbB-2 oncoprotein (ErbB-2 protein) in nipple discharge were evaluated together with those of carcinoembryonic antigen (CEA) in 9 patients with breast cancer, 2 patients with borderline lesions, 8 patients with intraductal papilloma, and 1 7901888 Human
erbb-2 intraductal papilloma Two of the 8 patients with intraductal papilloma had high ErbB-2 protein levels. 7901888 Human
erbb-2 solid carcinomas Thus, measurement of ErbB-2 protein levels in nipple discharge can assist in the diagnosis of intraductal carcinoma and also in detecting tumors with a high proliferation rate and an overexpression of ErbB-2 protein: usually comedo or solid carcinomas. 7901888 Human
erbb2 ovarian cancer BACKGROUND: While in breast cancer the amplification and overexpression of the erbB2 gene has been reported in numerous studies and found to be correlated to poor prognosis, information about this oncogene with respect to ovarian cancer is still limited. 7904177 Human
erbb2 ovarian cancer A recent study reported that approximately 30% of tumor biopsies from ovarian cancer patients exhibited erbB2 amplification and overexpression and suggested that the overexpression of this oncogene is an indicator of bad prognosis in ovarian cancer. 7904177 Human
her2 secondary tumor Women with measurable metastatic breast cancer whose primary or secondary tumor overexpressed HER2 were eligible for inclusion. 12722022 Human
erbb2 breast cancer We report for the first time that phenylethanolamine N-methyltransferase (PNMT), proteasome subunit, beta type 3 (PSMB3), ribosomal protein L19 (RPL19), and nuclear receptor subfamily 1, group D, member 1 (NR1D1) are coexpressed with ERBB2 in 34 breast ca 12727839 Human
neu ovarian adenocarcinoma Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. 1346236 Human
neu ovarian adenocarcinoma This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell 1346236 Mouse
neu serous carcinoma Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline se 1347282 Human
neu papillary serous carcinomas Immunohistochemical staining (IHC) of a total of 86 specimens (including 17 of those studied by ISH) localized NEU antigen expression to epithelial cells in 36 of 86 samples with strong membrane staining observed in 12, including 1 benign, 1 borderline se 1347282 Human
her2 stage-ii breast cancers Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. 1349163 Human
her2 neck cancer The applicability of this strategy has been expanded beyond the treatment of NHL as demonstrated by the clinical application of the chimeric monoclonal antibody directed at the Her2/neu receptor in breast cancer, the epidermal growth factor receptor in co 12743905 Human
neu neck cancer The applicability of this strategy has been expanded beyond the treatment of NHL as demonstrated by the clinical application of the chimeric monoclonal antibody directed at the Her2/neu receptor in breast cancer, the epidermal growth factor receptor in co 12743905 Human
erbb-2 thyroid cancer Amplification of ERBB-2 was detected in 14 out of 63 (22%) cases of breast carcinoma, in 1 out of 23 patients with ovarian cancers, in 1 out of 19 cases of colon carcinoma and in 1 out of 27 patients with thyroid cancer. 1349430 Human
erbb-2 adenocarcinomas Amplification and/or overexpression of the erbB-2 gene have been demonstrated in 20-30% of adenocarcinomas of the breast, ovary, lung, and stomach and are associated with aggressive clinical course and poor prognosis. 1349849 Human
her2 gastro-intestinal cancer Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. 1352439 Human
neu gastro-intestinal cancer Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. 1352439 Human
erbb2 gastro-intestinal cancer Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. 1352439 Human
her2 gastrointestinal carcinomas To determine whether the sporadically occurring amplification of the oncogene erbB2/HER2 in gastrointestinal carcinomas is associated with additional changes of this sequence, DNA from 17 colorectal and 5 stomach carcinomas was analyzed for copy number, s 1352439 Human
erbb2 gastrointestinal carcinomas To determine whether the sporadically occurring amplification of the oncogene erbB2/HER2 in gastrointestinal carcinomas is associated with additional changes of this sequence, DNA from 17 colorectal and 5 stomach carcinomas was analyzed for copy number, s 1352439 Human
erbb2 colon tumors Whereas in colon tumors with non-amplified erbB2 this status was unchanged, one case with erbB2 amplification showed additional MspI bands indicating a methylation of the amplified gene sequences. 1352439 Human
neu endometrioid tumors Different subtypes of ovarian carcinomas had significantly different amounts of neu oncogene product as measured by capture ELISA; endometrioid tumors had the highest, and poorly differentiated carcinomas not otherwise specified had the lowest (p less tha 1353878 Human
neu colon tumors HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. 12767065 Human
erbb-2 early gastric cancers For the prediction of nodal status of early gastric cancer, sections of formalin-fixed, paraffin-embedded tissue from 220 early gastric cancers were analyzed immunohistochemically, using a polyclonal antibody against erbB-2 protein. 1356259 Human
erbb-2 early gastric cancer For the prediction of nodal status of early gastric cancer, sections of formalin-fixed, paraffin-embedded tissue from 220 early gastric cancers were analyzed immunohistochemically, using a polyclonal antibody against erbB-2 protein. 1356259 Human
erbb-2 early gastric cancer These results indicate that early gastric cancer with erbB-2 protein expression may represent a potential risk of lymph node metastasis. 1356259 Human
neu embryonal carcinoma Transfection of murine P19S18 embryonal carcinoma cells with the oncogene neu induces an epithelioid phenotype. 1361918 Mouse
neu embryonal carcinoma An embryonal carcinoma cell line, P19S18, was transfected with the rat oncogene neu to investigate the function of its protein product, p185*, in a multipotential cellular environment. 1361918 Human
neu ovarian adenocarcinomas Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas. 1672104 Human
neu carcinosarcoma Five fibroadenomas, one benign variant of phylloid tumor, one carcinosarcoma, and one of two proliferative fibrocystic diseases of the breast showed lacking or normal baseline expression of the neu oncogene, as did one monomorphous cystadenolymphoma of th 1672262 Human
neu parotid pleomorphic adenomas In contrast, four parotid pleomorphic adenomas and one salivary gland adenocarcinoma showed enhanced neu expression. 1672262 Human
neu salivary gland adenocarcinoma In contrast, four parotid pleomorphic adenomas and one salivary gland adenocarcinoma showed enhanced neu expression. 1672262 Human
erbb2 malignant salivary gland tumors Expression of the ERBB2 protein in benign and malignant salivary gland tumors. 1676907 Human
erbb2 malignant salivary gland tumors These results indicate that ERBB2 activation and overexpression could be an important genetic event with possible prognostic implications in a subset of malignant salivary gland tumors. 1676907 Human
neu female breast cancer Archival surgical specimens from 1,210 female breast cancer patients treated between 1968 and 1971 and with a 19-year follow-up were reanalyzed with special reference to several parameters, such as size of the primary tumor, axillary nodal involvement, hi 1678734 Human
erbb2 brain tumor ERBB2 confers a poor clinical outcome in medulloblastoma, the most common malignant pediatric brain tumor. 12709419 Human
neu non-small cell carcinomas Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. 1967224 Human
neu non-small cell carcinoma The neu protein product (p185neu) was present in eight of 22 non-small cell carcinoma cell lines derived from human lung tumors. 1967224 Human
her2 soft-tissue tumors But the role of HER2/neu alterations in soft tissue tumors remains poorly understood. 12874758 Human
neu soft-tissue tumors But the role of HER2/neu alterations in soft tissue tumors remains poorly understood. 12874758 Human
her-2 premalignant states The transmembrane (TM) receptor encoded by the HER-2 proto-oncogene (HER-2) is amplified in several types of human carcinomas and premalignant states and provides an important target for cancer therapy. 12168050 Human
her2 gastrointestinal carcinoid tumors HER2 Expression in Gastrointestinal Carcinoid Tumors: High in Intestinal but not in Gastric Tumors. 17342373 Human
her2 gastric tumors HER2 Expression in Gastrointestinal Carcinoid Tumors: High in Intestinal but not in Gastric Tumors. 17342373 Human
her2 brain metastases Brain metastases: the HER2 paradigm. 17363517 Human
her2 benign prostatic hyperplasia (bph) Using tissue microarrays, we did immunohistochemistry and fluorescence in situ hybridization for HER2 and TOP2A in 100 prostate cancers (41 localized and 59 advanced) and 42 cases of benign prostatic hyperplasia (BPH). 17363613 Human
her2 hodgkin's lymphoma EXPERIMENTAL DESIGN: Sixty-six infiltrating breast carcinomas from patients treated with radiation therapy for Hodgkin's lymphoma or other pediatric solid tumors and a control series of 61 consecutive sporadic breast tumors were analyzed by immunohis 17200337 Human
her2 pediatric solid tumors EXPERIMENTAL DESIGN: Sixty-six infiltrating breast carcinomas from patients treated with radiation therapy for Hodgkin's lymphoma or other pediatric solid tumors and a control series of 61 consecutive sporadic breast tumors were analyzed by immunohis 17200337 Human
neu early stage cervical cancer Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. 14529687 Human
her-2 complete mole A positive immunohistochemical Her-2/neu stain was found in 6 (18.2%) of the patients with hydatidiform mole (3 with a complete mole). 17126893 Human
her2 calgb We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status. 17129383 Human
erbb2 inflammatory breast cancers Moreover, patients with ErbB2-overexpressing inflammatory breast cancers responded to lapatinib monotherapy regardless of PTEN status. 17283152 Human
c-erb b2 adenoid-cystic carcinomas This study was undertaken to define the role of c-erb B2 and c-erbB3 in adenoid cystic carcinomas (A.C.C.) of the salivary glands. 8669836 Human
erbb-2 mammary tumor The high levels of the erbB-2 product associated with malignant transformation of NIH/3T3 cells were observed in human mammary tumor cells that overexpressed this gene. 2885917 Human
erbb-2 stomach tumors Quantitation of erbB-2 mRNA in these tumors demonstrated that gene amplification coincided with overexpression of erbB-2 mRNA ranging from 8- to 32-fold above levels observed in stomach tumors without gene amplification. 2573419 Human
erbb-2 stomach tumors Thus, overexpression of normal size erbB-2 mRNA accompanies gene amplification in primary stomach tumors. 2573419 Human
erbb-2 endometrial tumour ErbB-2 over-expression was only seen in one HPV-18 infected advanced endometrial tumour. 1661047 Human
erbb-2 adenocarcinomas of the breast Amplification and/or overexpression of the erbB-2 gene have been demonstrated in 20-30% of adenocarcinomas of the breast, ovary, lung, and stomach and are associated with aggressive clinical course and poor prognosis. 1349849 Human
erbb-2 benign breast tumors RESULTS. Eleven (9%) of 114 preoperative samples from patients with a histologically verified breast cancer and 2 of 113 (1.8%) from patients with benign breast tumors had elevated (greater than 20 U/ml) serum erbB-2 antigen levels. 7905363 Human
erbb-2 serous cystadenocarcinomas METHODS: A total of 17 serous cystadenocarcinomas were analyzed for epidermal growth factor receptor (EGF-R or ErbB-1) and ErbB-2, ErbB-3, and ErbB-4 receptor expression by Western blot analysis. 9614647 Human
erbb-2 calgb METHODS: To validate those findings, we conducted immunohistochemical analyses of erbB-2 and p53 protein expression in an additional cohort of 595 patients (set B) from CALGB 8541, as well as a molecular analysis of erbB-2 gene amplification in tumors fro 9747866 Human
erbb-2 thyroid tumours We investigated human thyroid tumours for erbB-2 gene amplification, activating mutations in the transmembrane domain, quantitative mRNA expression and protein expression. 10197079 Human
erbb-2 thyroid tumours CONCLUSION: There are no mutations or amplifications of the erbB-2 gene in human thyroid tumours. 10197079 Human
erbb-2 thyroid tumours Elevated erbB-2 mRNA expression in some thyroid tumours is not associated with clinical features of poor prognosis; however, the significance of the elevated mRNA levels is unclear, as it did not result in protein overexpression. 10197079 Human
erbb-2 thyroid tumours Instead, cytoplasmic erbB-2 protein detection by IHC correlates with differentiation of human thyroid tumours and may be a feature of good prognosis. 10197079 Human
erbb-2 leukoplakias Aberrations of erbB-1 and erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity. 10687911 Human
erbb-2 leukoplakias In eight patients with leukoplakias, the results indicated aberrations of the erbB-1 oncogene, and two patients had gene dosage changes of erbB-2. 10687911 Human
erbb-2 pleural malignant mesotheliomas Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. 10849094 Human
erbb-2 minimal residual disease RESULTS: Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, 11948114 Human
erbb-2 mrd RESULTS: Of 8 patients with erbB-2 amplification, 5 had a complete response (CR) or minimal residual disease (MRD), 3 had a partial response (PR), and none had stable (StD) or progressive disease (PD) at the time of mastectomy, versus 3 CR or MRD, 16 PR, 11948114 Human
erbb-2 oropharyngeal cancer Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncoge 15236790 Human
erbb-2 oropharyngeal cancer We propose that trastuzumab as an adjuvant treatment may decrease process of tumor metastasis in oropharyngeal cancer patients who completed primary treatment (surgery and/or radiotherapy) and show expression of both HPV16 E6/E7 and erbB-2 oncoproteins. 15236790 Human
erbb-2 middle ear cholesteatoma RESULTS: In matrix of middle ear cholesteatoma, ErbB-2 and ssDNA were expressed in the keratinocytes of all layers and Ki-67 was expressed in the keratinocytes of the basal, lower spinous, and occasionally granular layer. 15510028 Human
erbb-2 uterine sarcomas ERBB-2 gene overexpression and amplification in uterine sarcomas. 15581967 Human
erbb-2 uterine sarcomas BACKGROUND: The aim of this study was to determine ERBB-2 (HER-2/neu) gene alterations in different subtypes of uterine sarcomas. 15581967 Human
erbb-2 undifferentiated uterine sarcomas ERBB-2 immunopositivity (3+) and ERBB-2 amplification by FISH were confirmed in the recurrent tumor, resulting in a gene amplification rate of 1/4 in undifferentiated uterine sarcomas. 15581967 Human
erbb-2 uterine leiomyosarcoma CONCLUSION: The current results suggest absence of ERBB-2 overexpression in uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and undifferentiated ut 15581967 Human
erbb-2 endometrial stromal sarcoma CONCLUSION: The current results suggest absence of ERBB-2 overexpression in uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and undifferentiated ut 15581967 Human
erbb-2 adenosarcoma CONCLUSION: The current results suggest absence of ERBB-2 overexpression in uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and undifferentiated ut 15581967 Human
erbb-2 undifferentiated uterine sarcomas CONCLUSION: The current results suggest absence of ERBB-2 overexpression in uterine leiomyosarcoma, uterine adenosarcoma, and endometrial stromal sarcoma, whereas the ERBB-2 gene might have a biologic role in uterine carcinosarcoma and undifferentiated ut 15581967 Human
erbb2 squamous cell carcinoma of the uterine cervix ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. 7905784 Human
erbb2 pancreatic tumours This occurs in approximately one-third of breast and pancreatic tumours (and in a smaller proportion of other tumours) and involves transcriptional up-regulation of the ERBB2 gene with or without gene amplification. 7584078 Human
erbb2 skin tumor Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. 9136987 Mouse
erbb2 benign schwannomas While none of the malignant schwannomas exhibited ERBB2 expression, weak expression was seen in a small proportion of the benign schwannomas. 9824645 Human
erbb2 skin tumor Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. 10980598 Mouse
erbb2 tumour infiltrating lymphocytes Some of the parameters investigated (tumour size, histologic and nuclear grade, tumour infiltrating lymphocytes, p53 and Ki 67) were found to be influenced by age, some (necrosis and oestrogen receptors) were influenced by menopausal status and/or age, so 14965755 Human
erbb2 malignant thyroid tumors Overexpression of the CCND1 gene was observed in both the benign and malignant thyroid tumors, whereas the ERBB2 gene was mainly overexpressed in malignant thyroid tumors. 11288983 Human
erbb2 metastatic osteosarcoma ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 12569382 Human
erbb2 metastatic osteosarcoma To identify markers suitable for detecting osteosarcoma cells in aphereses we analysed the expression of bone-specific genes (Bone Sialoprotein (BSP) and Osteocalcin) and oncogenes (Met and ErbB2) in 22 patients with metastatic osteosarcoma and six health 12569382 Human
erbb2 pediatric brain tumor ERBB2 confers a poor clinical outcome in medulloblastoma, the most common malignant pediatric brain tumor. 12709419 Human
erbb2 medulloblastoma ERBB2 confers a poor clinical outcome in medulloblastoma, the most common malignant pediatric brain tumor. 12709419 Human
erbb2 medulloblastoma Here, we show that medulloblastoma cell sensitivity to 17-AAG is directly related to ERBB2 expression level. 12709419 Human
erbb2 medulloblastoma Rather, we show that 17-AAG generates a dose- and time-dependent increase in MEK/ERK signaling that is required for the drug to inhibit the proliferation of medulloblastoma cells and that ERBB2 sensitizes medulloblastoma cells to 17-AAG by up-regulating b 12709419 Human
erbb2 liver tumours Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. 12846405 Human
erbb2 minor salivary gland mucoepidermoid carcinoma MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. 15054739 Human
erbb2 minor salivary gland mucoepidermoid carcinoma This study investigates MUC4 and ErbB2 receptor expression in major and minor salivary gland mucoepidermoid carcinoma and correlates patterns of expression with clinical outcomes. 15054739 Human
erbb2 papillary carcinoma Additional studies indicated a similar result in papillary carcinoma cells; mRNAs of erbB2 and erbB3 were increased but erbB4 mRNA was decreased, suggesting distorted erbB expression may be associated with tumorigenesis. 15279891 Human
erbb2 breast cancer For example, amplification and overexpression of the ERBB2 oncogene is associated with poor prognosis in breast cancer and ERBB2 serves as a target for antibody-based therapy. 15300811 Human
erbb2 high grade intraepithelial neoplasia Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma. 15386389 Human
erbb2 barrett's adenocarcinoma GRB7 is localized in close proximity to the ERBB2 gene within an amplicon previously identified in Barrett's adenocarcinoma (BCA). 15386389 Human
erbb2 intraepithelial neoplasia Moreover, coamplification (r(s) = 0.97, p < 0.001) and coexpression (r(s) = 0.81, p < 0.001) of GRB7 and ERBB2 are shown to be already present in a subset of BCA associated high-grade intraepithelial neoplasia (HGIN), possibly reflecting a role of a conce 15386389 Human
erbb2 barrett's esophagus No alterations, neither gene amplification nor overexpression were detected in Barrett's carcinoma associated low grade intraepithelial neoplasia (LGIN), intestinal metaplasia (IM) and squamous epithelium, indicating that alterations of GRB7 and ERBB 15386389 Human
erbb2 metaplasia No alterations, neither gene amplification nor overexpression were detected in Barrett's carcinoma associated low grade intraepithelial neoplasia (LGIN), intestinal metaplasia (IM) and squamous epithelium, indicating that alterations of GRB7 and ERBB 15386389 Human
erbb2 low grade intraepithelial neoplasia No alterations, neither gene amplification nor overexpression were detected in Barrett's carcinoma associated low grade intraepithelial neoplasia (LGIN), intestinal metaplasia (IM) and squamous epithelium, indicating that alterations of GRB7 and ERBB 15386389 Human
erbb2 high grade intraepithelial neoplasia These findings may be of particular interest because the transition from high grade intraepithelial neoplasia to invasive carcinoma is a crucial step in malignant transformation in Barrett's carcinogenesis and might underline the putative role of GRB 15386389 Human
erbb2 lobular carcinomas Because HMGA1 expression was similar among ductal breast carcinomas with different histologic grading, we evaluated the association between HMGA1 expression and that of other markers of breast carcinoma invasion (estrogen and progesterone receptors, Ki-67 15569996 Human
erbb2 colon carcinoma In this study we show that constitutively high levels of active, i.e. autophosphorylated, ErbB2 in HCT116 colon carcinoma cells and TA3/St mammary carcinoma cells are dependent on endogenous hyaluronan-CD44 interaction. 15632176 Human
erbb2 breast cancer metastasis ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis. 15753384 Human
erbb2 colon cancer Reorganization of ErbB Family and Cell Survival Signaling after Knock-down of ErbB2 in Colon Cancer Cells. 15888451 Human
erbb2 human colon carcinoma The role of the ErbB family in supporting the malignant phenotype was characterized by stable transfection of a single chain antibody (ScFv5R) against ErbB2 containing a KDEL endoplasmic reticulum retention sequence into GEO human colon carcinoma cells. 15888451 Human
erbb2 pediatric cancer ERBB2 in pediatric cancer: innocent until proven guilty. 16079318 Human
erbb2 pediatric cancers This review addresses the issues surrounding the identification of molecular targets in pediatric cancers by focusing on studies of the ERBB2 oncogene. 16079318 Human
her-2 salivary gland tumours Prompted by recent findings on the amplification of c-erbB-2 (HER-2, neu) oncogene in salivary gland tumours, the present study was conducted to analyse the expression of c-erbB-2 in both benign and malignant salivary gland tumours, with special emphasis 7915830 Human
her-2 malignant salivary gland tumours Prompted by recent findings on the amplification of c-erbB-2 (HER-2, neu) oncogene in salivary gland tumours, the present study was conducted to analyse the expression of c-erbB-2 in both benign and malignant salivary gland tumours, with special emphasis 7915830 Human
her-2 gist In contrast, HER-2 is not expressed in any GIST. 10599309 Human
her-2 salivary duct carcinoma [About the prognostic value of Her-2 gene-amplification and cell-proliferation in salivary duct carcinoma of the major salivary glands - a pilot-study] INTRODUCTION: The salivary duct carcinoma (sdc) represents a rare variant of the group of adeno-carcino 11555785 Human
her-2 metaplasia The expression patterns of KIT, EGFR, and HER-2 differed between the epithelial and mesenchymal components, and the regulation of their expression appeared important in the acquisition of mesenchymal metaplasia in uterine carcinosarcoma. 14611676 Human
her-2 recurrent breast cancer Her-2 protein expression of 10 CTCs was sufficient to make a definitive diagnosis of the HER-2 gene status of the whole population of CTCs in 19 patients with recurrent breast cancer. 15194824 Human
her-2 malignant glioma It has recently been demonstrated that malignant glioma cells express certain known tumor-associated antigens, such as HER-2, gp100, and MAGE-1. 15256472 Human
her-2 feline invasive mammary carcinomas Overexpression of HER-2 in Feline Invasive Mammary Carcinomas: An Immunohistochemical Survey and Evaluation of Its Prognostic Potential. 15657269 Cat
her-2 low-grade endometrial stromal sarcomas Twenty-three cases of endometrial sarcomas consisting of 20 low-grade endometrial stromal sarcomas and 3 undifferentiated endometrial sarcomas were examined immunohistochemically for EGFR (HER-1), HER-2, HER-3, and HER-4. 15767802 Human
her-2 metastatic squamous cell carcinoma Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. 15865067 Human
her-2 benign breast tumors To determine whether phenotypic field changes occur in tissues adjacent to carcinoma, we assayed, by immunohistochemistry, the expression of HER-2, p53, Fas, and FasL in 72 breast cancers (BC) and multiple autologous peritumoral tissues (PTTs) sampled up 15622519 Human
her-2 colon cancer HER-2 is constitutively activated and overexpressed in many cancers, and its inhibition in colon cancer cells diminishes tumorigenicity and induces apoptosis. 15757908 Human
her-2 colon cancer The inhibition of HER-2 signaling represents a potential mechanism by which integrin alpha5/beta1 exerts its tumor suppressor-like activity in colon cancer cells. 15757908 Human
her-2 metaplastic breast carcinomas Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? 15976335 Human
her-2 bilateral breast carcinomas Simultaneous Bilateral Breast Carcinomas: A Category with Frequent Coexpression of HER-2 and ER-alpha, High Ki-67 and bcl-2, and Low p53. 16086078 Human
her-2 axillary metastases Her-2 positive cases tended to have higher rates of axillary metastases, but this did not reach statistical significance. 16168103 Human
her-2/neu metaplasia In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
her-2/neu condyloma In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
her-2/neu gastric tumors Using the modified DNA in-gel renaturation assay to detect down to 7-8 copies of amplified DNA sequences, we identified 3 gastric tumors with amplified DNA sequences and confirmed by Southern hybridization analysis that HER-2/neu was amplified greater tha 2400999 Human
her-2/neu gastric adenocarcinomas Immunohistochemical staining of tumor tissue sections with p185 HER-2/neu antibodies demonstrated that only the 3 gastric adenocarcinomas with corresponding HER-2/neu gene amplification displayed membrane immunoreactivity. 2400999 Human
her-2/neu low-grade tumors Losses of heterozygosity on chromosome 6 as well as HER-2/neu amplification, in contrast, were present in several low grade tumors and were not more frequent in high grade lesions. 1677312 Human
her-2/neu endocrine tumors CONCLUSIONS. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. 1353638 Human
her-2/neu ovarian epithelial neoplasms BACKGROUND. It is unclear whether HER-2/neu proto-oncogene expression in ovarian epithelial neoplasms is related to prognosis. 1360327 Human
her-2/neu follicular adenomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
her-2/neu follicular carcinomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
her-2/neu iv epithelial ovarian cancer STUDY DESIGN: We determined expression of HER-2/neu by immunohistochemistry, with monoclonal antibody 9G6 and the indirect immunoperoxidase technique, on frozen tumor specimens from 105 patients with stage III or IV epithelial ovarian cancer. 8093588 Human
her-2/neu tumor infiltrated lymph nodes Three hundred and one primary breast cancers from patients with tumor infiltrated lymph nodes were analyzed for the presence of HER-2/neu oncoprotein by two procedures: Western blot (WB) and immunohistochemistry (IHC). 1363511 Human
her-2/neu node-negative breast cancer In node-negative breast cancer patients, the subgroup for which accurate prognostic data could make a significant contribution to treatment decisions, the prognostic utility of HER-2/neu amplification and/or overexpression has been controversial. 8104689 Human
her-2/neu familial cancer Preliminary studies indicate a lack of overexpression of the HER-2/neu oncogene in the familial cancer members' tumors. 7903948 Human
her-2/neu clear cell tumors A significant increase was found in 3+ expression of HER-2/neu in clear cell tumors. 7906607 Human
her-2/neu gynecologic tumors P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. 7910219 Human
her-2/neu gastrinoma METHODS: The differential polymerase chain reaction (PCR) procedure was used to detect amplification of the HER-2/neu gene in DNA samples from the novel human gastrinoma cell line (PT) and from paraffin-embedded samples of gastrinomas. 7911296 Human
her-2/neu carcinomas of the salivary gland Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. 7522962 Human
her-2/neu mucoepidermoid carcinomas Here a cohort of mucoepidermoid carcinomas of the major (parotid and submandibular) salivary glands are analyzed for a molecular genetic alteration, HER-2/neu gene amplification, and gene amplification and expression results are compared with long-term cl 7522962 Human
her-2/neu mucoepidermoid carcinoma of salivary glands Archival tissues resected from 58 patients with mucoepidermoid carcinoma of salivary glands were evaluated for HER-2/neu gene amplification by fluorescence in situ hybridization and for gene expression by immunohistochemistry in a blinded fashion. 7522962 Human
her-2/neu mucoepidermoid carcinomas HER-2/neu is amplified and/or overexpressed in approximately one-third of mucoepidermoid carcinomas of salivary glands. 7522962 Human
her-2/neu uterine corpus cancer Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. 7977518 Human
her-2/neu uterine corpus cancer CONCLUSION: In this referral population, c-myc activation is more common than HER-2/neu activation in uterine corpus cancer and is associated with tumors of higher grade. 7977518 Human
her-2/neu oral leukoplakia To identify and modulate molecular SEBs in intraepithelial neoplasia of the upper aerodigestive tract, we studied expression of the epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha), and HER-2/neu genes in oral leukopla 7823600 Human
her-2/neu leukoplakia Pretreatment expression of EGFR, TGF-alpha, and HER-2/neu in leukoplakia was increased when compared to normal-appearing mucosa. 7823600 Human
her-2/neu high-grade prostatic intraepithelial neoplasia The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size a 7529857 Human
her-2/neu ovarian carcinomas [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas] C-erbB-2 (HER-2/neu) proto-oncogene is mainly expressed in epithelial tissue and activated due to its amplification. 7866905 Human
her-2/neu epithelial-myoepithelial carcinomas Thirty-one salivary gland epithelial-myoepithelial carcinomas from 26 patients were studied by DNA flow cytometry, and immunostaining for Ki-67 and HER-2/neu oncogene product. 7726139 Human
her-2/neu papillary carcinomas There has been continued work on prognostic factors in endometrial carcinomas with ploidy, hormone receptor status, HER-2/neu expression, and coexistent hyperplasia confirmed as independent prognostic factors, while clear cell and serous papillary carcino 7742498 Human
her-2/neu endometrial cancers Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. 7585656 Human
her-2/neu endometrial cancer Overexpression of HER-2/neu, transforming growth factor alpha, and p53 proteins have all been associated with poor prognosis in women with endometrial cancer. 7585656 Human
her-2/neu endometrial cancers In this study, the level of HER-2/neu gene amplification and expression was characterized in 92 endometrial cancers. 7585656 Human
her-2/neu endometrial cancer Women whose endometrial cancer exhibited HER-2/neu gene amplification by FISH had a shorter overall survival than women whose endometrial cancer lacked amplification (P = 0.018). 7585656 Human
her-2/neu endometrioid carcinoma STUDY DESIGN: Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic 8610771 Human
her-2/neu adenosarcoma The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. 8557233 Human
her-2/neu mmmt Immunohistochemistry was used to grade overexpression of p53 protein, HER-2/neu protein, epidermal growth factor receptor (EGFR), and Ki-67 antigen in both the glands and stroma of tissue from 20 women with MMMT and 6 women with AS. 8557233 Human
her-2/neu mmmt HER-2/neu protein was not overexpressed in any AS or primary MMMT. 8557233 Human
her-2/neu supraglottic squamous cell carcinoma Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma. 8604888 Human
her-2/neu supraglottic carcinomas Sections from 32 supraglottic carcinomas were studied immunohistochemically for the presence of HER-2/neu (c-erbB-2) oncogene expression. 8604888 Human
her-2/neu cancers of the uterus CONCLUSIONS: Determination of the frequency and levels of EGF receptors, HER-2/neu protein, and cathepsin D in uteri with and without cancer and the availability of reference materials developed in our laboratory, will allow evaluation of their prognostic 8616763 Human
her-2/neu borderline ovarian tumours Twenty-four advanced (surgical stage III and IV) ovarian carcinomas and 15 borderline ovarian tumours were studied for the overexpression of nm23 and HER-2/neu (c-erb-B2) by means of immunohistochemistry on sections from routinely processed, paraffin-embe 8702236 Human
her-2/neu gynecologic cancers The role of the HER-2/neu oncogene in gynecologic cancers. 8796816 Human
her-2/neu human lung cancer Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance. 8875978 Human
her-2/neu seborrheic keratoses Examination for the localization of epidermal growth factor receptor (EGF-R) and HER-2/neu oncoprotein by immunohistochemistry revealed positive staining on the epithelial strands branching downwards on the specimens of seborrheic keratoses. 8935630 Human
her-2/neu high-grade pin Potential SEBs for screening chemopreventive agents for prostate cancer in short-term Phase II trials include (1) histologic premalignant lesions, such as high-grade PIN; (2) biochemical markers, including prostate-specific antigen (PSA) serum concentrati 9027613 Human
her-2/neu benign ovarian cystadenomas Paraffin-embedded sections from the 42 BLOT, 5 normal ovaries, and 10 benign ovarian cystadenomas were stained using monoclonal antibodies against human p53 (DAKO-p53, DAKO, Denmark) and HER-2/neu (C-erB-2, Triton, Parkway, CA). 9159328 Human
her-2/neu ovarian cystadenomas None of the normal ovaries or ovarian cystadenomas demonstrated overexpression of p53 or HER-2/neu. 9159328 Human
her-2/neu stage i endometrial carcinoma OBJECTIVE: To determine if DNA ploidy, hormone receptors, vascular space invasion (VSI), perivascular lymphocytes (PVL), and the oncogenes HER-2/neu, p53, and bcl-2 are independent prognostic indicators for lymph node metastasis and cancer recurrence in c 9299250 Human
her-2/neu pancreatic tumors Our studies suggest a possible relationship of family cancer history to the expression of p53 and p21WAF in pancreatic tumors, but show no relationship to the expression of HER-2/neu or to the prevalence of K-ras mutations. 9322121 Human
her-2/neu pancreas cancer In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
her-2/neu pancreatic carcinoma In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
her-2/neu early vulvar cancer S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer. 9367708 Human
her-2/neu early vulvar cancer OBJECTIVE: Our aim was to determine the value of the S-phase fraction, p53, and HER-2/neu status as predictors of inguinal nodal metastasis in early vulvar cancer. 9367708 Human
her-2/neu early vulvar cancer CONCLUSION: Early vulvar cancer patients with inguinal node metastasis have a significantly higher S-phase fraction and are more likely to have HER-2/neu immunopositivity when compared to those without nodal metastasis. 9367708 Human
her-2/neu verrucous carcinoma of the oral cavity Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bcl-2, p53, and Her-2/neu, and indexes of cell turnover. 9398988 Human
her-2/neu renal cell carcinoma (rcc) To analyze whether Her-2/neu epitopes are tumor-associated antigens for renal cell carcinoma (RCC) and colon carcinoma, we induced Her-2/neu peptide-specific CTL responses by primary in vitro immunization and used these CTLs to determine the presentation 9485028 Human
her-2/neu stage ii breast carcinoma METHODS: This study evaluated data from 226 patients with TNM Stage I and early Stage II breast carcinoma and included the variables p53 and c-erbB-2 (HER-2/neu). 9486576 Human
her-2/neu bladder adenocarcinoma METHODS AND RESULTS: We investigated the usefulness of a panel of antibodies against cytokeratin 7, E48, cytokeratin 20, PSA, PSAP, CEA, vimentin, OC125 and HER-2/neu, to discriminate primary bladder adenocarcinoma from adenocarcinomas arising from the pr 9522212 Human
her-2/neu stage i adenocarcinoma of lung Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. 9800799 Human
her-2/neu stage i lung adenocarcinoma CONCLUSIONS: Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. 9800799 Human
her-2/neu colorectal adenocarcinomas HLA-A2+ patients with metastatic breast, ovarian, or colorectal adenocarcinomas that overexpressed HER-2/neu were immunized with the HLA-A2-binding epitope p369-377 (p369). 9809997 Human
her-2/neu invasive adenocarcinomas Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2/neu mucinous neoplasms Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2/neu pancreatic cancer Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2/neu oral squamous-cell carcinoma Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. 10632356 Human
her-2/neu primary fallopian tube carcinoma Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. 10629373 Human
her-2/neu fallopian tube adenocarcinoma The high incidence of p53, HER-2/neu and c-myc overexpression in fallopian tube adenocarcinoma suggests these genes may play a role in its tumorigenesis. 10629373 Human
her-2/neu lobular breast cancers Although Her-21neu overexpression was a common finding in lobular breast cancers, Her-2/neu amplification was not observed in these tumors. 10656439 Human
her-2/neu breast carcinoma Her-2/neu (H2N) status in breast carcinoma has been considered a prognostic factor that may have therapeutic implications; however, the correlation between H2N overexpression and gene amplification has not been completely defined. 10658908 Human
her-2/neu smooth muscle neoplasms STUDY DESIGN: Forty-five uterine smooth muscle neoplasms were assessed for DNA ploidy; silver-staining nucleolar organizer regions (AgNORs); percent nuclear proliferating cell nuclear antigen (PCNA); expression of p53, Her-2/neu, and MDM-2 protein; mitoti 10656730 Human
her-2/neu adenocarcinomas of the esophagus Using M68 immunohistochemistry and a scoring system similar to that used for HER-2/neu, we found that M68 protein was overexpressed in 30 of 68 (44%) human adenocarcinomas of the esophagus, stomach, colon, and rectum. 10655513 Human
her-2/neu epithelial hyperplasia In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia, as well as abnormalities of several cell 10762008 Human
her-2/neu human breast cancers The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20-30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin. 10889820 Human
her-2/neu human kidney tumor Immunohistochemical analysis of human kidney tumor lesions using 2 HER-2/neu-specific antibodies revealed HER-2/neu expression in more than 40% of primary epithelial renal tumors and more than 30% of primary renal cell carcinoma (RCC) specimens. 10897039 Human
her-2/neu renal tumors Immunohistochemical analysis of human kidney tumor lesions using 2 HER-2/neu-specific antibodies revealed HER-2/neu expression in more than 40% of primary epithelial renal tumors and more than 30% of primary renal cell carcinoma (RCC) specimens. 10897039 Human
her-2/neu kidney tumors A distinctive HER-2/neu expression pattern was found in different subtypes of kidney tumors with the highest frequency in chromophilic and chromophobic RCC, but neither associated with disease stage nor tumor grade. 10897039 Human
her-2/neu melanoma These results demonstrated that HER-2/neu amplification and overexpression are not common in advanced stage melanoma and thus, HER-2/neu would have limited value as a biomarker or as a target for immunotherapy in melanoma. 10928135 Human
her-2/neu large-cell carcinomas HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. 10928158 Human
her-2/neu calgb We examine a possible interaction between HER-2/neu or p53 expression and tamoxifen effectiveness in patients with ER-positive, node-positive disease treated with cyclophosphamide, doxorubicin, and fluorouracil in a large adjuvant chemotherapy trial (Canc 11032587 Human
her-2/neu calgb PATIENTS AND METHODS: CALGB 8541 assessed HER-2/neu expression in patients with ER-positive disease by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) and amplification by differential polymerase chain reaction (PCR). 11032587 Human
her-2/neu acinic cell adenocarcinoma Morphologic examinations of salivary gland neoplasias arising in male BALB/c (H-2d) mice carrying the activated HER-2/neu (BALB-NeuT) indicate that expression of the oncogene product in the ductal-acinar structures results in a very human-like acinic cell 11054659 Mouse
her-2/neu extra-adrenal pheochromocytomas Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. 11127918 Human
her-2/neu cyst Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
her-2/neu ductal hyperplasia Overall, HER-2/neu was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 30, 11 of 20 (55%), 10 of 15 (67%), and 12 of 15 (80%), respectively, with progressive increase in the intensity of staining; p53 was positive in 1 10029438 Human
her-2/neu ovarian carcinoma HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
her-2/neu prostate cancers HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
her-2/neu lobular carcinoma in situ Prognostic factors evaluated were age, histologic type of invasive tumor, presence of associated ductal and/or lobular carcinoma in situ, lesion size, histologic and nuclear grades, DNA index, presence of multiploidy by flow cytometric analysis, and immun 10349989 Human
her-2/neu ovarian papillary serous carcinoma HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. 10409445 Human
her-2/neu ovarian papillary serous carcinoma In this study we used fluorescent in situ hybridization (FISH) to determine HER-2/neu amplification in ovarian papillary serous carcinoma and compared the frequency of amplification in two stages of the disease. 10409445 Human
her-2/neu papillary serous ovarian carcinoma Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe. 10409445 Human
her-2/neu ovarian papillary serous carcinoma This study not only confirms the presence of a subset of ovarian papillary serous carcinoma with HER-2/neu gene amplification, but it also indicates that HER-2/neu oncogene amplification is more likely to be associated with a more advanced stage. 10409445 Human
her-2/neu breast cancer Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. 10502729 Human
her-2/neu metastasis Ki 67 and p34cdc2 proliferation marker overexpression, HER-2/neu oncogene amplification, large tumor size, high tumor grade, advanced tumor stage, positive lymph node status, and distant metastasis at the time of diagnosis predicted disease-related death 10510669 Human
her-2/neu lung cancer Biologic markers resulting from genetic lesions in lung cancer are grouped as follows: (a) oncogene amplification and overexpression (aberrant gene expression) and mutated tumor suppressor genes -- ras gene, myc gene, HER-2/neu and survivin gene, p53 and 11162866 Human
her-2/neu cancer Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
her-2/neu human breast cancers Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
her-2/neu advanced cancer Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. 11223076 Human
her-2/neu papillomatosis We investigated by immunohistochemistry expressions of topoisomerase alpha II, MIB-1, p53, p21, E-cadherin, retinoblastoma (RB) gene protein product, HER-2/neu, and steroid hormone receptors in a case of juvenile respiratory papillomatosis with malignant 11277421 Human
her-2/neu clear cell tumors Both endometrioid and clear cell tumors belonged to the largest subgroup with concomitant negativity for both HER-2/neu and EGFR. 11328410 Human
her-2/neu breast cancers The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. 11416960 Human
her-2/neu udh Increased proliferation (Ki67), overexpression of cyclin D1, HER-2/neu, p21 and p53, and decreased expression of bcl-2 and p27 could already be found in UDH. 11439365 Human
her-2/neu breast cancer In breast cancer amplification of the HER-2/neu oncogene and over-expression of the protein product is associated with poor prognosis, predicts response to some chemotherapeutic regimens and is the target for Herceptin treatment. 11455000 Human
her-2/neu pediatric osteosarcomas Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. 11505415 Human
her-2/neu pediatric osteosarcomas METHODS: The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (PathVysion, Vysis Inc., Downe 11505415 Human
her-2/neu pediatric osteosarcomas CONCLUSIONS: HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. 11505415 Human
her-2/neu testicular tumors PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
her-2/neu leydig cell tumor PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
her-2/neu adrenocortical neoplasms Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. 11556748 Human
her-2/neu malignant adrenocortical neoplasms HER-2/neu overexpression was not observed in any of the benign or malignant adrenocortical neoplasms. 11556748 Human
her-2/neu advanced stage cancer Interestingly, 90% of patients with advanced stage cancer (stage IIIB/IV NSCLC or extensive SCLC) overexpressed HER-2/neu. 11679181 Human
her-2/neu oropharyngeal squamous cell carcinoma Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. 11839675 Human
her-2/neu head-and-neck cancer The prognostic significance and clinical implications of HER-2/neu expression and amplification in head and neck cancer will require additional studies. 11839675 Human
her-2/neu primary carcinomas We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody). 11850540 Human
her-2/neu sporadic breast cancer To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we have performed fluorescence in situ hybridization on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation ca 11888924 Human
her-2/neu invasive breast cancer BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. 11893034 Human
her-2/neu burkitt's lymphoma After transfecting wild-type HER-2/neu or chimeric HER-2/CD19 into Raji Burkitt's lymphoma cells and wild-type CD19 or chimeric CD19/HER-2 into SK-BR-3 breast cancer cells, target cell lines were selected for high membrane expression of transfected A 11907082 Human
her-2/neu hodgkin lymphomas The aim of this study was to evaluate the expression of HER-2/neu in the malignant lymphomas: non-Hodgkin and Hodgkin lymphomas. 11958663 Human
her-2/neu hodgkin lymphomas CONCLUSIONS: Non-Hodgkin and Hodgkin lymphomas do not express the HER-2/neu oncoprotein. 11958663 Human
her-2/neu breast cancer HER-2/neu gene amplification and cell surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. 11986780 Human
her-2/neu papillary cancer Overexpression of HER-2/neu in uterine serous papillary cancer. 12006548 Human
her-2/neu bilateral breast cancer HER-2/neu expression in bilateral breast cancer has not been reported. 12058961 Human
her-2/neu noninvasive cancers Of the 21 paired specimens immunostained for HER-2/neu, 11 were invasive cancers in both breasts, nine were invasive cancers in one breast and noninvasive cancers in the other breast, and one was noninvasive cancers in both breasts. 12058961 Human
her-2/neu liver metastases HER-2/neu mRNA levels were significantly higher (P = 0.032) in tumors associated with liver metastases but not with tumor location or size. 12097278 Human
her-2/neu adenocarcinoma of the pancreas CONCLUSION: Her-2/neu overexpression detected by immunohistochemistry does not appear to be a poor prognostic factor in patients with adenocarcinoma of the pancreas. 12168842 Human
her-2/neu primary malignant brain tumors Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. 12168843 Human
her-2/neu primary brain tumors We retrospectively analyzed a large cohort of patients with primary brain tumors to evaluate the prognostic role of HER-2/neu overexpression and clinical characteristics at presentation in patients with shortened survival (< 6 months). 12168843 Human
her-2/neu primary brain tumor Interestingly, the presence of HER-2/neu overexpression was associated with a significantly increased risk of an associated second primary malignancy in addition to the primary brain tumor. 12168843 Human
her-2/neu primary brain tumors CONCLUSION: Her-2/neu overexpression was detected in 17% of patients with primary brain tumors, but, did not predict increased short-term mortality in patients with brain tumors surviving less than six months. 12168843 Human
her-2/neu malignant brain tumors Further studies are needed to specify whether certain tumor subtypes are more likely to overexpress HER-2/neu and to evaluate the role of HER-2/neu as a target for therapy in malignant brain tumors. 12168843 Human
her-2/neu germ-cell tumours CONCLUSIONS: The lack of concordance between IHC and FISH makes it unlikely that overexpression of the HER-2/neu protein in germ cell tumours is of prognostic or therapeutic relevance. 12194993 Human
her-2/neu adrenal tumors Expression of HER-2/neu receptor protein in adrenal tumors. 12234062 Human
her-2/neu adrenal adenomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2/neu adrenocortical carcinomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2/neu pheochromocytomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2/neu adrenocortical tumors From our data we conclude that specific and significant membranous immunostaining indicating strong overexpression (grade 3) of HER-2/neu protein is not present in adrenocortical tumors. 12234062 Human
her-2/neu hairy-cell leukemia Examples of new agents are: trastuzumab (Herceptin), a humanized monoclonal antibody that blocks the HER-2/neu proto-oncogene in combination with cytotoxic agents, is used in a percentage of breast cancer patients; signal transduction inhibitor of abl tyr 12375030 Human
her-2/neu familial breast cancer HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. 12412159 Human
her-2/neu primary malignancy METHODS: To determine whether a signet ring carcinoma was a primary malignancy of the gastrointestinal tract metastatic to the breast or vice versa, histochemical analysis was performed for Her-2/NEU, gross cystic disease fluid protein-15, estrogen recept 12464875 Human
her-2/neu chondrosarcomas [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
her-2/neu chondrosarcoma [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
her-2/neu breast cancer Amplification of gene HER-2/neu and overexpression of its gene product have been shown to have both prognostic and treatment implications in breast cancer. 12677894 Human
her-2/neu metastatic osteosarcoma Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed para 12544770 Human
her-2/neu breast cancer Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. 12653946 Human
her-2/neu salivary duct carcinoma CONCLUSIONS: In immunohistochemistry, over-expression of HER-2/neu protein was identified as distinct membrane staining in most carcinoma cells in all our salivary duct carcinoma cases, while only four cases revealed an amplification of HER-2/neu gene by 12653946 Human
her-2/neu mfh CS, MFH, and DFS specimens showed the highest incidence of HER-2/neu overexpression (40%, 26%, and 18.2%, respectively). 12714894 Human
her-2/neu breast cancer The amplification and/or overexpression of the HER-2/neu oncogene and its encoded receptor protein are increasingly used for prognostication and prediction of therapeutic response to Herceptin in breast cancer. 12733117 Human
her-2/neu atypical hyperplasia Within 33 weeks of life, all 10 mammary glands of virgin BALB/c mice transgenic for the transforming rat HER-2/neu oncogene under the mammary tumor virus promoter (BALB-neuT mice) progress from atypical hyperplasia to invasive palpable carcinoma. 12750275 Mouse
her-2/neu rhabdomyosarcoma Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. 12782574 Mouse
her-2/neu rhabdomyosarcoma We show that activation of the HER-2/neu oncogene coupled with inactivation of the oncosuppressor gene p53 causes rhabdomyosarcoma in mice. 12782574 Mouse
her-2/neu inclusion cyst In both the ovarian surface and inclusion cyst epithelia, the percentage of cells was determined that stained positively for Ki67, p21, p27, p53, cyclin A, cyclin D1, bcl-2 and the presence of HER-2/neu, oestrogen (ER-alpha) and progesterone receptors (PR 12823709 Human
her-2/neu stage iii nsclc Overexpression of HER-2/neu in tumor tissues was found in 70% (23 of 32) of patients with MPE-associated ADCLC, 30% (13 of 43) with stage I/II non-small cell lung cancer (NSCLC), and 44% (14 of 32) with stage III NSCLC. 12855637 Human
her-2/neu thymic epithelial tumours Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. 12877732 Human
her-2/neu thymic epithelial tumours AIMS: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF,1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether 12877732 Human
her-2/neu thymic carcinomas Nine thymic carcinomas revealed membranous positivity for HER-2/neu, but no HER2 gene amplification could be demonstrated by FISH in any of the cases. 12877732 Human
her-2/neu methylcholanthrene-induced sarcomas In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu tr 12867593 Human
her-2/neu pituitary carcinoma Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. 12924717 Human
her-2/neu pituitary carcinomas The results indicate that low-level amplification of the HER-2/neu gene might be associated with pituitary carcinomas in which more aggressive behavior is seen. 12924717 Human
her-2/neu pituitary carcinoma Further studies are needed to determine whether HER-2/neu plays a role in the pathogenesis of pituitary carcinoma. 12924717 Human
her-2/neu teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
her-2/neu mixed germ cell tumors PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
her-2/neu mixed tumors Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
her-2/neu choriocarcinoma Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
her-2/neu teratoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
her-2/neu choriocarcinoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
her-2/neu medullary carcinoma of breast CONCLUSIONS: Medullary carcinoma of breast is distinct from AMC and HGIDC with prominent lymphocytic infiltrates in amplification and overexpression of HER-2/neu. 14567723 Human
her-2/neu extensive stage small cell lung carcinoma Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. 14581360 Human
her-2/neu extensive-stage small-cell lung cancer PURPOSE: The aim of this study was to evaluate the relationship, if any, between pesticide exposure and overexpression of the HER-2/neu oncoprotein in extensive stage small cell lung cancer (ESSCLC). 14581360 Human
her-2/neu invasive cervical carcinoma The aim of this study was to investigate HER-2/neu (c-erbB2) overexpression/amplification in carcinoma of the uterine cervix using immunohistochemistry and fluorescent in situ hybridization (FISH) to assess whether anti-p185c-erbB2 therapy might have pote 14668544 Human
her-2/neu invasive cervical carcinoma Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients. 14668544 Human
her-2/neu ovarian tumor Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. 14625284 Human
her-2/neu cartilaginous tumors Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors. 14767542 Human
her-2/neu cartilaginous tumors To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. 14767542 Human
her-2/neu mesenchymal chondrosarcomas To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. 14767542 Human
her-2/neu cartilaginous tumors In conclusion, the amplification and overexpression of the HER-2/neu oncogene is absent or at least very rare in malignant cartilaginous tumors. 14767542 Human
her-2/neu cartilaginous tumor The level of expression of HER-2/neu was similar in all cartilaginous tumor types. 14767542 Human
her-2/neu gynecologic cancers There is increasing levels of evidence suggesting that some circulating factors involved in gynecologic cancers, such as alpha-fetoprotein (AFP), insulin-like growth factor binding protein-3 (IGFBP-3), c-erbB-2 (HER-2/neu), and epidermal growth factor (EG 15051037 Human
her-2/neu salivary gland cancer Several molecular targets (c-kit, HER-2/neu, androgen receptors) have been identified in salivary gland cancer. 15069319 Human
her-2/neu breast carcinoma In breast carcinoma, HER-2/neu gene amplification and receptor protein overexpression are tightly correlated and have prognostic and therapeutic implications. 15072912 Human
her-2/neu recurrent epithelial ovarian cancer A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. 15131023 Human
her-2/neu recurrent epithelial ovarian cancer A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. 15131034 Human
her-2/neu small-cell carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
her-2/neu papillary serous carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
her-2/neu uterine papillary serous carcinoma Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. 15284264 Human
her-2/neu germ-cell testicular tumors Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. 15330164 Human
her-2/neu testicular germ-cell tumors However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. 15330164 Human
her-2/neu testicular teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
her-2/neu teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
her-2/neu choriocarcinoma With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). 15330164 Human
her-2/neu testicular germ-cell tumors CONCLUSION: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. 15330164 Human
her-2/neu ovarian clear cell adenocarcinoma Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. 15350366 Human
her-2/neu ovarian clear cell adenocarcinoma OBJECTIVE: To evaluate the significance of the expression of HER-2/neu as a prognostic factor, we retrospectively examined its overexpression rates chiefly in ovarian clear cell adenocarcinoma (CCA) and their relationships with FIGO stage, lymph node meta 15350366 Human
her-2/neu hematologic malignancies In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu 15487459 Human
her-2/neu gallbladder cancers Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. c-erbB-2, proto-oncogene is amplified and overexpressed in a number of human adenocarcinomas. 15010878 Human
her-2/neu gallbladder cancer To investigate the therapeutic effect of Trastuzumab in gallbladder cancer, we studied HER-2/neu expression in 43 primary tumors, 12 metastatic lymph nodes and two liver metastasis, using the Hercep test. 15010878 Human
her-2/neu primary carcinoma This increased to 100% if the primary carcinoma was larger than 5 cm, if it was poorly differentiated, or if it showed HER-2/neu gene amplification. 15327491 Human
her-2/neu oral squamous-cell carcinoma (oscc) OBJECTIVES: Amplification of the proto-oncogene c-erbB-2 (HER-2/neu) has been shown to be a prognostic marker in many kinds of cancer including oral squamous cell carcinoma (OSCC). 15482324 Human
her-2/neu large-cell lymphoma Single reports mention HER-2/neu positivity in hematological malignancies like Hodgkins's disease and even diffuse large-cell lymphoma. 15510616 Human
her-2/neu large-cell lymphoma From those lymphoma patients, the paraffin-embedded lymph-node specimens of 25 cases with diffuse large-cell lymphoma were stained with the HER-2/neu DAKO HercepTest. 15510616 Human
her-2/neu large-cell lymphoma No patient with diffuse large-cell lymphoma showed HER-2/neu overexpression by immunhistochemistry of the lymph node. 15510616 Human
her-2/neu large-cell lymphoma CONCLUSION: HER-2/neu is not overexpressed in non-Hodgkin's lymphoma and especially not in diffuse large-cell lymphoma, using a standardized immunochemistry technique with complementary serum testing. 15510616 Human
her-2/neu non-small cell carcinomas (nsclc) Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
her-2/neu neuroendocrine tumours Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
her-2/neu neuroendocrine tumours Irrespective of protein overexpression, HER-2/neu gene amplification is rare in lung cancer and studies on its prevalence and clinicopathological implications in early stage non-small cell lung cancer (NCSLC) and neuroendocrine tumours (NET) of the lung a 15386424 Human
her-2/neu stage i nsclc We evaluated HER-2/neu abnormalities in 345 Stage I NSCLC and 207 Stage I-III NET of the lung of all the diverse histological types, by using immunohistochemistry and fluorescent in situ hybridization in selected cases. 15386424 Human
her-2/neu large-cell neuroendocrine carcinoma (lcnec) Gene amplification was seen in only 7 (7.4%) of the immunoreactive tumours, with high-level amplification (HER-2/neu gene to chromosome 17 ratio > 4.0) in 3 adenocarcinomas, 1 squamous-cell carcinoma and 1 large-cell neuroendocrine carcinoma (LCNEC), and 15386424 Human
her-2/neu lung carcinomas HER-2/neu gene amplification and protein overexpression are not closely correlated in lung carcinomas and do not bear any prognostic implication. 15386424 Human
her-2/neu neuroendocrine tumours Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression. 15386424 Human
her-2/neu rhabdomyosarcoma We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. 15548714 Mouse
her-2/neu salivary-gland carcinomas We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. 15548714 Human
her-2/neu primary malignancies Also, there was a higher incidence of associated primary malignancies (outside the CNS) in the HER-2/neu overexpression group (30% vs. 7%). 15565811 Human
her-2/neu metastatic pancreatic cancers Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. 15581051 Human
her-2/neu metastatic pancreatic adenocarcinomas PURPOSE: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. 15581051 Human
her-2/neu metastatic pancreatic cancer METHODS AND MATERIALS: Patients with metastatic pancreatic cancer with 2+/3 + HER-2/neu expression by immunohistochemistry were eligible. 15581051 Human
her-2/neu epithelial neoplasms Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. 15581965 Human
her-2/neu serous carcinomas RESULTS: FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. 15581965 Human
her-2/neu clear-cell carcinoma None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; 15581965 Human
her-2/neu uterine sarcomas BACKGROUND: The aim of this study was to determine ERBB-2 (HER-2/neu) gene alterations in different subtypes of uterine sarcomas. 15581967 Human
her-2/neu carcinoma ex-pleomorphic adenoma Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. 15693886 Human
her-2/neu cystic hypersecretory carcinoma of breast Report of five cases] OBJECTIVE: To describe a poorly recognized histological and immunohistochemical features of cystic hypersecretory carcinoma of breast, including the overexpression of HER-2/neu protein and androgen receptors. 15779300 Human
her-2/neu metastatic pancreatic adenocarcinomas Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p5 15725808 Human
her-2/neu malignant gliomas DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas. 15809708 Human
her-2/neu metachronous cancers Concordance of the hormone receptors and correlation of her-2/neu overexpression of the metachronous cancers of contralateral breasts. 15871703 Human
her-2/neu first primary cancer The primary objective of this study was to evaluate the relative prevalence of estrogen receptor-negative contralateral breast cancer to the first primary cancer and to assess the correlation between the relative overexpression of HER-2/neu in the first p 15871703 Human
her-2/neu first primary cancer The correlation between HER-2/neu overexpression in the matched first primary and contralateral breast cancers was statistically significant, suggesting that the diagnosis of HER-2/neu overexpression in contralateral breast cancer is associated with HER-2 15871703 Human
her-2/neu carcinosarcoma It still needs to be clarified whether HER-2/neu overexpression increases the aggressiveness of carcinosarcoma, or whether HER-2/neu has a direct role in its pathogenesis, as described in breast cancers. 15901136 Human
her-2/neu uterine carcinosarcoma Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of 15901136 Human
her-2/neu mucinous carcinoma of the breast Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. 15960065 Human
her-2/neu mucinous carcinoma Compared with the non-mucinous type, mucinous carcinoma specimens have more DCC expression (100% vs 48.7%; p = 0.0027) and more ER expression (90.9% vs 26.9%; p = 0.0023), but less HER-2/neu overexpression (0% vs 38.1%; p = 0.0302). 15960065 Human
her-2/neu large-cell neuroendocrine carcinoma Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic 16014119 Human
her-2/neu ovarian serous carcinomas An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. 16006797 Human
her-2/neu endometrial cancer A novel in vivo model of tamoxifen-stimulated endometrial cancer was developed and the role of HER-2/neu investigated by using trastuzumab. 16166331 Human
her2 squamous cell carcinoma of the uterine cervix ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. 7905784 Human
her2 metastatic tumor Elevated levels of circulating HER2 ECD were associated with the expression of HER2 in the primary tumor tissue and with the metastatic tumor burden (evaluated with the marker CA 15-3; P = 0.032 and P = 0.002, respectively) but not with variables such as 10873087 Human
her2 colorectal tumour The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24 colorectal tumour cell lines that endogenously overexpressed HER2 / neu. 11139320 Human
her2 stage iii nsclc In conclusion, this study did not demonstrate that expression of NE markers, p53 and HER2 were predictive of response to chemotherapy, combined chemotherapy/radiation or for survival in this group of patients with stage III NSCLC. 11551406 Human
her2 skeletal ewing's sarcoma Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. 11895910 Human
her2 apocrine breast carcinomas We analyzed the histopathological characteristics and tumor biology of apocrine breast carcinomas with regard to histological grade, p53, HER2, bcl-2, MIB-1 and hormone receptor status. 12196721 Human
her2 pnet MATERIALS: To investigate whether HER2 might be a rational target for ES/PNET therapy, five ES cell lines and 13 archival primary ES/PNET samples were examined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for evidence of HER 12794524 Human
her2 pnet CONCLUSIONS: These results suggest that HER2 is not a biologically or therapeutically important pathway in ES/PNET. 12794524 Human
her2 brain metastases Targeting HER2 in brain metastases from breast cancer. 14654521 Human
her2 salivary-gland carcinomas HER2 expression in salivary gland carcinomas: dependence on histological subtype. 14871971 Human
her2 salivary gland cancers PURPOSE: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. 14871971 Human
her2 salivary gland cancer As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened 137 tumors for HER2 expression. 14871971 Human
her2 malignant lung tumors Overexpression of EGFR and HER2 is frequently found in non-small-cell lung cancer (NSCLC), which accounts for over 80% of all malignant lung tumors, and has been associated with a worse clinical outcome. 15032719 Human
her2 lipid-rich carcinomas The incidence of HER2 overexpression (33% and 50%, respectively) and gene amplification (25% and 33%, respectively) among glycogen-rich and lipid-rich carcinomas was not higher than that observed in breast cancer generally. 15049898 Human
her2 apocrine breast carcinomas CONCLUSION: Our data suggest that preferential involvement of the HER2 gene in micropapillary and apocrine breast carcinomas may contribute to their aggressive behaviour. 15049898 Human
her2 metastatic melanoma Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence. 15179190 Human
her2 bronchioloalveolar carcinoma Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 15167937 Human
her2 bronchioloalveolar carcinoma In this study, we investigated the prognostic value of HER2/neu, p53, and vascular endothelial growth factor in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 15167937 Human
her2 bronchioloalveolar carcinoma In the bronchioloalveolar carcinoma, HER2/neu, p53, and vascular endothelial growth factor were expressed in 9/50 (18%), 3/50 (6%) and 12/50 (24%), respectively which was significantly less than in conventional adenocarcinoma (P < 0.05). 15167937 Human
her2 bronchioloalveolar carcinoma Also, in conventional adenocarcinoma, p53, and HER2/neu expression appeared to be poor prognostic markers, while in bronchioloalveolar carcinoma, only HER2/neu was associated with a poorer prognosis. 15167937 Human
her2 astrocytomas The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. 15328518 Human
her2 adult acute lymphoblastic leukemia Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. 15531467 Human
her2 stage ii colon cancer Expression of Vascular Endothelial Growth Factor and HER2/neu in Stage II Colon Cancer and Correlation with Survival. 15555209 Human
her2 adenocarcinomas of the colon Overexpression of the HER2/neu oncogene and VEGF has been reported to occur in adenocarcinomas of the colon. 15555209 Human
her2 stage ii colon cancer Assessing whether HER2/neu and VEGF overexpression could serve as prognostic indicators for stage II colon cancer may provide insight into optimal treatment following surgery. 15555209 Human
her2 stage ii colon cancer Demographic and tumor characteristics from 109 patients diagnosed with stage II colon cancer between 1991 and 1996 were assessed for HER2/neu and VEGF expression using immunohistochemical staining techniques. 15555209 Human
her2 stage ii colon cancer Our results do not support an association between HER2/neu or VEGF expression and overall survival or time to recurrence in stage II colon cancer. 15555209 Human
her2 tumor Promising approaches and molecular markers include gene expression profiles, DNA ploidy, loss of heterozygosity and chromosomal aberrations as detected by CGH and FISH (1q, 17p, 17q), as well as oncogenes/ tumor suppressor genes and their proteins (TP53, 15624758 Human
her2 squamous cell carcinoma of the larynx Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. 15592685 Human
her2 larynx tumors The low frequency of amplification of HER2 oncogene in larynx tumors showed that the mechanism responsible for the high level of receptor overexpression still remains unclear in the majority of cases. 15592685 Human
her2 colorectal tumors Using this approach, we found that HER2 and MMP7 may be down-regulated during distal dissemination of colorectal tumors. 15613710 Human
her2 ovarian adenocarcinomas Genomic analysis of primary tumors revealed HER2 gene amplification and overexpression in breast and ovarian adenocarcinomas and demonstrated strong correlation with poor prognosis. 15687589 Human
her2 vulvar paget's disease We evaluated p186Her2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease. 15272283 Human
her2 papillary cancer Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. 15746676 Human
her2 recurrent prostate cancer Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth. 15755991 Human
her2 recurrent prostate cancer We show that heregulin activates HER2 and HER3 and increases androgen-dependent AR transactivation of reporter genes in CWR-R1 cells. 15755991 Human
her2 recurrent prostate cancer CONCLUSIONS: These data indicate that heregulin signaling through HER2 and HER3 increases AR transactivation and alters growth in a recurrent prostate cancer cell line. 15755991 Human
her2 metastatic pancreatic adenocarcinomas Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0% 15725808 Human
her2 metastatic squamous cell carcinomas Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. 15809707 Human
her2 metastatic squamous cell carcinoma HER2, HER3, and HER4 were evaluated by immunohistochemistry in 19 cases of metastatic squamous cell carcinoma of the oral cavity and base of tongue. 15809707 Human
her2 breast cancer HER2 amplification and/or overexpression in breast cancer are adverse prognostic factors and can predict the response to trastuzumab therapy. 15809766 Human
her2 ovarian adenocarcinoma Exposure of 11,11'-dideoxy-verticillin for 1 h to EGFR-overexpressed MDA-MB-468 human breast carcinoma cells and HER2-overexpressed SK-OV-3 human ovarian adenocarcinoma cells resulted in obvious inhibition of EGF-induced phosphorylation of EGFR and H 15846117 Human
her2 metaplastic breast carcinoma Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. 15868445 Human
her2 ewing's sarcoma Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. 15913990 Human
her2 gist To determine whether known oncogenes take part in genomic rearrangements and to investigate the potential clinical significance of their amplifications, nine known oncogenes (CMYC, MDM2, GLI1, CDK4, HER2, EGFR1, CCND1, FGF3, EMS) were analyzed by fluoresc 15864317 Human
her2 cancers of the liver This pathway is a general signal, as it was also observed in cell lines in which Erk-primed inactivation of GSK-3beta was regulated by IGF-1, TGF-beta, and receptor tyrosine kinase HER2, and is further supported by immunohistochemical staining in differen 16039586 Human
her2 chordomas OBJECTIVE: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. 16103303 Human
her2 chordomas RESULTS: Most chordomas displayed strong expression of EGFR and c-Met, whereas a variable level of expression of HER2/neu was seen. 16103303 Human
her2 chordomas CONCLUSIONS: Chordomas, like many other solid-tissue tumors, express HER2/neu, EGFR, and the hepatocyte growth factor/scatter factor receptor c-Met. 16103303 Human
her2 breast cancer Background: HER2 overexpression/amplification has been reported to be a predictor of prognosis in breast cancer and a potential marker for selecting the optimal adjuvant chemotherapy. 16137437 Human
neu glioblastomas A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185). 6095109 Rat
neu glioblastomas The neu oncogene is repeatedly activated in neuro- and glioblastomas derived by transplacental mutagenesis of the BDIX strain of rat with ethylnitrosourea. 3945311 Rat
neu gliomas The normal cellular neu sequence for the transmembrane region, but not the mutated sequence, was identified in DNA from all 11 gliomas surveyed by oligonucleotide hybridization. 3476947 Rat
neu fibrocystic breast We have examined the genomic organisation of c-myc, N-myc, L-myc, neu and N-ras in tissue from 41 breast carcinomas, lymph node metastases from 10 of these carcinomas, one fibrosarcoma, 10 cases of benign fibrocystic breast and six fibroadenomas. 3330785 Human
neu tumor of the peripheral nervous system Polymerase chain reaction (PCR) analysis indicated that RT4-AC cells established from a tumor of the peripheral nervous system contain an activated neu gene with a T----A transversion in the transmembrane domain. 1702412 Human
neu tumors of the nervous system The activated neu gene was detected in tumors of the nervous system that arose in mice following transplacental exposure to N-ethyl-N-nitrosourea. 1685444 Mouse
neu leiomyosarcomas We studied neu mRNA expression by slot blot analysis and protein product expression by capture ELISA and immunohistochemistry in 57 primary and metastatic ovarian neoplasms, two paraovarian leiomyosarcomas, and eight normal ovaries. 1353878 Human
neu stromal tumors Epithelial ovarian tumors had significantly higher amounts of the neu oncogene product as determined by capture ELISA than either germ cell and stromal tumors or normal ovaries (p less than 0.025). 1353878 Human
neu squamous cell carcinoma of the uterine cervix ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. 7905784 Human
neu salivary gland tumours Prompted by recent findings on the amplification of c-erbB-2 (HER-2, neu) oncogene in salivary gland tumours, the present study was conducted to analyse the expression of c-erbB-2 in both benign and malignant salivary gland tumours, with special emphasis 7915830 Human
neu malignant salivary gland tumours Prompted by recent findings on the amplification of c-erbB-2 (HER-2, neu) oncogene in salivary gland tumours, the present study was conducted to analyse the expression of c-erbB-2 in both benign and malignant salivary gland tumours, with special emphasis 7915830 Human
neu benign tumours Transcripts coding for transcription factors (RB, P53, FOS, MYC, MYB, ERBA, REL), growth factors (FGF1, FGF2, INT2, TGFA, TGFB, PDGF, IGF1, IGF2), interleukins, (IL1, IL2, IL3, IL4, IL6, TNF), growth-factor receptors or cytosolic protein kinases (RAF, PIM 7768644 Human
neu carcinomas in situ of the breast The expression of hormone receptors (estrogen and progesterone), c-erb-B2 (neu), p53, and Ki-67) was studied by immunohistochemical analysis in a series of 94 carcinomas in situ of the breast. 9388058 Human
neu tumour infiltrating lymphocytes Some of the parameters investigated (tumour size, histologic and nuclear grade, tumour infiltrating lymphocytes, p53 and Ki 67) were found to be influenced by age, some (necrosis and oestrogen receptors) were influenced by menopausal status and/or age, so 14965755 Human
neu colorectal tumour The CTLs showed cytotoxic activity against not only the peptide-pulsed target cells but also HLA-A24 colorectal tumour cell lines that endogenously overexpressed HER2 / neu. 11139320 Human
neu skeletal ewing's sarcoma Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. 11895910 Human
neu malignant schwannomas Conversely, at least one genetic pathway in rodents involving point mutation in the coding region of a transforming gene (neu in malignant schwannomas) does not appear to operate in any human tumors. 15313589 Mouse
neu metastatic melanoma Our findings suggest that drugs that specifically target Her2/neu are not likely to be useful for the treatment of metastatic melanoma or as adjuvant therapy for melanoma patients at high risk for recurrence. 15179190 Human
neu mouse tumor We investigated the feasibility of using N-terminal rat neu DNA immunization on mouse tumor overexpressing endogenous p185neu and enhancing the therapeutic efficacy of this vaccine by fusion to various cytokine genes, including interleukin-2 (IL-2), inter 15294176 Mouse
neu bronchioloalveolar carcinoma Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 15167937 Human
neu bronchioloalveolar carcinoma In this study, we investigated the prognostic value of HER2/neu, p53, and vascular endothelial growth factor in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. 15167937 Human
neu bronchioloalveolar carcinoma In the bronchioloalveolar carcinoma, HER2/neu, p53, and vascular endothelial growth factor were expressed in 9/50 (18%), 3/50 (6%) and 12/50 (24%), respectively which was significantly less than in conventional adenocarcinoma (P < 0.05). 15167937 Human
neu bronchioloalveolar carcinoma Also, in conventional adenocarcinoma, p53, and HER2/neu expression appeared to be poor prognostic markers, while in bronchioloalveolar carcinoma, only HER2/neu was associated with a poorer prognosis. 15167937 Human
neu anaplasia Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. 15328518 Human
neu astrocytoma Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. 15328518 Human
neu astrocytomas The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. 15328518 Human
neu adult acute lymphoblastic leukemia Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. 15531467 Human
neu adenosquamous carcinomas RESULTS: On the basis of the expression of terminal differentiation markers, three types of neoplasm were identified: first, simple carcinomas composed exclusively of cells with a luminal phenotype are characteristic of neoplasms arising in mice transgeni 15535849 Human
neu papillary adenocarcinomas In sharp contrast, EMT was not detected in papillary adenocarcinomas arising in BALB/cJ mice, spontaneous adenoacanthomas, neoplasms associated with MMTV-infection, or in neoplasms arising in mice transgenic for Neu and Wnt1. 15535849 Human
neu stage ii colon cancer Expression of Vascular Endothelial Growth Factor and HER2/neu in Stage II Colon Cancer and Correlation with Survival. 15555209 Human
neu adenocarcinomas of the colon Overexpression of the HER2/neu oncogene and VEGF has been reported to occur in adenocarcinomas of the colon. 15555209 Human
neu stage ii colon cancer Assessing whether HER2/neu and VEGF overexpression could serve as prognostic indicators for stage II colon cancer may provide insight into optimal treatment following surgery. 15555209 Human
neu stage ii colon cancer Demographic and tumor characteristics from 109 patients diagnosed with stage II colon cancer between 1991 and 1996 were assessed for HER2/neu and VEGF expression using immunohistochemical staining techniques. 15555209 Human
neu stage ii colon cancer Our results do not support an association between HER2/neu or VEGF expression and overall survival or time to recurrence in stage II colon cancer. 15555209 Human
neu papillary cancer Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. 15746676 Human
neu metastatic pancreatic adenocarcinomas Significantly more (P < 0.05) metastatic pancreatic adenocarcinomas were positive for CK20 (76%), p53 (60%), TAG-72 (88%), mCEA (92%), HER2/neu (40%), and mesothelin (64%) and showed loss of Dpc4 (44%), in comparison to BDA (CK20, 40%; p53, 0%; TAG-72, 0% 15725808 Human
neu metaplastic breast carcinoma Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. 15868445 Human
neu chordomas OBJECTIVE: To examine the expression of c-Met, c-Erb-b2 (HER2/neu), and epidermal growth factor (EGFR) in a cohort of 12 chordomas, based on the current and future availability of targeted molecular inhibitors. 16103303 Human
neu endometrial tumors RESULTS: There was no difference in the distribution of COX-2, p53, and neu positive cases according to ER or PR positivity, while the percentage of ki67 positive endometrial tumors was significantly higher in ER negative versus ER positive tumors (54.5% 15979129 Human
neu metastatic endometrial cancer Our findings provide the rationale to design trials based on the combination of antihormones with inhibitors of COX-2 and neu in recurrent/metastatic endometrial cancer. 15979129 Human
the neu gene glioblastomas The c-erb-B-2 gene is conserved in vertebrates and it has been suggested that the neu gene, detected in a series of rat neuro/glioblastomas, is, in fact, the rat c-erb-B-2 gene. 3003577 Rat
the neu gene neural tumor Point mutation of the neu gene in rat neural tumor RT4-AC cells: suppression of tumorigenicity by s-Myc. 1702412 Rat
the neu gene schwannomas With the use of the polymerase chain reaction and allele-specific oligonucleotide hybridization, DNA isolated from individual myotubes was analyzed for the presence of a T----A transversion mutation at nucleotide 2012 of the neu gene, which is diagnostic 1683842 Rat
the neu gene schwannomas With the use of the polymerase chain reaction and allele-specific oligonucleotide hybridization, DNA isolated from individual myotubes was analysed for the presence of a T-->A transversion mutation at nucleotide 2007 of the neu gene, which is diagnostic o 7695496 Rat
the neu protein non-small cell carcinoma The neu protein product (p185neu) was present in eight of 22 non-small cell carcinoma cell lines derived from human lung tumors. 1967224 Human
the neu protein gastrointestinal carcinomas We report on our experience investigating the serum levels of the soluble domain of p185 and the neu protein expression in the corresponding tumour tissue in patients with advanced gastrointestinal carcinomas. 8576278 Human
neu proliferative fibrocystic diseases Five fibroadenomas, one benign variant of phylloid tumor, one carcinosarcoma, and one of two proliferative fibrocystic diseases of the breast showed lacking or normal baseline expression of the neu oncogene, as did one monomorphous cystadenolymphoma of th 1672262 Human
erbb2 tumourbearing We report that transgenic tumour-bearing mice, like some breast cancer patients erbB2 + X, develop anti-neu autoimmune responses, which can be boosted and skewed to a Th1 phenotype by DNA immunization. 9875670 Mouse
neu early stage cervical cancer CONCLUSIONS: Early stage cervical cancer may develop a population of HER-2/neu-positive cells with a selective growth advantage over HER-2/neu-negative cells. 14529687 Human
c-erb b2 uterine cervical cancer We examined HPV DNA typing and its gene expression, oncogenes (c-myc, EGF-R, c-erb B2) and p53 in cervical dysplasia and cancer with molecular biologic, immunohistochemical technique and binding assay to establish a gene diagnosis of uterine cervical canc 7909855 Human
c-erb b2 acquired cystic disease [Immunohistochemical study in acquired cystic disease of the kidney--expression of vimentin, epidermal growth factor, epidermal growth factor receptor and c-erb B2 gene product] Acquired cystic disease of the kidney (ACDK) reveals abnormal epithelial cell 8105122 Human
c-erb b2 posterior tongue tumors BACKGROUND AND OBJECTIVES: Expression of a panel of biomarkers, such as p53, Bcl-2, Cyclin D1, c-myc, p21ras, c-erb B2, cytokeratin-19 (CK-19), and factor VIII-related antigen (FVIII-RA), was studied together in anterior tongue tumors from the oral cavity 12501167 Human
c-erb b2 hepatocellular carcinoma Neither overexpression nor amplification of c-erb B2 (Her2/ ) can be regarded as a useful prognostic factor in hepatocellular carcinoma. 12373150 Human
c-erb b2 cyst In order to evaluate the growth and/or proliferative capabilities of cyst epithelia, epidermal growth factor (EGF), epidermal growth factor receptor (EGFR) and c-erb B2 gene product were determined in cyst epithelia, adenoma and adenocarcinoma. 8105122 Human
her2 autosomal recessive polycystic kidney disease Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease. c-ErbB2 (also referred to as Neu or HER2), a transmembrane glycoprotein with intrinsic tyrosine kinase activity, is structurally related to epidermal growth factor 11158230 Human
her 2 colon tumors HER 2/neu gene copy number was measured in 154 primary colon tumors, 15 liver metastases and matched normal tissues using a quantitative PCR/ligase detection reaction (LDR) technique developed and validated in our laboratory. 12767065 Human
neu germ-cell cancer Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. 10631474 Human
neu tumorinfiltrating lymphocytes To evaluate candidates for immunotherapy using HER-2/neu-derived, HLA-A2-restricted peptides, we examined the frequency of HLA-A2 relating to HER-2/neu overexpression or the infiltrating grade of tumor-infiltrating lymphocytes (TILs) in Japanese patients 11857411 Human
c-erb b-2 cysts Gene amplification (overexpression) of c-erb B-2 was tested in a variety of cystic renal diseases, renal cell neoplasms (adenomas and carcinomas) and end stage kidneys without cysts. 1686289 Human
c-erb b-2 cyst Three cystic disorders revealing c-erb B-2 overexpression also showed platelet-derived growth factors (PDGFs) expression in similar locations (cyst lining and adjacent tubules). 1686289 Human
c-erb b-2 transitional cell carcinoma of the urinary bladder Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. 1688050 Human
erbb2 adult glioblastomas Seventeen untreated primary adult glioblastomas were analyzed using immunocytochemistry for the expression of EGF-R, c-neu/erbB2, TGF-alpha, and phosphotyrosine. 7507162 Human
her2 stage ii breast cancers Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. 1349163 Human
her2 head and neck tumors No amplification or structural alterations of proto-oncogenes c-erbB-2/HER2, c-myc, H-ras-1, or K-ras-2 was detected in any of the head and neck tumors. 2193294 Human
neu ductal carcinomas in situ None of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type had neu overexpression. 2903446 Human
neu glioblastomas The c-erb-B-2 gene is conserved in vertebrates and it has been suggested that the neu gene, detected in a series of rat neuro/glioblastomas, is, in fact, the rat c-erb-B-2 gene. 3003577 Rat
neu thyroid tumours Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. 3390372 Human
neu adenoma The c-erbB2/neu and c-erbB oncogenes showed two- to three-fold higher levels of RNA in papillary carcinomas and lymph node metastases as well as in one adenoma when compared to non-tumour tissue. 3390372 Human
neu papillary carcinomas The c-erbB2/neu and c-erbB oncogenes showed two- to three-fold higher levels of RNA in papillary carcinomas and lymph node metastases as well as in one adenoma when compared to non-tumour tissue. 3390372 Human
neu papillary carcinomas of the thyroid We suggest that the epidermal growth factor or other ligands for the c-erbB and c-erbB2/neu receptors may contribute to the development and/or maintenance of the malignant phenotype of papillary carcinomas of the thyroid. 3390372 Human
neu familial cancer Preliminary studies indicate a lack of overexpression of the HER-2/neu oncogene in the familial cancer members' tumors. 7903948 Human
neu lung tumors Patients whose lung tumors contain K-ras oncogene mutation, accumulation of the protein product of the tumor suppressor gene p53, or erbB-2/neu oncoprotein overexpression have been shown to have a worse prognosis. 7905543 Human
neu clear cell tumors A significant increase was found in 3+ expression of HER-2/neu in clear cell tumors. 7906607 Human
neu thyroid carcinomas [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma] Amplification of oncogenes erbb-2, erbb-1, c-myc and losses of heterozygosity (LOH) at c 8103188 Human
neu node-negative breast cancer In node-negative breast cancer patients, the subgroup for which accurate prognostic data could make a significant contribution to treatment decisions, the prognostic utility of HER-2/neu amplification and/or overexpression has been controversial. 8104689 Human
neu endocrine tumors CONCLUSIONS. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. 1353638 Human
neu ovarian epithelial neoplasms BACKGROUND. It is unclear whether HER-2/neu proto-oncogene expression in ovarian epithelial neoplasms is related to prognosis. 1360327 Human
neu follicular adenomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
neu follicular carcinomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
neu head and neck tumors Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 1672262 Human
neu schwannomas With the use of the polymerase chain reaction and allele-specific oligonucleotide hybridization, DNA isolated from individual myotubes was analyzed for the presence of a T----A transversion mutation at nucleotide 2012 of the neu gene, which is diagnostic 1683842 Rat
neu neural tumor Point mutation of the neu gene in rat neural tumor RT4-AC cells: suppression of tumorigenicity by s-Myc. 1702412 Rat
neu metaplasia In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
neu metastases Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. c-erbB-2 gene amplification and protein over-expression we 1977466 Human
neu primary tumours Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. c-erbB-2 gene amplification and protein over-expression we 1977466 Human
neu adh Cases of ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) of the breast were examined for expression of the protein product of the c-erbB-2 (neu, HER-2) oncogene using two different polyclonal antibodies via an avidin-biotin immunoper 2170971 Human
neu gastric tumors Using the modified DNA in-gel renaturation assay to detect down to 7-8 copies of amplified DNA sequences, we identified 3 gastric tumors with amplified DNA sequences and confirmed by Southern hybridization analysis that HER-2/neu was amplified greater tha 2400999 Human
neu gastric adenocarcinomas Immunohistochemical staining of tumor tissue sections with p185 HER-2/neu antibodies demonstrated that only the 3 gastric adenocarcinomas with corresponding HER-2/neu gene amplification displayed membrane immunoreactivity. 2400999 Human
her-2 wilms' tumor In contrast, expression of the EGFR-related protooncogene HER-2 (erbB-2) was found to be decreased in 11 RCCs and one Wilms' tumor; HER-2 gene structure, however, appeared normal in all specimens. 2572319 Human
her-2 familial cancer Preliminary studies indicate a lack of overexpression of the HER-2/neu oncogene in the familial cancer members' tumors. 7903948 Human
her-2 clear cell tumors A significant increase was found in 3+ expression of HER-2/neu in clear cell tumors. 7906607 Human
her-2 parotid gland tumors erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors. 8102855 Human
her-2 tumors of the parotid gland In the present study, 21 tumors of the parotid gland were examined by Southern and Northern blot hybridization for amplification and possible overexpression of the erbB-2/Her-2 oncogene. 8102855 Human
her-2 pleomorphic adenomas Gene amplification was found in 1 of the pleomorphic adenomas, with 2 tumors showing a significant overexpression of the erbB-2/Her-2 oncogene. 8102855 Human
her-2 thyroid carcinomas [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma] Amplification of oncogenes erbb-2, erbb-1, c-myc and losses of heterozygosity (LOH) at c 8103188 Human
her-2 node-negative breast cancer In node-negative breast cancer patients, the subgroup for which accurate prognostic data could make a significant contribution to treatment decisions, the prognostic utility of HER-2/neu amplification and/or overexpression has been controversial. 8104689 Human
her-2 intracranial tumours C-erbB-2/HER-2 protein in human intracranial tumours. 8105841 Human
her-2 intracranial tumour Thus, the expression of the c-erbB-2/HER-2 protein is limited to intracranial tumour tissues, principally meningiomas and metastatic carcinomas to the brain. 8105841 Human
her-2 ovarian epithelial neoplasms BACKGROUND. It is unclear whether HER-2/neu proto-oncogene expression in ovarian epithelial neoplasms is related to prognosis. 1360327 Human
her-2 follicular adenomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
her-2 follicular carcinomas We studied 21 follicular adenomas and 20 follicular carcinomas by immunocytochemistry utilizing specific monoclonal antibodies against HER-2/neu and c-myc oncogenes. 1361106 Human
her-2 metaplasia In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
her-2 metastases Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. c-erbB-2 gene amplification and protein over-expression we 1977466 Human
her-2 primary tumours Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. c-erbB-2 gene amplification and protein over-expression we 1977466 Human
her-2 adh Cases of ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) of the breast were examined for expression of the protein product of the c-erbB-2 (neu, HER-2) oncogene using two different polyclonal antibodies via an avidin-biotin immunoper 2170971 Human
her-2 gastric tumors Using the modified DNA in-gel renaturation assay to detect down to 7-8 copies of amplified DNA sequences, we identified 3 gastric tumors with amplified DNA sequences and confirmed by Southern hybridization analysis that HER-2/neu was amplified greater tha 2400999 Human
c-erb b2 cyst [Immunohistochemical study in acquired cystic disease of the kidney--expression of vimentin, epidermal growth factor, epidermal growth factor receptor and c-erb B2 gene product] Acquired cystic disease of the kidney (ACDK) reveals abnormal epithelial cell 8105122 Human
erbb-2 lung tumors Patients whose lung tumors contain K-ras oncogene mutation, accumulation of the protein product of the tumor suppressor gene p53, or erbB-2/neu oncoprotein overexpression have been shown to have a worse prognosis. 7905543 Human
erbb-2 bladder tumor We examined 141 bladder tumor specimens (45 fresh tissue samples and 96 formalin fixed tissue blocks) for erbB-2 amplification using fluorescence in situ hybridization. 8097962 Human
erbb-2 barrett's esophagus We examined 13 cases with esophageal adenocarcinomas and 5 cases with Barrett's esophagus for amplification of the EGFR and erbB-2 genes. 8098013 Human
erbb-2 parotid gland tumors erbB-2/Her-2 gene amplification and overexpression in parotid gland tumors. 8102855 Human
erbb-2 tumors of the parotid gland In the present study, 21 tumors of the parotid gland were examined by Southern and Northern blot hybridization for amplification and possible overexpression of the erbB-2/Her-2 oncogene. 8102855 Human
erbb-2 pleomorphic adenomas Gene amplification was found in 1 of the pleomorphic adenomas, with 2 tumors showing a significant overexpression of the erbB-2/Her-2 oncogene. 8102855 Human
erbb-2 thyroid carcinomas [Amplification of the erbb-2 (Her-2/NEU), erbb-1 (HER-1) and c-myc oncogenes is often combined with the deletion of the short arm of chromosome 17 in human carcinoma] Amplification of oncogenes erbb-2, erbb-1, c-myc and losses of heterozygosity (LOH) at c 8103188 Human
erbb-2 cancer of the thyroid Amplification of ERBB-2 oncogene was established in 14 out of 63 (22%) patients with breast cancer, 1 out of 23 cases of ovarian tumor, 1 out of 19 cases of large bowel cancer and 1 out of 27 patients with cancer of the thyroid. 1300765 Human
her-2 brain metastasis Model systems for brain metastasis have been developed and are now yielding mechanistic insights into the roles of angiogenesis, energy metabolism, the Her-2 and Stat3 signaling pathways, and dormancy. 17363518 Human
her-2 metastatic carcinoma The different amplification of HER-2 and expression of its protein in primary and metastatic carcinoma could be important for planning adequate treatment. 17260496 Human
her-2 high-grade pin HER-2 expression and gene amplification in high-grade PIN and prostate cancer. 17269616 Human
her-2 prostate tumors A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors. 17192923 Human
her-2 malignant skin adnexal tumor We believe this to be the first demonstration of Her-2/neu amplification in a malignant skin adnexal tumor. 17214855 Human
her-2 adnexal carcinomas In analogy to breast carcinoma, these findings suggest the applicability of trastuzumab for patients with metastatic adnexal carcinomas demonstrating Her-2/neu amplification. 17214855 Human
her-2 oncogene [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer] The prognosis of HER-2-positive breast cancer (characterized by amplification of the HER-2 oncogene and/or overexpression of HER-2 receptor) is unfavourable. 17216002 Human
her-2 breast cancer [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer] The prognosis of HER-2-positive breast cancer (characterized by amplification of the HER-2 oncogene and/or overexpression of HER-2 receptor) is unfavourable. 17216002 Human
her-2 early breast cancer [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer] The prognosis of HER-2-positive breast cancer (characterized by amplification of the HER-2 oncogene and/or overexpression of HER-2 receptor) is unfavourable. 17216002 Human
her-2 tumour The current recommendations for HER-2 positive tumour diagnosis are discussed since accurate identification of HER-2 amplification or overexpression is key for allowing a correct risk assessment and treatment. 17223541 Human
her-2 thymic carcinoma Three thymic carcinoma patients had Her-2/neu coamplification and these 3 patients had rapidly growing tumor and extensive disease at initial diagnosis. 17154178 Human
her-2 phyllodes tumor of the prostate Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. 17192792 Human
her-2 phyllodes tumors of the prostate This study was undertaken to investigate both amplification of the epidermal growth factor receptor (EGFR) gene by fluorescence in situ hybridization and the overexpression of EGFR, Her-2/neu, CD117 (c-kit), and androgen receptor by immunohistochemical st 17192792 Human
her-2 phyllodes tumors Her-2/neu and c-kit were only weakly or infrequently expressed in the epithelial components of prostatic phyllodes tumors. 17192792 Human
her-2 oral squamous cell carcinoma Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. 17238969 Human
her-2 granulosa cell tumors STUDY DESIGN: Formalin-fixed paraffin-embedded archival tissue blocks of 20 unselected nonepithelial ovarian malignancies (12 granulosa cell tumors and 8 germ cell tumors) diagnosed between 1993 and 2005 were immunohistochemically stained for Her-2/neu. 17240244 Human
her-2 high-grade pin High-grade PIN. HER-2 overexpression was present in the secretory cells in 26% of HGPIN cases in the CyP group, 40% in the untreated clinically detected cancer group, and 83% in the treated group. 17269616 Human
erbb2 hca ErbB2 was expressed in 83.6% of RN, 72.9% HCA and 88.7% HCC. 17380077 Rat
her-2 hydatidiform mole A positive immunohistochemical Her-2/neu stain was found in 6 (18.2%) of the patients with hydatidiform mole (3 with a complete mole). 17126893 Human
her-2 hydatidiform moles Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. 17126893 Human
her-2 gestational trophoblastic neoplasia Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. 17126893 Human
her2 benign ovarian tumors RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors. 17266884 Human
her2 benign ovarian tumors PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries. 17266884 Human
her2 borderline tumours Overexpression of HER2/neu was found in 27.6% of ovarian cancer tissues and in 15% of ovarian borderline tumours. 17245339 Human
her2 gastric carcinoid tumors HER2 was highly expressed in the nine intestinal, but not in the three gastric carcinoid tumors. 17342373 Human
neu colorectal cancer CONCLUSION: HER-2/neu overexpression may constitute an independent prognostic factor in colorectal cancer patients, and patients exhibiting HER-2/neu overexpression might constitute potential candidates for a new adjuvant therapy which involves the use of 16947041 Human
neu benign ovarian tumors PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries. 17266884 Human
neu benign ovarian tumors RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors. 17266884 Human
neu complete mole A positive immunohistochemical Her-2/neu stain was found in 6 (18.2%) of the patients with hydatidiform mole (3 with a complete mole). 17126893 Human
neu gestational trophoblastic neoplasia OBJECTIVE: The aim of the present study was to asses the ability of Her-2/neu immunohistochemical staining of the molar tissue to predict the risk of developing gestational trophoblastic neoplasia (GTN). 17126893 Human
neu hydatidiform mole METHODS: Sections prepared from 33 consecutive formalin-fixed paraffin-embedded archival reconfirmed hydatidiform mole tissue blocks were immunohistochemically stained for Her-2/neu. 17126893 Human
neu clear cell carcinoma Anti-HER-2/neu targeted therapy might be a novel and attractive therapeutic option in patients with biologically aggressive variants (uterine serous papillary carcinoma, clear cell carcinoma) of endometrial cancer. 17196749 Human
neu borderline tumours Overexpression of HER2/neu was found in 27.6% of ovarian cancer tissues and in 15% of ovarian borderline tumours. 17245339 Human
neu phyllodes tumor of the prostate Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. 17192792 Human
neu phyllodes tumors of the prostate This study was undertaken to investigate both amplification of the epidermal growth factor receptor (EGFR) gene by fluorescence in situ hybridization and the overexpression of EGFR, Her-2/neu, CD117 (c-kit), and androgen receptor by immunohistochemical st 17192792 Human
neu thymic carcinoma Three thymic carcinoma patients had Her-2/neu coamplification and these 3 patients had rapidly growing tumor and extensive disease at initial diagnosis. 17154178 Human
c-erb b-2 systemic metastasis In primary tumors, amplification of c-erb B-2 and c-myc was detected in three and two cases, whereas at the stage with systemic metastasis, it was detected in four and three cases, respectively. 1674395 Human
c-erb b-2 simple renal cysts Simple renal cysts, cystic renal dysplasia, autosomal recessive polycystic kidney disease (ARPKD), and non-cystic, essentially normal kidneys failed to show c-erb B-2 overexpression. 1686289 Human
c-erb b-2 cystic disease In contrast, autosomal-dominant polycystic kidney disease (ADPKD), acquired (dialysis-associated) cystic disease (ACD), non-cystic end stage kidneys and renal cell neoplasms revealed overexpression of c-erb B-2 with some frequency (40% or more of cases te 1686289 Human
c-erb b-2 cystic diseases Other growth factors [insulin-like growth factor (IGF-I), fibroblast growth factor (FGF) and beta transforming growth factor (TGF beta)] were not noted to be overexpressed in either c-erb B-2 positive or negative cystic diseases. 1686289 Human
c-erb b-2 cystic diseases C-erb B-2 may be a marker related to the proliferative/growth capabilities of selected cystic diseases, including potential for associated genesis of benign and malignant renal cell tumors. 1686289 Human
erbb2 methylcholanthrene-induced fibrosarcoma Expression of various oncogenes (ras, myc, erbB2, src, fyn, yes and sis) in a high-metastatic clone (MH-02) derived from a murine methylcholanthrene-induced fibrosarcoma A (Meth A) was compared with those of its parent clone (ML-01) by Northern blot analy 8325712 Human
her2 stage ii cancers In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less than or equal to 0.025) and stage II cancers (p less than or equal to 0.0005). 1349163 Human
neu iv epithelial ovarian cancer STUDY DESIGN: We determined expression of HER-2/neu by immunohistochemistry, with monoclonal antibody 9G6 and the indirect immunoperoxidase technique, on frozen tumor specimens from 105 patients with stage III or IV epithelial ovarian cancer. 8093588 Human
neu abdominal tumors To further study the biological effect of c-erbB-2/neu overexpression in SK-OV-3 cells, we injected such cells i.p. into female nu/nu mice and found that this cell line forms extensive abdominal tumors and ascites. 8094034 Human
neu diffuse lymphoma [Aggressive diffuse lymphoma with malignant pleural effusion expressing c-erbB-2 (neu) oncogene products] An 83-year-old male was admitted with a right pleural effusion and generalized lymphadenopathy. 8102189 Human
neu lymph node metastases In many but not all studies, amplification and/or overexpression of the human c-erbB2/neu oncogene has been correlated with poor prognosis and the number of lymph node metastases in node-positive breast cancer patients. 1359495 Human
neu tumor infiltrated lymph nodes Three hundred and one primary breast cancers from patients with tumor infiltrated lymph nodes were analyzed for the presence of HER-2/neu oncoprotein by two procedures: Western blot (WB) and immunohistochemistry (IHC). 1363511 Human
neu low grade tumors Losses of heterozygosity on chromosome 6 as well as HER-2/neu amplification, in contrast, were present in several low grade tumors and were not more frequent in high grade lesions. 1677312 Human
neu condyloma In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
neu diffuse lymphoma Co-expression of N-ras p21 and C-erbB-2 (neu) oncogene products by common ALL antigen-positive aggressive diffuse lymphoma. 1976194 Human
her-2 iv epithelial ovarian cancer STUDY DESIGN: We determined expression of HER-2/neu by immunohistochemistry, with monoclonal antibody 9G6 and the indirect immunoperoxidase technique, on frozen tumor specimens from 105 patients with stage III or IV epithelial ovarian cancer. 8093588 Human
her-2 tumor infiltrated lymph nodes Three hundred and one primary breast cancers from patients with tumor infiltrated lymph nodes were analyzed for the presence of HER-2/neu oncoprotein by two procedures: Western blot (WB) and immunohistochemistry (IHC). 1363511 Human
her-2 low grade tumors Losses of heterozygosity on chromosome 6 as well as HER-2/neu amplification, in contrast, were present in several low grade tumors and were not more frequent in high grade lesions. 1677312 Human
her-2 condyloma In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. 1974342 Human
c-erb b2 stage iii breast cancer BACKGROUND: The aim was to investigate the expression of a panel of biomarkers such as prolactin (PRL), p53, Bcl-2, c-erb B2, Ki-67, CD44, and factor VIII-related antigen (FVIII-RA) in primary tumors of stage II and stage III breast cancer and its correla 10819372 Human
c-erb b2 anterior tongue tumors BACKGROUND AND OBJECTIVES: Expression of a panel of biomarkers, such as p53, Bcl-2, Cyclin D1, c-myc, p21ras, c-erb B2, cytokeratin-19 (CK-19), and factor VIII-related antigen (FVIII-RA), was studied together in anterior tongue tumors from the oral cavity 12501167 Human
c-erb b2 intracranial tumours In this study we have determined the prevalence of amplification of the proto-oncogenes c-erb B1 (= epidermal growth factor receptor gene), c-erb B2 and c-myc in 44 human intracranial tumours (27 gliomas, six metastases to the brain and 11 meningiomas). 2908290 Human
c-erb b2 hepatocellular adenomas Immunoreactivity for c-erb B2 was not demonstrated in hepatocellular adenomas, cirrhotic livers, or hepatocellular carcinomas using routine immunohistochemical methods. 12373150 Human
her2 axillary lymph node metastasis We therefore studied the differential expression of CCR7 and CXCR4, along with that of the biomarker HER2-neu, to evaluate whether these biomarkers could predict axillary lymph node metastasis in breast cancer. 16115904 Human
her2 feline mammary carcinoma Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. 15705889 Cat
her2 tumourbearing Biodistribution and tumour targeting were studied in HER2 receptor-positive and -negative tumour-bearing athymic mice. 15289297 Human
neu autosomal recessive polycystic kidney disease Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease. c-ErbB2 (also referred to as Neu or HER2), a transmembrane glycoprotein with intrinsic tyrosine kinase activity, is structurally related to epidermal growth factor 11158230 Human
her-2 tumorinfiltrating lymphocytes To evaluate candidates for immunotherapy using HER-2/neu-derived, HLA-A2-restricted peptides, we examined the frequency of HLA-A2 relating to HER-2/neu overexpression or the infiltrating grade of tumor-infiltrating lymphocytes (TILs) in Japanese patients 11857411 Human
erbb-2 tumour mucosa ErbB-2 amplification with a gene copy number > 1.6 in tumour tissue and erbB-1 deletion with a gene copy number < 0.4 in tumour-surrounding mucosa are of clinical relevance and indicate an early tumour recurrence or metastasis (p < 0.05). 10889928 Human
c-erb b-2 cyst of the ovary Using immunohistochemical techniques, we studied the expression of c-erb B-2 in normal human endometrial tissue (n = 8), endometriosis interna (adenomyosis) (n = 8) and endometriosis externa (endometriotic cyst of the ovary) (n = 6). 7650146 Human
c-erb b-2 proliferative breast lesions OBJECTIVE--to examine the c-erb B-2 expression and nuclear DNA content in samples of breast lesions to ascertain any relationship between c-erb B-2 expression and aneuploidy in the different types of proliferative breast lesions and in intraductal and inv 7668939 Human
c-erb b-2 gestational trophoblastic disease Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. 7911272 Human
c-erb b-2 gestational trophoblastic disease We used immunocytochemical techniques to retrospectively study the expression of the c-erb B-2 oncogene product in formalin-fixed, paraffin-embedded trophoblastic tissues as a potential indicator of the development of persistent gestational trophoblastic 7911272 Human
c-erb b-2 trophoblastic tumors STUDY DESIGN: In this retrospective study 56 trophoblastic tumors were examined by means of immunocytochemical techniques to stain for the oncogene product for evidence of c-erb B-2 expression. 7911272 Human
c-erb b-2 gestational trophoblastic disease RESULTS: Our results showed positive immunostaining for c-erb B-2 gene product in one case of persistent gestational trophoblastic disease, with negative staining in all other cases in the study groups and controls. 7911272 Human
c-erb b-2 gestational trophoblastic disease CONCLUSION: Analysis for the significance of c-erb B-2 expression in persistent gestational trophoblastic disease showed that this correlation between c-erb B-2 expression and persistent gestational trophoblastic disease is not significant, suggesting tha 7911272 Human
c-erb b-2 synovial chondromatosis Despite these results, there was no Ki-67 positive staining in synovial chondromatosis, which tends to suggest that the demonstrated expression of C-erb B-2 is not related to proliferative activity. 8869286 Human
c-erb b-2 carcinoid tumors In carcinoid tumors, immunoreactivities were detected for c-myc (63%), bcl-2 (28%), c-erb B-2 (31%), c-erb B-3 (6%), and c-jun (23%). 9264349 Human
c-erb b-2 carcinoid tumors There were significantly higher incidences of c-myc, bcl-2, and c-erb B-2 immunoreactivities in carcinoid tumors of the rectum than in those of the appendix, and significantly higher incidences of bcl-2 and c-jun immunoreactivities in carcinoid tumors of 9264349 Human
c-erb b-2 adenocarcinoma of the lung Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. 9537203 Human
c-erb b-2 adenocarcinoma of the lung This trial was undertaken to determine the prognostic role of K-ras (p21), c-erb B-2 (p185) protein expression, and the presence or nonpresence of a K-ras gene mutation in patients with adenocarcinoma of the lung. 9537203 Human
c-erb b-2 hodgkin's disease Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease. 9717525 Human
c-erb b-2 hodgkin's disease Expression of proliferating cell nuclear antigen (PCNA) as well as p53, bcl-2 and C-erb B-2 genes protein products on Reed-Sternberg/Hodgkin's (R-S/H) cells was analyzed by immunohistochemistry in 65 patients with Hodgkin's disease (HD). 9717525 Human
c-erb b-2 cancer of the larynx Expression of c-erb B-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis. 10068894 Human
c-erb b-2 laryngeal carcinoma This study was conducted to evaluate a possible link between amplification of c-erb B-2 oncoprotein and cartilage invasion in laryngeal carcinoma. 10068894 Human
c-erb b-2 cyst Tumor markers (CA 125, cancer-associated serum antigen (CASA), CA 72-4), hormones (estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH)), epidermal growth factor (EGF) receptor and c-erb B-2 amplification rate were detected in cyst 10227005 Human
c-erb b-2 metaplastic carcinomas METHODS: Histopathology and case notes of metaplastic carcinomas with predominant spindle cell differentiation were analysed for patient demographics, tumour pathology, c-erb B-2 oestrogen (ER) and progesterone (PR) receptor status and radiology. 12943626 Human
erbb2 lung carcinomas Point mutation of the ras oncogene, amplification of the myc oncogene, and overexpression of the erbB2 oncogene are associated with poor prognosis of lung carcinomas. 8176843 Human
erbb2 adenoid cystic carcinomas These results suggested that overexpression of ERBB2 and ERBB3 is related to tumor differentiation and invasion in adenoid cystic carcinomas. 8669836 Human
erbb2 diffuse type carcinoma [Expression of ras and erbB2 in benign and malignant lesions of the stomach] The expression of P185erbB2 and P21ras was examined immunohistochemically in normal mucosa, intestinal metaplasia, dysplasia, intestinal type and diffuse type carcinoma of the st 8697969 Human
erbb2 metaplasia [Expression of ras and erbB2 in benign and malignant lesions of the stomach] The expression of P185erbB2 and P21ras was examined immunohistochemically in normal mucosa, intestinal metaplasia, dysplasia, intestinal type and diffuse type carcinoma of the st 8697969 Human
erbb2 breast cancer ERBB2 amplification and/or surexpression is actually recognized as a prognostic factor in breast cancer and would be predictive in the therapeutic response. 9499914 Human
erbb2 squamous cell lung carcinomas The expression of the proteins ERBB2, JUN, RAS and tissue factor was significantly higher in adenocarcinomas compared to squamous cell lung carcinomas. 12174921 Human
erbb2 serous carcinoma The purpose of this study was to examine the frequency and clinicopathological correlations of gene amplification, protein expression, and mutations of EGFR and ERBB2 in serous carcinoma, the most common and aggressive type of ovarian cancer. 16607561 Human
erbb2 thyroid carcinoma Objective and Methods: Because the EGFR pathway has been reported to be important for the pathophysiology of thyroid carcinoma, we investigated the expression and mutational status of EGFR in 14 thyroid carcinoma cell lines as well as its functional role 16822827 Human
her2 aml However, cell surface expression of HER2 protein (p185HER2) was found exclusively on a subset of leukemic cells of the B-lymphoblastic lineage. p185HER2 expression was found on blasts in 2 of 15 samples from infants, 9 of 19 samples from adult patients wi 7544646 Human
her2 blast crisis However, cell surface expression of HER2 protein (p185HER2) was found exclusively on a subset of leukemic cells of the B-lymphoblastic lineage. p185HER2 expression was found on blasts in 2 of 15 samples from infants, 9 of 19 samples from adult patients wi 7544646 Human
her2 cll However, cell surface expression of HER2 protein (p185HER2) was found exclusively on a subset of leukemic cells of the B-lymphoblastic lineage. p185HER2 expression was found on blasts in 2 of 15 samples from infants, 9 of 19 samples from adult patients wi 7544646 Human
her2 t-all However, cell surface expression of HER2 protein (p185HER2) was found exclusively on a subset of leukemic cells of the B-lymphoblastic lineage. p185HER2 expression was found on blasts in 2 of 15 samples from infants, 9 of 19 samples from adult patients wi 7544646 Human
her2 pancreatic tumors Repeated stimulation of HLA-A2+ PBL from pancreatic cancer patients using the HER2/neu-derived peptide resulted in specific recognition of this peptide and, more importantly, HER2/neu+ pancreatic tumors in an HLA-A2-restricted fashion. 9174600 Human
her2 stage iiia breast cancer Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standa 9816327 Human
her2 ovarian tumor HA binding to SK-OV-3.ipl cells promotes recruitment of both Grb2 and p185(HER2) to the CD44v3-Vav2 complex leading to Ras activation and ovarian tumor cell growth. 11606575 Human
her2 ovarian tumor Our results clearly indicate that the SH3 domain deletion mutants of Grb2 (i.e. the Delta N-Grb2 (and to a lesser extent the Delta C-Grb2) mutant) not only block their association with p185(HER2) but also significantly impair their binding to the CD44v3-V 11606575 Human
her2 nasopharyngeal carcinoma (npc) This study is therefore designed to identify changes of HER2 in nasopharyngeal carcinoma (NPC), an epithelia-derived malignancy with strong racial and geographic distribution. 11850071 Human
her2 atypical endometrial hyperplasia During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar 11873308 Human
her2 malignant lung tumors HER2/neu expression in malignant lung tumors. 11894014 Human
her2 sarcomas Our results show that HER2/neu is not expressed by these sarcomas, and we conclude that HER2/neu is therefore not an important prognostic factor and that anti-HER2/neu monoclonal antibody therapy is not appropriate for these patients. 11895910 Human
her2 stage ii breast cancer The National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-31 is designed to test the advantage of adding Herceptin to the adjuvant chemotherapeutic regimen of doxorubicin and cyclophosphamide followed by paclitaxel (Taxol) in the treatmen 12048273 Human
her2 adenoid cystic carcinoma of salivary gland HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. 12220353 Human
her2 desmoplastic small round cell tumors Desmoplastic small round cell tumors showed reactivity with calretinin in 4/21, desmin in 21/23, myoglobin in 5/17, placental alkaline phosphatase in 17/21, HER2/neu in 7/18 (3+ in 1 and 1+ in 6), c-kit in 2/14, MIC2 in 13/23, WT1 in 16/23, CAM5.2 in 21/2 12640103 Human
her2 desmoplastic small round cell tumors HER2/neu overexpression (3+) and c-kit expression are uncommon in desmoplastic small round cell tumors. 12640103 Human
her2 differentiated thyroid carcinomas Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. 12715168 Human
her2 soft tissue tumors But the role of HER2/neu alterations in soft tissue tumors remains poorly understood. 12874758 Human
her2 c-cell hyperplasia Her2/neu expression in C-cell hyperplasia and medullary thyroid carcinomas. 12894498 Human
her2 medullary thyroid carcinomas Her2/neu expression in C-cell hyperplasia and medullary thyroid carcinomas. 12894498 Human
her2 anaplastic thyroid carcinomas Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. 12894514 Human
her2 anaplastic thyroid cancer (atc) The Her2/neu expression in poorly-differentiated thyroid carcinomas (PDTC) and in anaplastic thyroid cancer (ATC) was investigated retrospectively. 12894514 Human
her2 cervical carcinoma Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. 14675323 Human
her2 cervical carcinoma This paper looks at whether c-erbB-2/HER2 expression in uterine cervical carcinoma before treatment is a predictive parameter of prognosis in patients with para-aortic lymph node metastasis (PALN) in advanced disease after treatment with radiation therapy 14675323 Human
her2 cervical carcinoma The present study suggests that c-erbB-2/HER2 expression of cervical tumors might be a predictive parameter of prognosis after radiation therapy for PALN of very advanced uterine cervical carcinoma patients. 14675323 Human
her2 cervical tumors The present study suggests that c-erbB-2/HER2 expression of cervical tumors might be a predictive parameter of prognosis after radiation therapy for PALN of very advanced uterine cervical carcinoma patients. 14675323 Human
her2 transitional cell carcinomas (tcc) Polysomy 17, gene amplification and HER2/neu protein overexpression are associated with a poor prognosis in transitional cell carcinomas (TCC) of the bladder. 14687790 Human
her2 gastrointestinal stromal tumors (gist) Notable successes include imatinib mesylate (STI571, Gleevec) in Chronic Myelogenous Leukemia (CML), and Gastrointestinal Stromal Tumors (GIST) and trastuzumab (Herceptin) in HER2 amplified breast carcinoma. 14688462 Human
her2 salivary gland carcinomas HER2 expression in salivary gland carcinomas: dependence on histological subtype. 14871971 Human
her2 mucoepidermoid carcinoma of salivary glands HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. 14974865 Human
her2 osteosarcoma In conclusion, as our study showed amplification of HER2/neu oncogene in low-grade osteosarcoma, we assume that expression of HER2/neu is not a poor prognostic factor in low-grade osteosarcoma. 15201972 Human
her2 vulvar paget's disease Overexpression of p185Her2 and HER2 oncogene amplification appears to be common in recurrent vulvar Paget's disease. 15272283 Human
her2 colon adenocarcinoma Intravenously administered Her2Bi-armed ATCs localized to PC-3 xenografts mediated cytotoxicity toward tumor cells and produced significant tumor growth delay of PC-3 tumors, but not Her2/neu-negative LS174T colon adenocarcinoma xenografts. 15479495 Mouse
her2 advanced cancer [Generation of HER2 specific, HLA-A24 restricted CTLs derived from a healthy donor] Cancer vaccine therapy is one of the latest treatment modalities for advanced cancer. 15553718 Human
her2 gastrointestinal tumors [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
her2 metastatic breast cancer [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
her2 non-small cell lung cancers [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
her2 tumor [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
her2 adenosquamous carcinoma HER2/neu over-expression was seen in only one (1/26) adenosquamous carcinoma (3 + membranous staining of the malignant glandular component). 15868445 Human
her2 malignant ascites In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM- or Her2/neu-antigen on tumor cells. 15906359 Human
her2 peritoneal carcinomatosis In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM- or Her2/neu-antigen on tumor cells. 15906359 Human
her2 mds The HER2 digital scoring application of the Micrometastasis Detection System (MDS) was used, together with manual scoring of FISH and HercepTest, to determine whether this system provides an accurate alternative. 15976337 Human
her2 stage iiia nsclc The role of the expressions of P53, K-ras, HER2, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), CD44, and matrix metalloproteinase-9 (MMP-9) in predicting efficacy of neoadjuvant chemotherapy on stage IIIA NSCLC is sti 16004813 Human
her2 breast carcinomas Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2 protein overexpression, adversely affecting prognosis and predicting response to Herceptin therapy. 16096413 Human
her2 bronchioloalveolar carcinoma (bac) METHODS: EGFR and HER2 gene amplification was examined in atypical adenomatous hyperplasia (AAH), bronchioloalveolar carcinoma (BAC), and adenocarcinoma with mixed subtypes (MX) by chromogenic in situ hybridisation (CISH), and protein expression was exami 16189154 Human
her2 high-grade prostatic intraepithelial neoplasia High-grade prostatic intraepithelial neoplasia showed HER2 overexpression in 26% of the CyP cases and in 40% and 83% of the untreated and treated cases, respectively. 16938518 Human
neu carcinomas of the salivary gland Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. 7522962 Human
neu mucoepidermoid carcinomas Here a cohort of mucoepidermoid carcinomas of the major (parotid and submandibular) salivary glands are analyzed for a molecular genetic alteration, HER-2/neu gene amplification, and gene amplification and expression results are compared with long-term cl 7522962 Human
neu mucoepidermoid carcinoma of salivary glands Archival tissues resected from 58 patients with mucoepidermoid carcinoma of salivary glands were evaluated for HER-2/neu gene amplification by fluorescence in situ hybridization and for gene expression by immunohistochemistry in a blinded fashion. 7522962 Human
neu mucoepidermoid carcinomas HER-2/neu is amplified and/or overexpressed in approximately one-third of mucoepidermoid carcinomas of salivary glands. 7522962 Human
neu high-grade prostatic intraepithelial neoplasia The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size a 7529857 Human
neu endometrial cancer Overexpression of HER-2/neu, transforming growth factor alpha, and p53 proteins have all been associated with poor prognosis in women with endometrial cancer. 7585656 Human
neu endometrial cancer Women whose endometrial cancer exhibited HER-2/neu gene amplification by FISH had a shorter overall survival than women whose endometrial cancer lacked amplification (P = 0.018). 7585656 Human
neu schwannomas With the use of the polymerase chain reaction and allele-specific oligonucleotide hybridization, DNA isolated from individual myotubes was analysed for the presence of a T-->A transversion mutation at nucleotide 2007 of the neu gene, which is diagnostic o 7695496 Rat
neu epithelial-myoepithelial carcinomas Thirty-one salivary gland epithelial-myoepithelial carcinomas from 26 patients were studied by DNA flow cytometry, and immunostaining for Ki-67 and HER-2/neu oncogene product. 7726139 Human
neu breast tumors Amplification of the neu/erbB-2/HER-2 gene and/or overexpression of its receptor tyrosine kinase product, p185neu/erbB-2 (p185), occurs in 15-40% of primary human breast tumors and is variably correlated with poor patient prognosis. 7728765 Human
neu papillary carcinomas There has been continued work on prognostic factors in endometrial carcinomas with ploidy, hormone receptor status, HER-2/neu expression, and coexistent hyperplasia confirmed as independent prognostic factors, while clear cell and serous papillary carcino 7742498 Human
neu oral leukoplakia To identify and modulate molecular SEBs in intraepithelial neoplasia of the upper aerodigestive tract, we studied expression of the epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha), and HER-2/neu genes in oral leukopla 7823600 Human
neu leukoplakia Pretreatment expression of EGFR, TGF-alpha, and HER-2/neu in leukoplakia was increased when compared to normal-appearing mucosa. 7823600 Human
neu ovarian carcinomas [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas] C-erbB-2 (HER-2/neu) proto-oncogene is mainly expressed in epithelial tissue and activated due to its amplification. 7866905 Human
neu tumors of the palate To evaluate the role of the Ki-67 proliferation antigen and c-erbB-2/neu oncogene expression in the clinical assessment of salivary gland tumors, we followed up 71 patients with minor salivary tumors of the palate. 7870438 Human
neu gynecologic tumors P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. 7910219 Human
neu gastrinoma METHODS: The differential polymerase chain reaction (PCR) procedure was used to detect amplification of the HER-2/neu gene in DNA samples from the novel human gastrinoma cell line (PT) and from paraffin-embedded samples of gastrinomas. 7911296 Human
neu anaplastic astrocytoma The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
neu oligoastrocytoma The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
neu who grade i meningiomas The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
neu adenosarcoma The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. 8557233 Human
neu mmmt Immunohistochemistry was used to grade overexpression of p53 protein, HER-2/neu protein, epidermal growth factor receptor (EGFR), and Ki-67 antigen in both the glands and stroma of tissue from 20 women with MMMT and 6 women with AS. 8557233 Human
neu mmmt HER-2/neu protein was not overexpressed in any AS or primary MMMT. 8557233 Human
neu supraglottic squamous cell carcinoma Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma. 8604888 Human
neu supraglottic carcinomas Sections from 32 supraglottic carcinomas were studied immunohistochemically for the presence of HER-2/neu (c-erbB-2) oncogene expression. 8604888 Human
neu medullary carcinomas Statistically significant associations were observed between p53 expression or MIB-1 count and age below 50 years, high-grade tumours, medullary carcinomas, and absence of hormone receptors. p53 mutations were associated with increased MIB-1 count, HER-2/ 8608982 Human
neu endometrioid carcinoma STUDY DESIGN: Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic 8610771 Human
neu cancers of the uterus CONCLUSIONS: Determination of the frequency and levels of EGF receptors, HER-2/neu protein, and cathepsin D in uteri with and without cancer and the availability of reference materials developed in our laboratory, will allow evaluation of their prognostic 8616763 Human
neu small cell lung cancer Mutations in the ras family of oncogenes, overexpression of the myc and neu families of oncogenes, and mutations of p53, the recessive tumor suppressor gene, occur with differing frequencies in small cell lung cancer and non-small cell lung cancer, and ar 8635391 Human
neu small cell carcinomas DESIGN--Using immunohistochemical analysis of small cell carcinomas, the tissue expression of corticotropin, bcl-2, p-glycoprotein, cathepsin B, cathepsin D, CD44, carcinoembryonic antigen, collagenase IV, Leu-7, neu oncoprotein, p53, S100, and synaptophy 8639050 Human
neu in situ breast cancers In 50 in situ breast cancers an immunohistochemical study, evaluating estrogen (ER) and progesterone (PR) receptors, Proliferation Index (PI), c-erbB-2/Neu and p53 expression was performed. 8692711 Human
neu borderline ovarian tumours Twenty-four advanced (surgical stage III and IV) ovarian carcinomas and 15 borderline ovarian tumours were studied for the overexpression of nm23 and HER-2/neu (c-erb-B2) by means of immunohistochemistry on sections from routinely processed, paraffin-embe 8702236 Human
neu gynecologic cancers The role of the HER-2/neu oncogene in gynecologic cancers. 8796816 Human
neu human lung cancer Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance. 8875978 Human
neu seborrheic keratoses Examination for the localization of epidermal growth factor receptor (EGF-R) and HER-2/neu oncoprotein by immunohistochemistry revealed positive staining on the epithelial strands branching downwards on the specimens of seborrheic keratoses. 8935630 Human
neu high-grade pin Potential SEBs for screening chemopreventive agents for prostate cancer in short-term Phase II trials include (1) histologic premalignant lesions, such as high-grade PIN; (2) biochemical markers, including prostate-specific antigen (PSA) serum concentrati 9027613 Human
neu benign ovarian cystadenomas Paraffin-embedded sections from the 42 BLOT, 5 normal ovaries, and 10 benign ovarian cystadenomas were stained using monoclonal antibodies against human p53 (DAKO-p53, DAKO, Denmark) and HER-2/neu (C-erB-2, Triton, Parkway, CA). 9159328 Human
neu ovarian cystadenomas None of the normal ovaries or ovarian cystadenomas demonstrated overexpression of p53 or HER-2/neu. 9159328 Human
neu pituitary tumours The c-erbB-2/neu proto-oncogene in human pituitary tumours. 9231056 Human
neu stage i endometrial carcinoma OBJECTIVE: To determine if DNA ploidy, hormone receptors, vascular space invasion (VSI), perivascular lymphocytes (PVL), and the oncogenes HER-2/neu, p53, and bcl-2 are independent prognostic indicators for lymph node metastasis and cancer recurrence in c 9299250 Human
neu pancreatic tumors Our studies suggest a possible relationship of family cancer history to the expression of p53 and p21WAF in pancreatic tumors, but show no relationship to the expression of HER-2/neu or to the prevalence of K-ras mutations. 9322121 Human
neu pancreas cancer In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
neu pancreatic carcinoma In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
neu verrucous carcinoma of the oral cavity Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bcl-2, p53, and Her-2/neu, and indexes of cell turnover. 9398988 Human
neu renal cell carcinoma (rcc) To analyze whether Her-2/neu epitopes are tumor-associated antigens for renal cell carcinoma (RCC) and colon carcinoma, we induced Her-2/neu peptide-specific CTL responses by primary in vitro immunization and used these CTLs to determine the presentation 9485028 Human
neu stage ii breast carcinoma METHODS: This study evaluated data from 226 patients with TNM Stage I and early Stage II breast carcinoma and included the variables p53 and c-erbB-2 (HER-2/neu). 9486576 Human
neu bladder adenocarcinoma METHODS AND RESULTS: We investigated the usefulness of a panel of antibodies against cytokeratin 7, E48, cytokeratin 20, PSA, PSAP, CEA, vimentin, OC125 and HER-2/neu, to discriminate primary bladder adenocarcinoma from adenocarcinomas arising from the pr 9522212 Human
neu stage i adenocarcinoma of lung Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. 9800799 Human
neu stage i lung adenocarcinoma CONCLUSIONS: Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. 9800799 Human
neu colorectal adenocarcinomas HLA-A2+ patients with metastatic breast, ovarian, or colorectal adenocarcinomas that overexpressed HER-2/neu were immunized with the HLA-A2-binding epitope p369-377 (p369). 9809997 Human
neu stage iiia breast cancer Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standa 9816327 Human
neu invasive adenocarcinomas Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
neu mucinous neoplasms Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
neu pancreatic cancer Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
neu papillary carcinomas In contrast, ras mutations are rare (10%). erbB-2/neu gene amplification and activating mutations are not detected, although elevated mRNA levels were found in 20% of papillary carcinomas. 9889797 Human
neu ductal hyperplasia Overall, HER-2/neu was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 30, 11 of 20 (55%), 10 of 15 (67%), and 12 of 15 (80%), respectively, with progressive increase in the intensity of staining; p53 was positive in 1 10029438 Human
neu ovarian carcinoma HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
neu prostate cancers HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
neu lobular carcinoma in situ Prognostic factors evaluated were age, histologic type of invasive tumor, presence of associated ductal and/or lobular carcinoma in situ, lesion size, histologic and nuclear grades, DNA index, presence of multiploidy by flow cytometric analysis, and immun 10349989 Human
neu peripheral nerve tumors (pnt) Peripheral nerve tumors (PNT) and melanomas induced transplacentally on day 14 of gestation in Syrian golden hamsters by N-nitrosoethylurea were analyzed for activated oncogenes by the NIH 3T3 transfection assay, and for mutations in the neu oncogene by d 10473865 Human
neu breast cancer Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. 10502729 Human
neu metastasis Ki 67 and p34cdc2 proliferation marker overexpression, HER-2/neu oncogene amplification, large tumor size, high tumor grade, advanced tumor stage, positive lymph node status, and distant metastasis at the time of diagnosis predicted disease-related death 10510669 Human
neu oropharyngeal squamous cell carcinomas Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas. 10621852 Human
neu oropharyngeal squamous cell carcinomas Using immunohistochemistry, expression of p53, transforming growth factor-alpha (TGF-alpha), epidermal growth factor receptor (EGFR), c-erbB-2/neu and proliferating cell nuclear antigen (PCNA) was examined in 26 fresh frozen tissue specimens of oropharyng 10621852 Human
neu primary fallopian tube carcinoma Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. 10629373 Human
neu fallopian tube adenocarcinoma The high incidence of p53, HER-2/neu and c-myc overexpression in fallopian tube adenocarcinoma suggests these genes may play a role in its tumorigenesis. 10629373 Human
neu adenocarcinomas of the esophagus Using M68 immunohistochemistry and a scoring system similar to that used for HER-2/neu, we found that M68 protein was overexpressed in 30 of 68 (44%) human adenocarcinomas of the esophagus, stomach, colon, and rectum. 10655513 Human
neu smooth muscle neoplasms STUDY DESIGN: Forty-five uterine smooth muscle neoplasms were assessed for DNA ploidy; silver-staining nucleolar organizer regions (AgNORs); percent nuclear proliferating cell nuclear antigen (PCNA); expression of p53, Her-2/neu, and MDM-2 protein; mitoti 10656730 Human
neu breast carcinoma Her-2/neu (H2N) status in breast carcinoma has been considered a prognostic factor that may have therapeutic implications; however, the correlation between H2N overexpression and gene amplification has not been completely defined. 10658908 Human
neu epithelial hyperplasia In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia, as well as abnormalities of several cell 10762008 Human
neu human breast cancers The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20-30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin. 10889820 Human
neu melanoma These results demonstrated that HER-2/neu amplification and overexpression are not common in advanced stage melanoma and thus, HER-2/neu would have limited value as a biomarker or as a target for immunotherapy in melanoma. 10928135 Human
neu large cell carcinomas HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. 10928158 Human
neu calgb We examine a possible interaction between HER-2/neu or p53 expression and tamoxifen effectiveness in patients with ER-positive, node-positive disease treated with cyclophosphamide, doxorubicin, and fluorouracil in a large adjuvant chemotherapy trial (Canc 11032587 Human
neu calgb PATIENTS AND METHODS: CALGB 8541 assessed HER-2/neu expression in patients with ER-positive disease by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) and amplification by differential polymerase chain reaction (PCR). 11032587 Human
neu acinic cell adenocarcinoma Morphologic examinations of salivary gland neoplasias arising in male BALB/c (H-2d) mice carrying the activated HER-2/neu (BALB-NeuT) indicate that expression of the oncogene product in the ductal-acinar structures results in a very human-like acinic cell 11054659 Mouse
neu extra-adrenal pheochromocytomas Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. 11127918 Human
neu cyst Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
neu lung cancer Biologic markers resulting from genetic lesions in lung cancer are grouped as follows: (a) oncogene amplification and overexpression (aberrant gene expression) and mutated tumor suppressor genes -- ras gene, myc gene, HER-2/neu and survivin gene, p53 and 11162866 Human
neu cancer Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
neu human breast cancers Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
neu advanced cancer Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. 11223076 Human
neu papillomatosis We investigated by immunohistochemistry expressions of topoisomerase alpha II, MIB-1, p53, p21, E-cadherin, retinoblastoma (RB) gene protein product, HER-2/neu, and steroid hormone receptors in a case of juvenile respiratory papillomatosis with malignant 11277421 Human
neu clear cell tumors Both endometrioid and clear cell tumors belonged to the largest subgroup with concomitant negativity for both HER-2/neu and EGFR. 11328410 Human
neu breast cancers The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. 11416960 Human
neu udh Increased proliferation (Ki67), overexpression of cyclin D1, HER-2/neu, p21 and p53, and decreased expression of bcl-2 and p27 could already be found in UDH. 11439365 Human
neu breast cancer In breast cancer amplification of the HER-2/neu oncogene and over-expression of the protein product is associated with poor prognosis, predicts response to some chemotherapeutic regimens and is the target for Herceptin treatment. 11455000 Human
neu pediatric osteosarcomas Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. 11505415 Human
neu pediatric osteosarcomas METHODS: The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (PathVysion, Vysis Inc., Downe 11505415 Human
neu leydig cell tumor PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
neu testicular tumors PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
neu adrenocortical neoplasms Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. 11556748 Human
neu malignant adrenocortical neoplasms HER-2/neu overexpression was not observed in any of the benign or malignant adrenocortical neoplasms. 11556748 Human
neu malignant glioma Tamoxifen interacts with NEU/C-ERBB-2 receptor and inhibits growth of human malignant glioma cell lines. 11729374 Human
neu malignant glioma The effects of tamoxifen, an antiestrogen, on the inhibition of protein tyrosine phosphorylation in neu/c-erbB-2 receptor, DNA synthesis and proliferation were evaluated using the malignant glioma cell lines U25 IMG and T98G which overexpressing neu/c-erb 11729374 Human
neu bone metastases MCF-7/Neu cells grew without estrogen and developed osteosclerotic bone metastases in 10-12 weeks in animals. 11830552 Mouse
neu bone metastases Mice bearing these MCF-7/Neu cells with antisense showed reduced bone metastases with decreased plasma hPDGF-BB levels (54 +/- 20 and 35 +/- 21 in two different antisense and 696 +/- 312 pg/ml in empty vector; mean +/- SE; n = 5). 11830552 Mouse
neu oropharyngeal squamous cell carcinoma Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. 11839675 Human
neu head and neck cancer The prognostic significance and clinical implications of HER-2/neu expression and amplification in head and neck cancer will require additional studies. 11839675 Human
neu adh Twenty-six patients with Her-2/neu-overexpressing invasive ductal carcinomas (as judged by strong immunoreactivity with Her-2/neu antibody) and coexisting lesions of ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCI 11850540 Human
neu adh Among these patients, amplification of Her-2/neu in ADH was demonstrated in 7 of 13 cases with ADH, and in DCIS, in 21 of 22 cases with DCIS. 11850540 Human
neu primary carcinomas We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody). 11850540 Human
neu adh This FISH study indicates that amplification of Her-2/neu can emerge de novo in any stage of the disease process, from ADH to metastatic lesions, but most often appears first in ADH or DCIS. 11850540 Human
neu atypical endometrial hyperplasia During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar 11873308 Human
neu sporadic breast cancer To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we have performed fluorescence in situ hybridization on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation ca 11888924 Human
neu invasive breast cancer BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. 11893034 Human
neu malignant lung tumors HER2/neu expression in malignant lung tumors. 11894014 Human
neu sarcomas Our results show that HER2/neu is not expressed by these sarcomas, and we conclude that HER2/neu is therefore not an important prognostic factor and that anti-HER2/neu monoclonal antibody therapy is not appropriate for these patients. 11895910 Human
neu burkitt's lymphoma After transfecting wild-type HER-2/neu or chimeric HER-2/CD19 into Raji Burkitt's lymphoma cells and wild-type CD19 or chimeric CD19/HER-2 into SK-BR-3 breast cancer cells, target cell lines were selected for high membrane expression of transfected A 11907082 Human
neu hodgkin lymphomas The aim of this study was to evaluate the expression of HER-2/neu in the malignant lymphomas: non-Hodgkin and Hodgkin lymphomas. 11958663 Human
neu hodgkin lymphomas CONCLUSIONS: Non-Hodgkin and Hodgkin lymphomas do not express the HER-2/neu oncoprotein. 11958663 Human
neu breast cancer HER-2/neu gene amplification and cell surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. 11986780 Human
neu papillary cancer Overexpression of HER-2/neu in uterine serous papillary cancer. 12006548 Human
neu bilateral breast cancer HER-2/neu expression in bilateral breast cancer has not been reported. 12058961 Human
neu malignant schwannomas The results indicate that LOHs on chromosomes 10 and 5 are required for the development of EtNU-induced malignant schwannomas from immature neu/Erbb-2 mutant glial cells, and that putative tumor suppressor genes are localized on chromosome 10q32.3, corres 12082026 Rat
neu liver metastases HER-2/neu mRNA levels were significantly higher (P = 0.032) in tumors associated with liver metastases but not with tumor location or size. 12097278 Human
neu adenocarcinoma of the pancreas CONCLUSION: Her-2/neu overexpression detected by immunohistochemistry does not appear to be a poor prognostic factor in patients with adenocarcinoma of the pancreas. 12168842 Human
neu primary brain tumors We retrospectively analyzed a large cohort of patients with primary brain tumors to evaluate the prognostic role of HER-2/neu overexpression and clinical characteristics at presentation in patients with shortened survival (< 6 months). 12168843 Human
neu malignant brain tumors Further studies are needed to specify whether certain tumor subtypes are more likely to overexpress HER-2/neu and to evaluate the role of HER-2/neu as a target for therapy in malignant brain tumors. 12168843 Human
neu germ cell tumours CONCLUSIONS: The lack of concordance between IHC and FISH makes it unlikely that overexpression of the HER-2/neu protein in germ cell tumours is of prognostic or therapeutic relevance. 12194993 Human
neu mesothelioma Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. 12209878 Human
neu adenoid cystic carcinoma of salivary gland HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. 12220353 Human
neu adrenal tumors Expression of HER-2/neu receptor protein in adrenal tumors. 12234062 Human
neu adrenal adenomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
neu adrenocortical carcinomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
neu pheochromocytomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
neu adrenocortical tumors From our data we conclude that specific and significant membranous immunostaining indicating strong overexpression (grade 3) of HER-2/neu protein is not present in adrenocortical tumors. 12234062 Human
neu hairy-cell leukemia Examples of new agents are: trastuzumab (Herceptin), a humanized monoclonal antibody that blocks the HER-2/neu proto-oncogene in combination with cytotoxic agents, is used in a percentage of breast cancer patients; signal transduction inhibitor of abl tyr 12375030 Human
neu familial breast cancer HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. 12412159 Human
neu chondrosarcoma [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
neu chondrosarcomas [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
neu metastatic osteosarcoma Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed para 12544770 Human
neu desmoplastic small round cell tumors Desmoplastic small round cell tumors showed reactivity with calretinin in 4/21, desmin in 21/23, myoglobin in 5/17, placental alkaline phosphatase in 17/21, HER2/neu in 7/18 (3+ in 1 and 1+ in 6), c-kit in 2/14, MIC2 in 13/23, WT1 in 16/23, CAM5.2 in 21/2 12640103 Human
neu desmoplastic small round cell tumors HER2/neu overexpression (3+) and c-kit expression are uncommon in desmoplastic small round cell tumors. 12640103 Human
neu breast cancer Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. 12653946 Human
neu salivary duct carcinoma CONCLUSIONS: In immunohistochemistry, over-expression of HER-2/neu protein was identified as distinct membrane staining in most carcinoma cells in all our salivary duct carcinoma cases, while only four cases revealed an amplification of HER-2/neu gene by 12653946 Human
neu head and neck squamous cell carcinoma In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. 12673202 Human
neu breast cancer Amplification of gene HER-2/neu and overexpression of its gene product have been shown to have both prognostic and treatment implications in breast cancer. 12677894 Human
neu mfh CS, MFH, and DFS specimens showed the highest incidence of HER-2/neu overexpression (40%, 26%, and 18.2%, respectively). 12714894 Human
neu differentiated thyroid carcinomas Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. 12715168 Human
neu breast cancer The amplification and/or overexpression of the HER-2/neu oncogene and its encoded receptor protein are increasingly used for prognostication and prediction of therapeutic response to Herceptin in breast cancer. 12733117 Human
neu atypical hyperplasia Within 33 weeks of life, all 10 mammary glands of virgin BALB/c mice transgenic for the transforming rat HER-2/neu oncogene under the mammary tumor virus promoter (BALB-neuT mice) progress from atypical hyperplasia to invasive palpable carcinoma. 12750275 Mouse
neu rhabdomyosarcoma Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. 12782574 Mouse
neu rhabdomyosarcoma We show that activation of the HER-2/neu oncogene coupled with inactivation of the oncosuppressor gene p53 causes rhabdomyosarcoma in mice. 12782574 Mouse
neu hydatidiform mole Immunohistochemical staining reactions were performed with the following monoclonal antibodies for hydatidiform mole: beta-hCG, HPL, MIB1, CK18, HER-2/neu, p53 and carbohydrate antibodies, Thomsen-Friedenreich antigen, Glycodelin A, Mucl and Mucl-cor. 12820349 Human
neu inclusion cyst In both the ovarian surface and inclusion cyst epithelia, the percentage of cells was determined that stained positively for Ki67, p21, p27, p53, cyclin A, cyclin D1, bcl-2 and the presence of HER-2/neu, oestrogen (ER-alpha) and progesterone receptors (PR 12823709 Human
neu stage iii nsclc Overexpression of HER-2/neu in tumor tissues was found in 70% (23 of 32) of patients with MPE-associated ADCLC, 30% (13 of 43) with stage I/II non-small cell lung cancer (NSCLC), and 44% (14 of 32) with stage III NSCLC. 12855637 Human
neu soft tissue tumors But the role of HER2/neu alterations in soft tissue tumors remains poorly understood. 12874758 Human
neu thymic epithelial tumours Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. 12877732 Human
neu thymic epithelial tumours AIMS: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF,1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether 12877732 Human
neu thymic carcinomas Nine thymic carcinomas revealed membranous positivity for HER-2/neu, but no HER2 gene amplification could be demonstrated by FISH in any of the cases. 12877732 Human
neu c-cell hyperplasia Her2/neu expression in C-cell hyperplasia and medullary thyroid carcinomas. 12894498 Human
neu medullary thyroid carcinomas Her2/neu expression in C-cell hyperplasia and medullary thyroid carcinomas. 12894498 Human
neu anaplastic thyroid carcinomas Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. 12894514 Human
neu anaplastic thyroid cancer (atc) The Her2/neu expression in poorly-differentiated thyroid carcinomas (PDTC) and in anaplastic thyroid cancer (ATC) was investigated retrospectively. 12894514 Human
neu pituitary carcinoma Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. 12924717 Human
neu pituitary carcinomas The results indicate that low-level amplification of the HER-2/neu gene might be associated with pituitary carcinomas in which more aggressive behavior is seen. 12924717 Human
neu pituitary carcinoma Further studies are needed to determine whether HER-2/neu plays a role in the pathogenesis of pituitary carcinoma. 12924717 Human
neu mixed germ cell tumors PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
neu teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
neu choriocarcinoma Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
neu mixed tumors Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
neu choriocarcinoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
neu teratoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
neu medullary carcinoma of breast CONCLUSIONS: Medullary carcinoma of breast is distinct from AMC and HGIDC with prominent lymphocytic infiltrates in amplification and overexpression of HER-2/neu. 14567723 Human
neu gastrointestinal stromal tumors If the correct targets are carefully selected for inhibition in tumors in which the targets are present (clear cell histologic features and loss of VHL expression), then results should resemble those others have observed with targeted therapy, such as the 14569078 Human
neu extensive stage small cell lung carcinoma Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. 14581360 Human
neu mpd However, previous studies on HER-2/neu expression in MPD and EPD have given conflicting results. 14616943 Human
neu mpd We examined 58 cases of MPD and EPD for HER-2/neu overexpression and vimentin status to study the role of these markers in the production of the Paget's phenotype. 14616943 Human
neu mpd Thirty-six of the 38 cases of MPD (94.7%) overexpressed the HER-2/neu oncoprotein and 17 cases (44.7%) showed vimentin expression. 14616943 Human
neu mpd Our results indicate that the cell motility enhancing effect of HER-2/neu oncoprotein and possibly vimentin plays a significant role in the pathogenesis of MPD which appears to be a pagetoid spread of an underlying ductal malignancy (secondary), while EPD 14616943 Human
neu ovarian tumor Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. 14625284 Human
neu transitional cell carcinomas (tcc) Polysomy 17, gene amplification and HER2/neu protein overexpression are associated with a poor prognosis in transitional cell carcinomas (TCC) of the bladder. 14687790 Human
neu clear cell carcinomas As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%). 14751152 Human
neu cartilaginous tumors Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors. 14767542 Human
neu mesenchymal chondrosarcomas To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. 14767542 Human
neu cartilaginous tumors In conclusion, the amplification and overexpression of the HER-2/neu oncogene is absent or at least very rare in malignant cartilaginous tumors. 14767542 Human
neu mucoepidermoid carcinoma of salivary glands HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands. 14974865 Human
neu gallbladder cancers Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. c-erbB-2, proto-oncogene is amplified and overexpressed in a number of human adenocarcinomas. 15010878 Human
neu gallbladder cancer To investigate the therapeutic effect of Trastuzumab in gallbladder cancer, we studied HER-2/neu expression in 43 primary tumors, 12 metastatic lymph nodes and two liver metastasis, using the Hercep test. 15010878 Human
neu gynecologic cancers There is increasing levels of evidence suggesting that some circulating factors involved in gynecologic cancers, such as alpha-fetoprotein (AFP), insulin-like growth factor binding protein-3 (IGFBP-3), c-erbB-2 (HER-2/neu), and epidermal growth factor (EG 15051037 Human
neu salivary gland cancer Several molecular targets (c-kit, HER-2/neu, androgen receptors) have been identified in salivary gland cancer. 15069319 Human
neu breast carcinoma In breast carcinoma, HER-2/neu gene amplification and receptor protein overexpression are tightly correlated and have prognostic and therapeutic implications. 15072912 Human
neu osteosarcoma In conclusion, as our study showed amplification of HER2/neu oncogene in low-grade osteosarcoma, we assume that expression of HER2/neu is not a poor prognostic factor in low-grade osteosarcoma. 15201972 Human
neu papillary serous carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
neu small cell carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
neu uterine papillary serous carcinoma Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. 15284264 Human
neu primary carcinoma This increased to 100% if the primary carcinoma was larger than 5 cm, if it was poorly differentiated, or if it showed HER-2/neu gene amplification. 15327491 Human
neu testicular germ-cell tumors However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. 15330164 Human
neu teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
neu testicular teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
neu choriocarcinoma With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). 15330164 Human
neu testicular germ-cell tumors CONCLUSION: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. 15330164 Human
neu neuroendocrine tumours Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
neu neuroendocrine tumours Irrespective of protein overexpression, HER-2/neu gene amplification is rare in lung cancer and studies on its prevalence and clinicopathological implications in early stage non-small cell lung cancer (NCSLC) and neuroendocrine tumours (NET) of the lung a 15386424 Human
neu stage i nsclc We evaluated HER-2/neu abnormalities in 345 Stage I NSCLC and 207 Stage I-III NET of the lung of all the diverse histological types, by using immunohistochemistry and fluorescent in situ hybridization in selected cases. 15386424 Human
neu large-cell neuroendocrine carcinoma (lcnec) Gene amplification was seen in only 7 (7.4%) of the immunoreactive tumours, with high-level amplification (HER-2/neu gene to chromosome 17 ratio > 4.0) in 3 adenocarcinomas, 1 squamous-cell carcinoma and 1 large-cell neuroendocrine carcinoma (LCNEC), and 15386424 Human
neu lung carcinomas HER-2/neu gene amplification and protein overexpression are not closely correlated in lung carcinomas and do not bear any prognostic implication. 15386424 Human
neu neuroendocrine tumours Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression. 15386424 Human
neu hematologic malignancies In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu 15487459 Human
neu large-cell lymphoma Single reports mention HER-2/neu positivity in hematological malignancies like Hodgkins's disease and even diffuse large-cell lymphoma. 15510616 Human
neu salivary gland carcinomas We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. 15548714 Human
neu metastatic pancreatic adenocarcinomas PURPOSE: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. 15581051 Human
neu metastatic pancreatic cancer METHODS AND MATERIALS: Patients with metastatic pancreatic cancer with 2+/3 + HER-2/neu expression by immunohistochemistry were eligible. 15581051 Human
neu epithelial neoplasms Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. 15581965 Human
neu serous carcinomas RESULTS: FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. 15581965 Human
neu clear cell carcinoma None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; 15581965 Human
neu uterine sarcomas BACKGROUND: The aim of this study was to determine ERBB-2 (HER-2/neu) gene alterations in different subtypes of uterine sarcomas. 15581967 Human
neu carcinoma ex pleomorphic adenoma Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. 15693886 Human
neu metastatic pancreatic adenocarcinomas Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p5 15725808 Human
neu gastrointestinal tumors [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
neu metastatic breast cancer [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
neu non-small cell lung cancers [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
neu tumor [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
neu cystic hypersecretory carcinoma of breast Report of five cases] OBJECTIVE: To describe a poorly recognized histological and immunohistochemical features of cystic hypersecretory carcinoma of breast, including the overexpression of HER-2/neu protein and androgen receptors. 15779300 Human
neu malignant gliomas DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas. 15809708 Human
neu adenosquamous carcinoma HER2/neu over-expression was seen in only one (1/26) adenosquamous carcinoma (3 + membranous staining of the malignant glandular component). 15868445 Human
neu carcinosarcoma It still needs to be clarified whether HER-2/neu overexpression increases the aggressiveness of carcinosarcoma, or whether HER-2/neu has a direct role in its pathogenesis, as described in breast cancers. 15901136 Human
neu uterine carcinosarcoma Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of 15901136 Human
neu mucinous carcinoma of the breast Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. 15960065 Human
neu mucinous carcinoma Compared with the non-mucinous type, mucinous carcinoma specimens have more DCC expression (100% vs 48.7%; p = 0.0027) and more ER expression (90.9% vs 26.9%; p = 0.0023), but less HER-2/neu overexpression (0% vs 38.1%; p = 0.0302). 15960065 Human
neu ovarian serous carcinomas An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. 16006797 Human
neu large cell neuroendocrine carcinoma Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic 16014119 Human
neu large cell neuroendocrine carcinomas We studied the immunohistochemical expression of HER-2/neu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), estrogen receptor (ER), and progesterone receptor (PR) in uterine cervical small cell 16014119 Human
neu endometrial cancer A novel in vivo model of tamoxifen-stimulated endometrial cancer was developed and the role of HER-2/neu investigated by using trastuzumab. 16166331 Human
neu breast carcinoma HER-2/neu protein expression has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease, and with a poor prognosis, and constitute a predictive factor of 16868827 Human
neu gastric cancer HER-2/neu amplification may constitute an independent prognostic factor in gastric cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclo 16868827 Human
neu murine neuroblastoma The iv administration of Gd-DOTAMA-C6-Gln allowed the MRI visualization of tumor masses in A/J mice grafted with the murine neuroblastoma cell line Neuro-2a and in Her-2/neu transgenic mice developing multiple mammary carcinoma, respectively. 16884304 Human
neu leukoplakia HER-2/neu expression in plasma and biopsy of patients with oral lichen planus in comparison to leukoplakia. 16922972 Human
her-2 carcinomas of the salivary gland Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. 7522962 Human
her-2 mucoepidermoid carcinomas Here a cohort of mucoepidermoid carcinomas of the major (parotid and submandibular) salivary glands are analyzed for a molecular genetic alteration, HER-2/neu gene amplification, and gene amplification and expression results are compared with long-term cl 7522962 Human
her-2 mucoepidermoid carcinoma of salivary glands Archival tissues resected from 58 patients with mucoepidermoid carcinoma of salivary glands were evaluated for HER-2/neu gene amplification by fluorescence in situ hybridization and for gene expression by immunohistochemistry in a blinded fashion. 7522962 Human
her-2 high-grade prostatic intraepithelial neoplasia The consensus panel identified a small and manageable group of biomarkers measured in tissue or serum as the most promising in prostate cancer chemoprevention, including (1) prostate specific antigen (PSA); (2) morphometric markers, such as nuclear size a 7529857 Human
her-2 fallopian tube carcinomas Data suggest that the HER-2 oncogene does not play a role in tumor transformation and progression in fallopian tube carcinomas. 7637958 Human
her-2 epithelial-myoepithelial carcinomas Thirty-one salivary gland epithelial-myoepithelial carcinomas from 26 patients were studied by DNA flow cytometry, and immunostaining for Ki-67 and HER-2/neu oncogene product. 7726139 Human
her-2 breast tumors Amplification of the neu/erbB-2/HER-2 gene and/or overexpression of its receptor tyrosine kinase product, p185neu/erbB-2 (p185), occurs in 15-40% of primary human breast tumors and is variably correlated with poor patient prognosis. 7728765 Human
her-2 papillary carcinomas There has been continued work on prognostic factors in endometrial carcinomas with ploidy, hormone receptor status, HER-2/neu expression, and coexistent hyperplasia confirmed as independent prognostic factors, while clear cell and serous papillary carcino 7742498 Human
her-2 oral leukoplakia To identify and modulate molecular SEBs in intraepithelial neoplasia of the upper aerodigestive tract, we studied expression of the epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha), and HER-2/neu genes in oral leukopla 7823600 Human
her-2 leukoplakia Pretreatment expression of EGFR, TGF-alpha, and HER-2/neu in leukoplakia was increased when compared to normal-appearing mucosa. 7823600 Human
her-2 ovarian carcinomas [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas] C-erbB-2 (HER-2/neu) proto-oncogene is mainly expressed in epithelial tissue and activated due to its amplification. 7866905 Human
her-2 gynecologic tumors P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. 7910219 Human
her-2 gastrinoma METHODS: The differential polymerase chain reaction (PCR) procedure was used to detect amplification of the HER-2/neu gene in DNA samples from the novel human gastrinoma cell line (PT) and from paraffin-embedded samples of gastrinomas. 7911296 Human
her-2 adenosarcoma The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. 8557233 Human
her-2 mmmt Immunohistochemistry was used to grade overexpression of p53 protein, HER-2/neu protein, epidermal growth factor receptor (EGFR), and Ki-67 antigen in both the glands and stroma of tissue from 20 women with MMMT and 6 women with AS. 8557233 Human
her-2 mmmt HER-2/neu protein was not overexpressed in any AS or primary MMMT. 8557233 Human
her-2 supraglottic squamous cell carcinoma Evaluation of HER-2/neu (c-erbB-2) oncogene expression in whole organ sections of supraglottic squamous cell carcinoma. 8604888 Human
her-2 supraglottic carcinomas Sections from 32 supraglottic carcinomas were studied immunohistochemically for the presence of HER-2/neu (c-erbB-2) oncogene expression. 8604888 Human
her-2 medullary carcinomas Statistically significant associations were observed between p53 expression or MIB-1 count and age below 50 years, high-grade tumours, medullary carcinomas, and absence of hormone receptors. p53 mutations were associated with increased MIB-1 count, HER-2/ 8608982 Human
her-2 endometrioid carcinoma STUDY DESIGN: Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic 8610771 Human
her-2 cancers of the uterus CONCLUSIONS: Determination of the frequency and levels of EGF receptors, HER-2/neu protein, and cathepsin D in uteri with and without cancer and the availability of reference materials developed in our laboratory, will allow evaluation of their prognostic 8616763 Human
her-2 borderline ovarian tumours Twenty-four advanced (surgical stage III and IV) ovarian carcinomas and 15 borderline ovarian tumours were studied for the overexpression of nm23 and HER-2/neu (c-erb-B2) by means of immunohistochemistry on sections from routinely processed, paraffin-embe 8702236 Human
her-2 gynecologic cancers The role of the HER-2/neu oncogene in gynecologic cancers. 8796816 Human
her-2 human lung cancer Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance. 8875978 Human
her-2 seborrheic keratoses Examination for the localization of epidermal growth factor receptor (EGF-R) and HER-2/neu oncoprotein by immunohistochemistry revealed positive staining on the epithelial strands branching downwards on the specimens of seborrheic keratoses. 8935630 Human
her-2 high-grade pin Potential SEBs for screening chemopreventive agents for prostate cancer in short-term Phase II trials include (1) histologic premalignant lesions, such as high-grade PIN; (2) biochemical markers, including prostate-specific antigen (PSA) serum concentrati 9027613 Human
her-2 benign ovarian cystadenomas Paraffin-embedded sections from the 42 BLOT, 5 normal ovaries, and 10 benign ovarian cystadenomas were stained using monoclonal antibodies against human p53 (DAKO-p53, DAKO, Denmark) and HER-2/neu (C-erB-2, Triton, Parkway, CA). 9159328 Human
her-2 ovarian cystadenomas None of the normal ovaries or ovarian cystadenomas demonstrated overexpression of p53 or HER-2/neu. 9159328 Human
her-2 stage i endometrial carcinoma OBJECTIVE: To determine if DNA ploidy, hormone receptors, vascular space invasion (VSI), perivascular lymphocytes (PVL), and the oncogenes HER-2/neu, p53, and bcl-2 are independent prognostic indicators for lymph node metastasis and cancer recurrence in c 9299250 Human
her-2 pancreatic tumors Our studies suggest a possible relationship of family cancer history to the expression of p53 and p21WAF in pancreatic tumors, but show no relationship to the expression of HER-2/neu or to the prevalence of K-ras mutations. 9322121 Human
her-2 pancreas cancer In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
her-2 pancreatic carcinoma In a series of 81 patients with pancreatic carcinoma, we analyzed the status of K-ras gene mutations and the expression of P21WAF-1, p53, and HER-2/neu protein to identify possible molecular associations in pancreas cancer cases of these molecular markers 9322121 Human
her-2 verrucous carcinoma of the oral cavity Comparative study of invasive squamous cell carcinoma and verrucous carcinoma of the oral cavity: expression of bcl-2, p53, and Her-2/neu, and indexes of cell turnover. 9398988 Human
her-2 renal cell carcinoma (rcc) To analyze whether Her-2/neu epitopes are tumor-associated antigens for renal cell carcinoma (RCC) and colon carcinoma, we induced Her-2/neu peptide-specific CTL responses by primary in vitro immunization and used these CTLs to determine the presentation 9485028 Human
her-2 stage ii breast carcinoma METHODS: This study evaluated data from 226 patients with TNM Stage I and early Stage II breast carcinoma and included the variables p53 and c-erbB-2 (HER-2/neu). 9486576 Human
her-2 bladder adenocarcinoma METHODS AND RESULTS: We investigated the usefulness of a panel of antibodies against cytokeratin 7, E48, cytokeratin 20, PSA, PSAP, CEA, vimentin, OC125 and HER-2/neu, to discriminate primary bladder adenocarcinoma from adenocarcinomas arising from the pr 9522212 Human
her-2 stage i adenocarcinoma of lung Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. 9800799 Human
her-2 stage i lung adenocarcinoma CONCLUSIONS: Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. 9800799 Human
her-2 colorectal adenocarcinomas HLA-A2+ patients with metastatic breast, ovarian, or colorectal adenocarcinomas that overexpressed HER-2/neu were immunized with the HLA-A2-binding epitope p369-377 (p369). 9809997 Human
her-2 invasive adenocarcinomas Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2 mucinous neoplasms Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2 pancreatic cancer Among the findings: peptic ulcer disease is a significant predisposing risk factor (odds ratio = 3.9) for pancreatic cancer; as many as 50% of all intraductal papillary mucinous neoplasms are associated with invasive adenocarcinomas; alteration of gene ex 9821173 Human
her-2 fap Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. 10025882 Human
her-2 fap As a part of the mechanisms of action in reversing FAP adenomas by the low-dose sulindac maintenance therapy (2 x 25 mg/patient per day), the extent of HER-2 proto-oncogene expression in the rectal mucosa seems to be of interest. 10025882 Human
her-2 ductal hyperplasia Overall, HER-2/neu was positive in normal ducts, ductal hyperplasia, dysplasia, and carcinoma cells in 0 of 30, 11 of 20 (55%), 10 of 15 (67%), and 12 of 15 (80%), respectively, with progressive increase in the intensity of staining; p53 was positive in 1 10029438 Human
her-2 ovarian carcinoma HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
her-2 prostate cancers HER-2/neu gene amplification and protein overexpression have been associated with prognosis in breast, lung and prostate cancers but have not been extensively studied in ovarian carcinoma. 10078105 Human
her-2 lobular carcinoma in situ Prognostic factors evaluated were age, histologic type of invasive tumor, presence of associated ductal and/or lobular carcinoma in situ, lesion size, histologic and nuclear grades, DNA index, presence of multiploidy by flow cytometric analysis, and immun 10349989 Human
her-2 breast cancer Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. 10502729 Human
her-2 metastasis Ki 67 and p34cdc2 proliferation marker overexpression, HER-2/neu oncogene amplification, large tumor size, high tumor grade, advanced tumor stage, positive lymph node status, and distant metastasis at the time of diagnosis predicted disease-related death 10510669 Human
her-2 gastrointestinal stromal tumours (gists) We studied the expression of TGF-alpha and two EGFRs (HER-1 and HER-2) in gastrointestinal stromal tumours (GISTs) of the stomach (n = 9) and small intestine (n = 6) using standard immunostaining techniques in paraffin-embedded sections. 10599309 Human
her-2 primary fallopian tube carcinoma Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. 10629373 Human
her-2 fallopian tube adenocarcinoma The high incidence of p53, HER-2/neu and c-myc overexpression in fallopian tube adenocarcinoma suggests these genes may play a role in its tumorigenesis. 10629373 Human
her-2 adenocarcinomas of the esophagus Using M68 immunohistochemistry and a scoring system similar to that used for HER-2/neu, we found that M68 protein was overexpressed in 30 of 68 (44%) human adenocarcinomas of the esophagus, stomach, colon, and rectum. 10655513 Human
her-2 smooth muscle neoplasms STUDY DESIGN: Forty-five uterine smooth muscle neoplasms were assessed for DNA ploidy; silver-staining nucleolar organizer regions (AgNORs); percent nuclear proliferating cell nuclear antigen (PCNA); expression of p53, Her-2/neu, and MDM-2 protein; mitoti 10656730 Human
her-2 breast carcinoma Her-2/neu (H2N) status in breast carcinoma has been considered a prognostic factor that may have therapeutic implications; however, the correlation between H2N overexpression and gene amplification has not been completely defined. 10658908 Human
her-2 epithelial hyperplasia In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia, as well as abnormalities of several cell 10762008 Human
her-2 rectal cancer Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. 10765127 Human
her-2 human breast cancers The Her-2/neu protein is overexpressed, mostly as a result of gene amplification, in 20-30% of human breast cancers, and has been shown to have prognostic and predictive value for treatment with chemotherapy or the new monoclonal antibody, Herceptin. 10889820 Human
her-2 melanoma These results demonstrated that HER-2/neu amplification and overexpression are not common in advanced stage melanoma and thus, HER-2/neu would have limited value as a biomarker or as a target for immunotherapy in melanoma. 10928135 Human
her-2 large cell carcinomas HER-2/neu overexpression was detected in 27% of the tumors of different histological types including adenocarcinomas, large cell carcinomas, and squamous cell carcinomas. 10928158 Human
her-2 calgb We examine a possible interaction between HER-2/neu or p53 expression and tamoxifen effectiveness in patients with ER-positive, node-positive disease treated with cyclophosphamide, doxorubicin, and fluorouracil in a large adjuvant chemotherapy trial (Canc 11032587 Human
her-2 calgb PATIENTS AND METHODS: CALGB 8541 assessed HER-2/neu expression in patients with ER-positive disease by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) and amplification by differential polymerase chain reaction (PCR). 11032587 Human
her-2 acinic cell adenocarcinoma Morphologic examinations of salivary gland neoplasias arising in male BALB/c (H-2d) mice carrying the activated HER-2/neu (BALB-NeuT) indicate that expression of the oncogene product in the ductal-acinar structures results in a very human-like acinic cell 11054659 Mouse
her-2 breast carcinoma Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. 11119122 Human
her-2 extra-adrenal pheochromocytomas Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. 11127918 Human
her-2 cyst Gross (tumor size, weight, local extension, cyst formation, hemorrhage, necrosis), microscopic (pleomorphism, hyaline globules, intranuclear inclusion, mitotic count, capsular and vascular invasion, ganglionic/neuronal differentiation), and immunohistoche 11127918 Human
her-2 lung cancer Biologic markers resulting from genetic lesions in lung cancer are grouped as follows: (a) oncogene amplification and overexpression (aberrant gene expression) and mutated tumor suppressor genes -- ras gene, myc gene, HER-2/neu and survivin gene, p53 and 11162866 Human
her-2 cancer Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
her-2 human breast cancers Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
her-2 advanced cancer Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. 11223076 Human
her-2 papillomatosis We investigated by immunohistochemistry expressions of topoisomerase alpha II, MIB-1, p53, p21, E-cadherin, retinoblastoma (RB) gene protein product, HER-2/neu, and steroid hormone receptors in a case of juvenile respiratory papillomatosis with malignant 11277421 Human
her-2 clear cell tumors Both endometrioid and clear cell tumors belonged to the largest subgroup with concomitant negativity for both HER-2/neu and EGFR. 11328410 Human
her-2 ovarian adenocarcinomas The HER-2/ErbB-2 oncoprotein is overexpressed in human breast and ovarian adenocarcinomas and is clearly associated with the malignant phenotype. 11340582 Human
her-2 breast cancers The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. 11416960 Human
her-2 udh Increased proliferation (Ki67), overexpression of cyclin D1, HER-2/neu, p21 and p53, and decreased expression of bcl-2 and p27 could already be found in UDH. 11439365 Human
her-2 breast cancer In breast cancer amplification of the HER-2/neu oncogene and over-expression of the protein product is associated with poor prognosis, predicts response to some chemotherapeutic regimens and is the target for Herceptin treatment. 11455000 Human
her-2 leydig cell tumor PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
her-2 testicular tumors PURPOSE: The goal of this work was to study the expression of epidermal growth factor receptor (by use of monoclonal antibody EGFR 1) and HER-2/neu (by use of monoclonal antibody EGFR 2), as well as EGFR activation [phosphorylated EGFR (P-EGFR)] and autoc 11555591 Human
her-2 salivary duct carcinoma (sdc) [About the prognostic value of Her-2 gene-amplification and cell-proliferation in salivary duct carcinoma of the major salivary glands - a pilot-study] INTRODUCTION: The salivary duct carcinoma (sdc) represents a rare variant of the group of adeno-carcino 11555785 Human
her-2 adrenocortical neoplasms Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. 11556748 Human
her-2 malignant adrenocortical neoplasms HER-2/neu overexpression was not observed in any of the benign or malignant adrenocortical neoplasms. 11556748 Human
her-2 oropharyngeal squamous cell carcinoma Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. 11839675 Human
her-2 head and neck cancer The prognostic significance and clinical implications of HER-2/neu expression and amplification in head and neck cancer will require additional studies. 11839675 Human
her-2 adh Twenty-six patients with Her-2/neu-overexpressing invasive ductal carcinomas (as judged by strong immunoreactivity with Her-2/neu antibody) and coexisting lesions of ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCI 11850540 Human
her-2 adh Among these patients, amplification of Her-2/neu in ADH was demonstrated in 7 of 13 cases with ADH, and in DCIS, in 21 of 22 cases with DCIS. 11850540 Human
her-2 primary carcinomas We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody). 11850540 Human
her-2 adh This FISH study indicates that amplification of Her-2/neu can emerge de novo in any stage of the disease process, from ADH to metastatic lesions, but most often appears first in ADH or DCIS. 11850540 Human
her-2 sporadic breast cancer To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we have performed fluorescence in situ hybridization on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation ca 11888924 Human
her-2 invasive breast cancer BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. 11893034 Human
her-2 burkitt's lymphoma After transfecting wild-type HER-2/neu or chimeric HER-2/CD19 into Raji Burkitt's lymphoma cells and wild-type CD19 or chimeric CD19/HER-2 into SK-BR-3 breast cancer cells, target cell lines were selected for high membrane expression of transfected A 11907082 Human
her-2 hodgkin lymphomas The aim of this study was to evaluate the expression of HER-2/neu in the malignant lymphomas: non-Hodgkin and Hodgkin lymphomas. 11958663 Human
her-2 hodgkin lymphomas CONCLUSIONS: Non-Hodgkin and Hodgkin lymphomas do not express the HER-2/neu oncoprotein. 11958663 Human
her-2 breast cancer HER-2/neu gene amplification and cell surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. 11986780 Human
her-2 papillary cancer Overexpression of HER-2/neu in uterine serous papillary cancer. 12006548 Human
her-2 bilateral breast cancer HER-2/neu expression in bilateral breast cancer has not been reported. 12058961 Human
her-2 liver metastases HER-2/neu mRNA levels were significantly higher (P = 0.032) in tumors associated with liver metastases but not with tumor location or size. 12097278 Human
her-2 adenocarcinoma of the pancreas CONCLUSION: Her-2/neu overexpression detected by immunohistochemistry does not appear to be a poor prognostic factor in patients with adenocarcinoma of the pancreas. 12168842 Human
her-2 primary brain tumors We retrospectively analyzed a large cohort of patients with primary brain tumors to evaluate the prognostic role of HER-2/neu overexpression and clinical characteristics at presentation in patients with shortened survival (< 6 months). 12168843 Human
her-2 malignant brain tumors Further studies are needed to specify whether certain tumor subtypes are more likely to overexpress HER-2/neu and to evaluate the role of HER-2/neu as a target for therapy in malignant brain tumors. 12168843 Human
her-2 germ cell tumours CONCLUSIONS: The lack of concordance between IHC and FISH makes it unlikely that overexpression of the HER-2/neu protein in germ cell tumours is of prognostic or therapeutic relevance. 12194993 Human
her-2 adrenal tumors Expression of HER-2/neu receptor protein in adrenal tumors. 12234062 Human
her-2 adrenal adenomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2 adrenocortical carcinomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2 pheochromocytomas Therefore, we studied expression of the HER-2/neu cell surface receptor protein using three different antibodies in 12 adrenal adenomas, 17 adrenocortical carcinomas and 5 pheochromocytomas. 12234062 Human
her-2 adrenocortical tumors From our data we conclude that specific and significant membranous immunostaining indicating strong overexpression (grade 3) of HER-2/neu protein is not present in adrenocortical tumors. 12234062 Human
her-2 hairy-cell leukemia Examples of new agents are: trastuzumab (Herceptin), a humanized monoclonal antibody that blocks the HER-2/neu proto-oncogene in combination with cytotoxic agents, is used in a percentage of breast cancer patients; signal transduction inhibitor of abl tyr 12375030 Human
her-2 familial breast cancer HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. 12412159 Human
her-2 chondrosarcoma [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
her-2 chondrosarcomas [Prognostic significance of p53, HER-2/neu, Ki-67 and VEGF expression in chondrosarcomas] Expression of the mutant protein-suppressor of tumor growth p53 and the receptor of epidermal growth factor of type II--HER-2/neu may serve as prognostic factors for 12534219 Human
her-2 metastatic osteosarcoma Human epidermal growth factor (Her-2/neu) expression in 25 initial pretreatment osteosarcoma biopsies and 12 posttreatment pulmonary metastatic osteosarcoma resection specimens was assessed by standard immunohistochemical techniques on formalin-fixed para 12544770 Human
her-2 breast cancer Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. 12653946 Human
her-2 breast cancer Amplification of gene HER-2/neu and overexpression of its gene product have been shown to have both prognostic and treatment implications in breast cancer. 12677894 Human
her-2 mfh CS, MFH, and DFS specimens showed the highest incidence of HER-2/neu overexpression (40%, 26%, and 18.2%, respectively). 12714894 Human
her-2 breast cancer The amplification and/or overexpression of the HER-2/neu oncogene and its encoded receptor protein are increasingly used for prognostication and prediction of therapeutic response to Herceptin in breast cancer. 12733117 Human
her-2 atypical hyperplasia Within 33 weeks of life, all 10 mammary glands of virgin BALB/c mice transgenic for the transforming rat HER-2/neu oncogene under the mammary tumor virus promoter (BALB-neuT mice) progress from atypical hyperplasia to invasive palpable carcinoma. 12750275 Mouse
her-2 hydatidiform mole Immunohistochemical staining reactions were performed with the following monoclonal antibodies for hydatidiform mole: beta-hCG, HPL, MIB1, CK18, HER-2/neu, p53 and carbohydrate antibodies, Thomsen-Friedenreich antigen, Glycodelin A, Mucl and Mucl-cor. 12820349 Human
her-2 inclusion cyst In both the ovarian surface and inclusion cyst epithelia, the percentage of cells was determined that stained positively for Ki67, p21, p27, p53, cyclin A, cyclin D1, bcl-2 and the presence of HER-2/neu, oestrogen (ER-alpha) and progesterone receptors (PR 12823709 Human
her-2 stage iii nsclc Overexpression of HER-2/neu in tumor tissues was found in 70% (23 of 32) of patients with MPE-associated ADCLC, 30% (13 of 43) with stage I/II non-small cell lung cancer (NSCLC), and 44% (14 of 32) with stage III NSCLC. 12855637 Human
her-2 thymic epithelial tumours Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. 12877732 Human
her-2 thymic epithelial tumours AIMS: To correlate the expression of a series of apoptotic and oncogene markers (including p53, Bcl-2, BAX, Bcl-XL, p21WAF,1/CIP1, cyclin D1, HER-2/neu) in thymic epithelial tumours with histological type, stage and resectability and to determine whether 12877732 Human
her-2 thymic carcinomas Nine thymic carcinomas revealed membranous positivity for HER-2/neu, but no HER2 gene amplification could be demonstrated by FISH in any of the cases. 12877732 Human
her-2 c-cell hyperplasia In our series of 6 patients with MTC, including 5 patients with adjacent C-cell hyperplasia, Her2/neu levels were immunohistochemically evaluated on formalin-fixed, paraffin-embedded tissues using c-erbB-2/Her-2/neu Oncoprotein Ab-17 monoclonal antibody(m 12894498 Human
her-2 pituitary carcinoma Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. 12924717 Human
her-2 pituitary carcinomas The results indicate that low-level amplification of the HER-2/neu gene might be associated with pituitary carcinomas in which more aggressive behavior is seen. 12924717 Human
her-2 pituitary carcinoma Further studies are needed to determine whether HER-2/neu plays a role in the pathogenesis of pituitary carcinoma. 12924717 Human
her-2 mixed germ cell tumors PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
her-2 teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu receptor status of 28 primary testicular tumors (7 pure teratomas, 21 mixed germ cell tumors containing teratomatous components) using a standardized im 12926088 Human
her-2 choriocarcinoma Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
her-2 mixed tumors Three of the 5 choriocarcinoma components of mixed tumors overexpressed HER-2/neu. 12926088 Human
her-2 choriocarcinoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
her-2 teratoma In one case (teratoma + choriocarcinoma) both components showed HER-2/neu overexpression. 12926088 Human
her-2 medullary carcinoma of breast CONCLUSIONS: Medullary carcinoma of breast is distinct from AMC and HGIDC with prominent lymphocytic infiltrates in amplification and overexpression of HER-2/neu. 14567723 Human
her-2 mpd However, previous studies on HER-2/neu expression in MPD and EPD have given conflicting results. 14616943 Human
her-2 mpd We examined 58 cases of MPD and EPD for HER-2/neu overexpression and vimentin status to study the role of these markers in the production of the Paget's phenotype. 14616943 Human
her-2 mpd Thirty-six of the 38 cases of MPD (94.7%) overexpressed the HER-2/neu oncoprotein and 17 cases (44.7%) showed vimentin expression. 14616943 Human
her-2 mpd Our results indicate that the cell motility enhancing effect of HER-2/neu oncoprotein and possibly vimentin plays a significant role in the pathogenesis of MPD which appears to be a pagetoid spread of an underlying ductal malignancy (secondary), while EPD 14616943 Human
her-2 clear cell carcinomas As compared to all other subtypes, clear cell carcinomas had significantly higher Her-2 neu expression (19%). 14751152 Human
her-2 cartilaginous tumors Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors. 14767542 Human
her-2 mesenchymal chondrosarcomas To clarify the actual frequency of HER-2/neu expression in primary malignant cartilaginous tumors, we examined 89 cases comprising 17 conventional chondrosarcomas, 33 mesenchymal chondrosarcomas, and 39 clear cell chondrosarcomas. 14767542 Human
her-2 gallbladder cancers Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. c-erbB-2, proto-oncogene is amplified and overexpressed in a number of human adenocarcinomas. 15010878 Human
her-2 gallbladder cancer To investigate the therapeutic effect of Trastuzumab in gallbladder cancer, we studied HER-2/neu expression in 43 primary tumors, 12 metastatic lymph nodes and two liver metastasis, using the Hercep test. 15010878 Human
her-2 gynecologic cancers There is increasing levels of evidence suggesting that some circulating factors involved in gynecologic cancers, such as alpha-fetoprotein (AFP), insulin-like growth factor binding protein-3 (IGFBP-3), c-erbB-2 (HER-2/neu), and epidermal growth factor (EG 15051037 Human
her-2 non-hodgkin's lymphoma The current success of molecular targeting therapy is shown by: imatinib mesylate (STI571, Gleevec), targeted to the Bcr/Abl fusion protein derived from a translocation between chromosomes 9 and 22 in chronic myelogenous leukemia; rituximab (Rituxan), a m 15052442 Human
her-2 salivary gland cancer Several molecular targets (c-kit, HER-2/neu, androgen receptors) have been identified in salivary gland cancer. 15069319 Human
her-2 breast carcinoma In breast carcinoma, HER-2/neu gene amplification and receptor protein overexpression are tightly correlated and have prognostic and therapeutic implications. 15072912 Human
her-2 stage ii breast carcinoma Forty-eight patients (68%) had Stage II breast carcinoma and 23 (32%) had Stage III disease. her-2 gene amplification was detected in 19 tumor specimens (28%). 15241821 Human
her-2 papillary serous carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
her-2 small cell carcinoma There was a differential immunoreactivity between the two components: the cells of the papillary serous carcinoma were positive for cytokeratin, CA-125, CEA, and HER-2/Neu, whereas these markers were negative in the small cell carcinoma. 15252320 Human
her-2 uterine papillary serous carcinoma Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. 15284264 Human
her-2 primary carcinoma This increased to 100% if the primary carcinoma was larger than 5 cm, if it was poorly differentiated, or if it showed HER-2/neu gene amplification. 15327491 Human
her-2 testicular germ-cell tumors However, the exact prognostic role of HER-2/neu expression in testicular germ-cell tumors is equivocal. 15330164 Human
her-2 teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
her-2 testicular teratomas PATIENTS AND METHODS: Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumors containing teratomatous components using the standardized immunohistochemical 15330164 Human
her-2 choriocarcinoma With IHC, teratomatous and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). 15330164 Human
her-2 testicular germ-cell tumors CONCLUSION: Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumors. 15330164 Human
her-2 neuroendocrine tumours Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
her-2 neuroendocrine tumours Irrespective of protein overexpression, HER-2/neu gene amplification is rare in lung cancer and studies on its prevalence and clinicopathological implications in early stage non-small cell lung cancer (NCSLC) and neuroendocrine tumours (NET) of the lung a 15386424 Human
her-2 stage i nsclc We evaluated HER-2/neu abnormalities in 345 Stage I NSCLC and 207 Stage I-III NET of the lung of all the diverse histological types, by using immunohistochemistry and fluorescent in situ hybridization in selected cases. 15386424 Human
her-2 large-cell neuroendocrine carcinoma (lcnec) Gene amplification was seen in only 7 (7.4%) of the immunoreactive tumours, with high-level amplification (HER-2/neu gene to chromosome 17 ratio > 4.0) in 3 adenocarcinomas, 1 squamous-cell carcinoma and 1 large-cell neuroendocrine carcinoma (LCNEC), and 15386424 Human
her-2 lung carcinomas HER-2/neu gene amplification and protein overexpression are not closely correlated in lung carcinomas and do not bear any prognostic implication. 15386424 Human
her-2 neuroendocrine tumours Among neuroendocrine tumours, LCNEC show a slightly higher prevalence of either HER-2/neu gene amplification or protein overexpression. 15386424 Human
her-2 malignant bone tumours Soluble p185(HER-2) in patients with malignant bone tumours. 15468309 Human
her-2 malignant bone tumours BACKGROUND: This study was initiated to test the hypothesis that soluble p185(HER-2) could be of value as a diagnostic or predictive marker for patients with malignant bone tumours. 15468309 Human
her-2 hematologic malignancies In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu 15487459 Human
her-2 salivary gland carcinomas We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. 15548714 Human
her-2 metastatic pancreatic adenocarcinomas PURPOSE: To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. 15581051 Human
her-2 metastatic pancreatic cancer METHODS AND MATERIALS: Patients with metastatic pancreatic cancer with 2+/3 + HER-2/neu expression by immunohistochemistry were eligible. 15581051 Human
her-2 epithelial neoplasms Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. 15581965 Human
her-2 serous carcinomas RESULTS: FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. 15581965 Human
her-2 clear cell carcinoma None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; 15581965 Human
her-2 uterine sarcomas BACKGROUND: The aim of this study was to determine ERBB-2 (HER-2/neu) gene alterations in different subtypes of uterine sarcomas. 15581967 Human
her-2 carcinoma ex pleomorphic adenoma Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. 15693886 Human
her-2 metastatic pancreatic adenocarcinomas Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p5 15725808 Human
her-2 cystic hypersecretory carcinoma of breast Report of five cases] OBJECTIVE: To describe a poorly recognized histological and immunohistochemical features of cystic hypersecretory carcinoma of breast, including the overexpression of HER-2/neu protein and androgen receptors. 15779300 Human
her-2 malignant gliomas DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas. 15809708 Human
her-2 carcinosarcoma It still needs to be clarified whether HER-2/neu overexpression increases the aggressiveness of carcinosarcoma, or whether HER-2/neu has a direct role in its pathogenesis, as described in breast cancers. 15901136 Human
her-2 uterine carcinosarcoma Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of 15901136 Human
her-2 mucinous carcinoma of the breast Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast. 15960065 Human
her-2 mucinous carcinoma Compared with the non-mucinous type, mucinous carcinoma specimens have more DCC expression (100% vs 48.7%; p = 0.0027) and more ER expression (90.9% vs 26.9%; p = 0.0023), but less HER-2/neu overexpression (0% vs 38.1%; p = 0.0302). 15960065 Human
her-2 ovarian serous carcinomas An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. 16006797 Human
her-2 large cell neuroendocrine carcinoma Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic 16014119 Human
her-2 large cell neuroendocrine carcinomas We studied the immunohistochemical expression of HER-2/neu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), estrogen receptor (ER), and progesterone receptor (PR) in uterine cervical small cell 16014119 Human
her-2 endometrial cancer A novel in vivo model of tamoxifen-stimulated endometrial cancer was developed and the role of HER-2/neu investigated by using trastuzumab. 16166331 Human
her-2 tongue carcinoma [Effect on apoptosis of Tca8113 of interference of Bcl-2 and HER-2 genes antisense oligodeoxynucleotides transfection] OBJECTIVE: To investigate the interference and the mechanisms of Bcl-2 and HER-2 genes antisense oligodeoxynucleotides combined transfec 16704097 Human
her-2 tongue carcinoma Bcl-2 and HER-2 combined ASODN was superior to single ASODN in the intervention of tongue carcinoma. 16704097 Human
her-2 breast carcinoma HER-2/neu protein expression has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease, and with a poor prognosis, and constitute a predictive factor of 16868827 Human
her-2 gastric cancer HER-2/neu amplification may constitute an independent prognostic factor in gastric cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclo 16868827 Human
her-2 murine neuroblastoma The iv administration of Gd-DOTAMA-C6-Gln allowed the MRI visualization of tumor masses in A/J mice grafted with the murine neuroblastoma cell line Neuro-2a and in Her-2/neu transgenic mice developing multiple mammary carcinoma, respectively. 16884304 Human
her-2 leukoplakia HER-2/neu expression in plasma and biopsy of patients with oral lichen planus in comparison to leukoplakia. 16922972 Human
c-erb b2 adenoid cystic carcinomas This study was undertaken to define the role of c-erb B2 and c-erbB3 in adenoid cystic carcinomas (A.C.C.) of the salivary glands. 8669836 Human
c-erb b2 prolactin-secreting pituitary adenomas Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. 16622555 Human
c-erb b2 pituitary adenomas In this study we investigated the presence of p53, Ki-67 and c-erb B2 in 38 pituitary adenomas with immunohistochemical positivity for GH and prolactin (n=26; 68.4%), for prolactin (n=9; 23.7%) and for GH (n=3. 7.8%). 16622555 Human
erbb-2 breast tumors Amplification of the neu/erbB-2/HER-2 gene and/or overexpression of its receptor tyrosine kinase product, p185neu/erbB-2 (p185), occurs in 15-40% of primary human breast tumors and is variably correlated with poor patient prognosis. 7728765 Human
erbb-2 hepatic disorders Patients with hepatic disorders also had positive serum ErbB-2 protein levels, ie, 43.8% (7/16) for hepatocellular carcinoma and 28.9% (11/38) for hepatitis and liver cirrhosis, although the increase was slight and barely exceeded 10 ng/ml. 7913312 Human
erbb-2 anaplastic astrocytoma The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
erbb-2 oligoastrocytoma The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
erbb-2 who grade i meningiomas The results of in situ hybridization using a 32P-labeled neu/erbB-2 RNA probe performed on four WHO grade I and II astrocytomas, seven WHO grade IV glioblastomas, one WHO grade II oligoastrocytoma, one WHO grade III anaplastic astrocytoma, and three WHO g 7914508 Human
erbb-2 lacrimal gland tumors [c-erbB-2 oncogene product expression in lacrimal gland tumors] Using a polyclonal antibody to the c-erbB-2 oncogene product (ErbB-2 protein), an immunohistochemical study on the expression of ErbB-2 protein in lacrimal gland tumors was performed. 7915079 Human
erbb-2 malignant lacrimal gland tumors The relation ErbB-2 protein with the malignant lacrimal gland tumors in general is not clear, but pleomorphic adenomas of lacrimal gland could have some relation with this protein. 7915079 Human
erbb-2 prostatic adenocarcinoma Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma. 8900374 Human
erbb-2 papillary carcinomas In contrast, ras mutations are rare (10%). erbB-2/neu gene amplification and activating mutations are not detected, although elevated mRNA levels were found in 20% of papillary carcinomas. 9889797 Human
erbb-2 adenomatous polyp Overexpression of the ERBB-2 protein was detected in 1 adenomatous polyp with malignant transformation. 10547536 Human
erbb-2 small cell carcinoma Only seven of 23 (30. 4%) patients with small cell carcinoma had elevated ErbB-2 levels. 10754210 Human
erbb-2 rectal cancer Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. 10765127 Human
erbb-2 breast carcinoma Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. 11119122 Human
erbb-2 ovarian adenocarcinomas The HER-2/ErbB-2 oncoprotein is overexpressed in human breast and ovarian adenocarcinomas and is clearly associated with the malignant phenotype. 11340582 Human
erbb-2 squamous cell cancers PURPOSE: This study was conducted to evaluate the clinical significance of the localization of epidermal growth factor receptor (EGF-r), transforming growth factor (TGF)-alpha, and erbB-2 in the development, progression and prognosis of squamous cell canc 11895903 Human
erbb-2 malignant schwannomas The results indicate that LOHs on chromosomes 10 and 5 are required for the development of EtNU-induced malignant schwannomas from immature neu/Erbb-2 mutant glial cells, and that putative tumor suppressor genes are localized on chromosome 10q32.3, corres 12082026 Rat
erbb-2 axillary metastases In our study, 40.91% of cases were erbB-2 positive, p185 expression being maintained from the primary tumors to axillary metastases and associated with positive nodal status and with the absence of hormonal receptors expression (p < 0.05). 14755939 Human
erbb-2 embryonal rhabdomyosarcoma Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. 16729016 Human
erbb-2 alveolar rhabdomyosarcoma Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. 16729016 Human
erbb-2 embryonal rhabdomyosarcoma Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. 16729016 Human
erbb-2 embryonal rhabdomyosarcoma Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma. 16729016 Human
erbb-2 biliary tract cancer Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. 16926628 Mouse
erbb-2 biliary tract cancer Protein expression of epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 was assessed in seven human biliary tract cancer cell lines by immunoblotting. 16926628 Human
erbb-2 biliary tract cancer Immunoblotting revealed expression of epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 in all biliary tract cancer cell lines. 16926628 Human
erbb-2 biliary tract cancer Epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 expression was detectable in biliary tract cancer, and receptor inhibition exerts marked effects on tumor growth in vitro and in vivo, which was strongest for the 16926628 Mouse
her-2 colorectal cancer CONCLUSION: HER-2/neu overexpression may constitute an independent prognostic factor in colorectal cancer patients, and patients exhibiting HER-2/neu overexpression might constitute potential candidates for a new adjuvant therapy which involves the use of 16947041 Human
her-2 gestational trophoblastic neoplasia OBJECTIVE: The aim of the present study was to asses the ability of Her-2/neu immunohistochemical staining of the molar tissue to predict the risk of developing gestational trophoblastic neoplasia (GTN). 17126893 Human
her2 bilateral breast cancer HER2 status in bilateral breast cancer. 17269588 Human
her2 bilateral breast cancer BACKGROUND: The purpose of this study was to identify correlates of HER2 status for patients with bilateral breast cancer. 17269588 Human
neu granulosa cell tumors STUDY DESIGN: Formalin-fixed paraffin-embedded archival tissue blocks of 20 unselected nonepithelial ovarian malignancies (12 granulosa cell tumors and 8 germ cell tumors) diagnosed between 1993 and 2005 were immunohistochemically stained for Her-2/neu. 17240244 Human
neu oral squamous cell carcinoma Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. 17238969 Human
neu hydatidiform mole A positive immunohistochemical Her-2/neu stain was found in 6 (18.2%) of the patients with hydatidiform mole (3 with a complete mole). 17126893 Human
neu hydatidiform moles Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. 17126893 Human
neu prostate tumors A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors. 17192923 Human
neu malignant skin adnexal tumor We believe this to be the first demonstration of Her-2/neu amplification in a malignant skin adnexal tumor. 17214855 Human
neu phyllodes tumors Her-2/neu and c-kit were only weakly or infrequently expressed in the epithelial components of prostatic phyllodes tumors. 17192792 Human
neu adnexal carcinomas In analogy to breast carcinoma, these findings suggest the applicability of trastuzumab for patients with metastatic adnexal carcinomas demonstrating Her-2/neu amplification. 17214855 Human
neu gestational trophoblastic neoplasia Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. 17126893 Human
c-erb b-2 primary synovial chondromatosis C-erb B-2 staining in primary synovial chondromatosis: a comparison with other cartilaginous tumours. 8869286 Human
c-erb b-2 primary synovial chondromatosis In this study C-erb B-2 immunostaining has been used to highlight distinct differences between the cartilage found in primary synovial chondromatosis (n = 20), normal articular cartilage (n = 10), benign enchondromas (n = 10), and chondrosarcomas (n = 10) 8869286 Human
c-erb b-2 gastroenteropancreatic neuroendocrine tumors (gpnts) METHODS: Monoclonal antibodies were employed, along with microwave antigen retrieval and the avidin-biotin immunohistochemical method, to investigate the expression of c-myc, bcl-2, c-erb B-2, c-erb B-3, c-jun, and proliferating cell nuclear antigen (PCNA 9264349 Human
c-erb b-2 pancreatic neuroendocrine tumors (pnts) RESULTS: Immunoreactivities for c-myc, bcl-2, c-erb B-2, c-erb B-3, and c-jun were detected in 100%, 45%, 24%, 7%, and 24% of pancreatic neuroendocrine tumors (PNTs), respectively. 9264349 Human
erbb2 early stage breast cancer CONCLUSIONS: For early stage breast cancer patients treated with adjuvant tamoxifen, overexpression of erbB2 is an independent marker of poor prognosis. 11205461 Human
erbb2 oral squamous carcinoma Tumour-specific overexpression of ErbB receptors and their co-expression, most frequently involving EGFR and ErbB2, in the same cell layer of neoplastic epithelium, implicate receptor heterodimers in the pathogenesis of oral squamous carcinoma. 11673832 Human
erbb2 ductal breast cancers In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. 12032832 Human
her2 germ-cell cancer Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. 10631474 Human
her2 differentiated cancers In DCIS, HER2 overexpression is found specifically in poorly histologically differentiated disease and not in well differentiated cancers. 11167086 Human
her2 synchronous bilateral breast carcinoma Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. 12016392 Human
her2 primary peritoneal carcinoma Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. 12525520 Human
her2 primary peritoneal carcinoma PATIENTS AND METHODS: Eligible patients had measurable persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with 2+ or 3+ HER2 overexpression documented by immunohistochemistry. 12525520 Human
her2 paraffin embedded tumor METHOD: Immunohistochemical staining for PR and HER2 was performed on paraffin embedded tumor specimens obtained from 185 patients with breast cancer, and follow-up studies were conducted and the survival time of the patients recorded. 12697480 Human
her2 measurable metastatic breast cancer Women with measurable metastatic breast cancer whose primary or secondary tumor overexpressed HER2 were eligible for inclusion. 12722022 Human
her2 metastatic malignant melanoma Absence of HER2 overexpression in metastatic malignant melanoma. 14502781 Human
her2 metastatic malignant melanoma This study examined the incidences of HER2 protein overexpression and HER2 gene amplification in metastatic malignant melanoma, which remain unclear in the literature. 14502781 Human
her2 metastatic malignant melanoma CONCLUSIONS: We found a low incidence of HER2 expression and no evidence of HER2 protein overexpression or HER2 gene amplification in metastatic malignant melanoma tissues. 14502781 Human
her2 lymph node metastasis Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. 14675323 Human
her2 lymph node metastasis This paper looks at whether c-erbB-2/HER2 expression in uterine cervical carcinoma before treatment is a predictive parameter of prognosis in patients with para-aortic lymph node metastasis (PALN) in advanced disease after treatment with radiation therapy 14675323 Human
her2 metastatic bladder cancer Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. 14998864 Human
her2 urinary tract transitional cell carcinoma OBJECTIVES: To investigate HER2 (c-erbB-2) protein overexpression and HER2 gene amplification in upper urinary tract transitional cell carcinoma (TCC) with respect to its association with tumor grade and stage, as well as the prognostic significance. 15667899 Human
her2 high-risk breast cancers High-level expression of S14 identifies a subset of high-risk breast cancers that is not specified by analysis of sex steroid receptors, Her2/neu, or cyclin D1, and provides a molecular correlate to histologic features that predict recurrence. 16552628 Human
neu uterine corpus cancer Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. 7977518 Human
neu uterine corpus cancer CONCLUSION: In this referral population, c-myc activation is more common than HER-2/neu activation in uterine corpus cancer and is associated with tumors of higher grade. 7977518 Human
neu early onset breast cancer FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. 8872329 Human
neu early vulvar cancer S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer. 9367708 Human
neu early vulvar cancer OBJECTIVE: Our aim was to determine the value of the S-phase fraction, p53, and HER-2/neu status as predictors of inguinal nodal metastasis in early vulvar cancer. 9367708 Human
neu early vulvar cancer CONCLUSION: Early vulvar cancer patients with inguinal node metastasis have a significantly higher S-phase fraction and are more likely to have HER-2/neu immunopositivity when compared to those without nodal metastasis. 9367708 Human
neu ovarian papillary serous carcinoma HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. 10409445 Human
neu ovarian papillary serous carcinoma In this study we used fluorescent in situ hybridization (FISH) to determine HER-2/neu amplification in ovarian papillary serous carcinoma and compared the frequency of amplification in two stages of the disease. 10409445 Human
neu papillary serous ovarian carcinoma Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe. 10409445 Human
neu ovarian papillary serous carcinoma This study not only confirms the presence of a subset of ovarian papillary serous carcinoma with HER-2/neu gene amplification, but it also indicates that HER-2/neu oncogene amplification is more likely to be associated with a more advanced stage. 10409445 Human
neu oral squamous cell carcinoma Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. 10632356 Human
neu lobular breast cancers Although Her-21neu overexpression was a common finding in lobular breast cancers, Her-2/neu amplification was not observed in these tumors. 10656439 Human
neu villoglandular adenocarcinomas Twelve well-differentiated villoglandular adenocarcinomas (WDVAs) of the uterine cervix were retrospectively analyzed for the presence and specific genotype of human papillomavirus (HPV), tumor suppressor loss (p53, MCC, APC, BRCA1), cancer gene mutation 10782406 Human
neu advanced stage cancer Interestingly, 90% of patients with advanced stage cancer (stage IIIB/IV NSCLC or extensive SCLC) overexpressed HER-2/neu. 11679181 Human
neu noninvasive cancers Of the 21 paired specimens immunostained for HER-2/neu, 11 were invasive cancers in both breasts, nine were invasive cancers in one breast and noninvasive cancers in the other breast, and one was noninvasive cancers in both breasts. 12058961 Human
neu primary malignant brain tumors Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. 12168843 Human
neu paraffin embedded tumors Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. 12297183 Human
neu primary malignancy METHODS: To determine whether a signet ring carcinoma was a primary malignancy of the gastrointestinal tract metastatic to the breast or vice versa, histochemical analysis was performed for Her-2/NEU, gross cystic disease fluid protein-15, estrogen recept 12464875 Human
neu methylcholanthrene-induced sarcomas In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu tr 12867593 Human
neu early stage cervical cancer OBJECTIVE: The purpose of this study was to compare HER-2/neu expression on biopsies obtained from early stage cervical cancer, primary cell lines established therefrom, established cervical cancer cell lines, and metastatic or recurrent sites of disease; 14529687 Human
neu invasive cervical carcinoma The aim of this study was to investigate HER-2/neu (c-erbB2) overexpression/amplification in carcinoma of the uterine cervix using immunohistochemistry and fluorescent in situ hybridization (FISH) to assess whether anti-p185c-erbB2 therapy might have pote 14668544 Human
neu invasive cervical carcinoma Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients. 14668544 Human
neu recurrent epithelial ovarian cancer A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. 15131023 Human
neu early stage cervical cancer The upregulation of uPA by HER-2/neu seen in cancer cells in vitro appears to occur in vivo in early stage cervical cancer. 15247985 Human
neu germ-cell testicular tumors Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. 15330164 Human
neu ovarian clear cell adenocarcinoma Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. 15350366 Human
neu non-small cell carcinomas (nsclc) Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
neu oral squamous cell carcinoma (oscc) OBJECTIVES: Amplification of the proto-oncogene c-erbB-2 (HER-2/neu) has been shown to be a prognostic marker in many kinds of cancer including oral squamous cell carcinoma (OSCC). 15482324 Human
neu primary malignancies Also, there was a higher incidence of associated primary malignancies (outside the CNS) in the HER-2/neu overexpression group (30% vs. 7%). 15565811 Human
neu metastatic pancreatic cancers Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. 15581051 Human
neu metachronous cancers Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts. 15871703 Human
neu first primary cancer The primary objective of this study was to evaluate the relative prevalence of estrogen receptor-negative contralateral breast cancer to the first primary cancer and to assess the correlation between the relative overexpression of HER-2/neu in the first p 15871703 Human
neu first primary cancer The correlation between HER-2/neu overexpression in the matched first primary and contralateral breast cancers was statistically significant, suggesting that the diagnosis of HER-2/neu overexpression in contralateral breast cancer is associated with HER-2 15871703 Human
neu high-risk breast cancers High-level expression of S14 identifies a subset of high-risk breast cancers that is not specified by analysis of sex steroid receptors, Her2/neu, or cyclin D1, and provides a molecular correlate to histologic features that predict recurrence. 16552628 Human
neu intestinal-type cancers Intestinal-type cancers exhibited higher rates of HER-2/neu amplification than did diffuse-type cancers (P < 0.05). 16868827 Human
her-2 uterine corpus cancer Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. 7977518 Human
her-2 uterine corpus cancer CONCLUSION: In this referral population, c-myc activation is more common than HER-2/neu activation in uterine corpus cancer and is associated with tumors of higher grade. 7977518 Human
her-2 early onset breast cancer FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. 8872329 Human
her-2 early vulvar cancer S-Phase fraction, p53, and HER-2/neu status as predictors of nodal metastasis in early vulvar cancer. 9367708 Human
her-2 early vulvar cancer OBJECTIVE: Our aim was to determine the value of the S-phase fraction, p53, and HER-2/neu status as predictors of inguinal nodal metastasis in early vulvar cancer. 9367708 Human
her-2 early vulvar cancer CONCLUSION: Early vulvar cancer patients with inguinal node metastasis have a significantly higher S-phase fraction and are more likely to have HER-2/neu immunopositivity when compared to those without nodal metastasis. 9367708 Human
her-2 cardiac carcinoma [Expression of Cath-D, P-gp and Her-2 in carcinoma of the cardia] OBJECTIVE: To investigate if Cath-D, P-gp and Her-2 are correlated with prognosis in patients with cardiac carcinoma. 9596938 Human
her-2 cardiac carcinoma The P-gp and Cath-D were not significant in differential level of cardiac carcinoma and expression of Her-2 was significant (P < 0.05). 9596938 Human
her-2 ovarian papillary serous carcinoma HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. 10409445 Human
her-2 ovarian papillary serous carcinoma In this study we used fluorescent in situ hybridization (FISH) to determine HER-2/neu amplification in ovarian papillary serous carcinoma and compared the frequency of amplification in two stages of the disease. 10409445 Human
her-2 papillary serous ovarian carcinoma Archival tissues from 23 cases of papillary serous ovarian carcinoma (9 cases of stage I and 14 cases of stage III) were analyzed by FISH using a HER-2/neu probe and a chromosome 17 centromere control probe. 10409445 Human
her-2 ovarian papillary serous carcinoma This study not only confirms the presence of a subset of ovarian papillary serous carcinoma with HER-2/neu gene amplification, but it also indicates that HER-2/neu oncogene amplification is more likely to be associated with a more advanced stage. 10409445 Human
her-2 oral squamous cell carcinoma Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. 10632356 Human
her-2 villoglandular adenocarcinomas Twelve well-differentiated villoglandular adenocarcinomas (WDVAs) of the uterine cervix were retrospectively analyzed for the presence and specific genotype of human papillomavirus (HPV), tumor suppressor loss (p53, MCC, APC, BRCA1), cancer gene mutation 10782406 Human
her-2 noninvasive breast cancer Using in vitro models, recent studies have shown that HER-2 overexpression may not be a prerequisite for invasion of breast cancer cells, as HER-2 activation by heregulin, which binds to HER-3 or HER-4 and transphosphorylates HER in noninvasive breast can 11236033 Human
her-2 advanced stage cancer Interestingly, 90% of patients with advanced stage cancer (stage IIIB/IV NSCLC or extensive SCLC) overexpressed HER-2/neu. 11679181 Human
her-2 noninvasive cancers Of the 21 paired specimens immunostained for HER-2/neu, 11 were invasive cancers in both breasts, nine were invasive cancers in one breast and noninvasive cancers in the other breast, and one was noninvasive cancers in both breasts. 12058961 Human
her-2 primary malignant brain tumors Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. 12168843 Human
her-2 paraffin embedded tumor METHODS: Archival paraffin embedded tumor tissue was obtained from potentially eligible patients and was screened for HER-2 expression by immunohistochemistry (IHC) using a specialized test kit. 12173324 Human
her-2 paraffin embedded tumors Seven paraffin embedded tumors from six patients were available for DNA flow cytomeric analysis and immunohistochemical staining of p53, HER-2/neu and COX-2. 12297183 Human
her-2 primary malignancy METHODS: To determine whether a signet ring carcinoma was a primary malignancy of the gastrointestinal tract metastatic to the breast or vice versa, histochemical analysis was performed for Her-2/NEU, gross cystic disease fluid protein-15, estrogen recept 12464875 Human
her-2 methylcholanthrene-induced sarcomas In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu tr 12867593 Human
her-2 oral cavity cancer Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. 12915878 Human
her-2 early stage cervical cancer Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. 14529687 Human
her-2 early stage cervical cancer OBJECTIVE: The purpose of this study was to compare HER-2/neu expression on biopsies obtained from early stage cervical cancer, primary cell lines established therefrom, established cervical cancer cell lines, and metastatic or recurrent sites of disease; 14529687 Human
her-2 early stage cervical cancer CONCLUSIONS: Early stage cervical cancer may develop a population of HER-2/neu-positive cells with a selective growth advantage over HER-2/neu-negative cells. 14529687 Human
her-2 invasive cervical carcinoma The aim of this study was to investigate HER-2/neu (c-erbB2) overexpression/amplification in carcinoma of the uterine cervix using immunohistochemistry and fluorescent in situ hybridization (FISH) to assess whether anti-p185c-erbB2 therapy might have pote 14668544 Human
her-2 invasive cervical carcinoma Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients. 14668544 Human
her-2 primary osteosarcoma Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. 15026342 Human
her-2 early stage cervical cancer The upregulation of uPA by HER-2/neu seen in cancer cells in vitro appears to occur in vivo in early stage cervical cancer. 15247985 Human
her-2 germ-cell testicular tumors Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. 15330164 Human
her-2 urothelial transitional cell carcinoma OBJECTIVES: To elucidate the clinical significance of the HER-2 gene alterations in urine-exfoliated cells detected by fluorescence in situ hybridization (FISH) in patients with urothelial transitional cell carcinoma. 15351620 Human
her-2 non-small cell carcinomas (nsclc) Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. 15386424 Human
her-2 oral squamous cell carcinoma (oscc) OBJECTIVES: Amplification of the proto-oncogene c-erbB-2 (HER-2/neu) has been shown to be a prognostic marker in many kinds of cancer including oral squamous cell carcinoma (OSCC). 15482324 Human
her-2 primary malignancies Also, there was a higher incidence of associated primary malignancies (outside the CNS) in the HER-2/neu overexpression group (30% vs. 7%). 15565811 Human
her-2 metastatic pancreatic cancers Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. 15581051 Human
her-2 feline invasive mammary carcinomas (fmcs) The role of c-erbB-2 protooncogene status in feline invasive mammary carcinomas (FMCs) was assessed through the HER-2 receptor immunohistochemical expression. 15657269 Human
her-2 muscle invasive bladder cancer METHODS: Fluorescence in situ hybridisation analysis was performed to evaluate chromosomes 3, 7, 9, and 17 and the 9p21 (p16), 17p13.1 (p53), 13q14 (RB1), and 17q11.2 (HER-2) chromosomal loci in 48 muscle invasive bladder cancer specimens and the adjacent 15790699 Human
her-2 metachronous cancers Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts. 15871703 Human
her-2 first primary cancer The primary objective of this study was to evaluate the relative prevalence of estrogen receptor-negative contralateral breast cancer to the first primary cancer and to assess the correlation between the relative overexpression of HER-2/neu in the first p 15871703 Human
her-2 first primary cancer The correlation between HER-2/neu overexpression in the matched first primary and contralateral breast cancers was statistically significant, suggesting that the diagnosis of HER-2/neu overexpression in contralateral breast cancer is associated with HER-2 15871703 Human
her-2 intestinal-type cancers Intestinal-type cancers exhibited higher rates of HER-2/neu amplification than did diffuse-type cancers (P < 0.05). 16868827 Human
erbb-2 metastatic bladder cancer Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. 8529469 Human
erbb-2 common cancer Because breast cancer is the most common cancer and second leading cause of cancer-related deaths in women in the United States, we investigated whether flavopiridol could be an effective agent against a series of isogenic breast- cancer cell lines having 10656453 Human
erbb-2 non-dysplastic oral leukoplakia The purpose of this study was to analyse erbB-1 and erbB-2 oncogenes in non-dysplastic oral leukoplakia to see if we could pinpoint the first steps towards dysplasia and possible carcinogenesis. 10687911 Human
erbb-2 biliary tract carcinomas There is increasing evidence that overexpression of tyrosine kinase growth factor receptors such as ErbB-2, epidermal growth factor receptor (EGFR), and Met may play important roles in the development of biliary tract carcinomas. 15892172 Human
c-erb b2 cyst C-erb B2 gene product was positive in 9.7% of cyst with single-layered epithelia, in 100% of cyst with multi-layered epithelia and in 3 of 7 RCCs. 8105122 Human
erbb2 adenosquamous carcinomas Here, we performed mutational analysis of the ERBB2 kinase domain by polymerase chain reaction-single strand conformation polymorphism assay in 114 non-adenocarcinoma type non-small cell lung cancers (NSCLCs) tissue samples, including 100 squamous cell ca 16029927 Human
erbb2 testicular germ cell tumors Amplification and/or overexpression of genes encoding tyrosine kinase receptors KIT and ERBB2 have been reported in testicular germ cell tumors (TGCTs). 16354586 Human
erbb2 ureteral tumor The incidence of subsequent tumor recurrence in the urinary bladder correlated significantly with ureteral tumor involvement and ErbB2 expression (P = 0.04 and P = 0.04, respectively). 16360440 Human
erbb2 human colon adenocarcinoma In this study, we tested the efficacy of a novel reversible dual inhibitor GW572016 compared with the selective EGFR and ErbB2 tyrosine kinase inhibitors (TKI) AG1478 and AG879 and their combination, using the human colon adenocarcinoma GEO mode. 16397255 Human
erbb2 invasive ductal carcinomas ERBB2 amplification is present in 15-30% of invasive ductal carcinomas, and its overexpression was associated with poor prognosis. c-MYC amplification is present in 13-19%, but other forms of oncogene activation are rare. 16529032 Human
erbb2 invasive cancer With the exception of the 17q21 (ERBB2) amplicon, the overall frequency of copy number alterations was higher in invasive tumors than that in DCIS, with several of them present only in invasive cancer. 16618726 Human
erbb2 mpnst Increased copy numbers were seen for the ERBB2 and TOP2A genes in eight and nine cases, respectively, supporting a potential role for these two genes in MPNST tumourigenesis. 16721726 Human
erbb2 ethmoid sinus adenocarcinomas OBJECTIVE: Assess the amplification of CCND1, EMS1, PIK3CA, ERBB1, and ERBB2 oncogenes in ethmoid sinus adenocarcinomas. 16815198 Human
her2 carcinosarcoma EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 16157366 Human
her2 carcinosarcoma The aim of this study was to evaluate for HER2 and EGFR expression in cases of endometrial carcinosarcoma. 16157366 Human
her2 soft tissue tumor Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provid 16158422 Human
her2 soft tissue tumors CONCLUSIONS: These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. 16158422 Human
her2 anaplasia HER2 is not expressed in adult glial cells, but its expression increases with the degree of astrocytomas anaplasia. 16200345 Human
her2 multiple myeloma (mm) We show that multiple myeloma (MM), the second most commonly diagnosed hematologic malignancy, is responsive to hsp90 inhibitors in vitro and in a clinically relevant orthotopic in vivo model, even though this disease does not depend on HER2/neu, bcr/abl, 16234364 Human
her2 desmoid tumours Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens.METHODS: One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid 16254103 Human
her2 metaplastic breast carcinomas Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. 16280056 Human
her2 metaplastic breast carcinomas We investigated whether HER2 and EGFR overexpression was present and evaluated gene amplification in a series of metaplastic breast carcinomas. 16280056 Human
her2 malignant gliomas METHODS: We sequenced kinase domains in the EGFR and human EGFR type 2 (Her2/neu) genes and analyzed the expression of EGFR, EGFR deletion mutant variant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients wh 16282176 Human
her2 advanced cancer Does HER2 overexpression affect response to endocrine therapy in advanced cancer? 16462845 Human
her2 acinic cell adenocarcinoma Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. 16470840 Mouse
her2 salivary gland adenocarcinoma We developed and characterized a HER2/neu and Fas overexpressing cell line (BNT.888 ACA2) from a salivary gland adenocarcinoma that arose in a HER2/neu transgenic mouse. 16470840 Mouse
her2 breast cancer Overexpression of HER2 protein and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and chemotherapy. 16525662 Human
her2 meningiomas This work was designed to study HER2 protein expression and HER2 gene amplification in meningiomas and to evaluate their prognostic value. 16564915 Human
her2 anaplastic meningiomas Five atypical/anaplastic meningiomas and 5 classic meningiomas of the whole 35 (28.5%) meningiomas expressed HER2 protein. 16564915 Human
her2 meningeal carcinomatosis A 39-year-old female presenting with HER2-overexpressing MBC and suffering from meningeal carcinomatosis was treated with the humanized antibody trastuzumab directed to HER2 by intrathecal administration. 16596213 Human
neu carcinosarcoma EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 16157366 Human
neu soft tissue tumor Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, also termed HER2/neu) may contribute to the tumor phenotype and provid 16158422 Human
neu soft tissue tumors CONCLUSIONS: These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. 16158422 Human
neu multiple myeloma (mm) We show that multiple myeloma (MM), the second most commonly diagnosed hematologic malignancy, is responsive to hsp90 inhibitors in vitro and in a clinically relevant orthotopic in vivo model, even though this disease does not depend on HER2/neu, bcr/abl, 16234364 Human
neu malignant gliomas METHODS: We sequenced kinase domains in the EGFR and human EGFR type 2 (Her2/neu) genes and analyzed the expression of EGFR, EGFR deletion mutant variant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients wh 16282176 Human
neu cholangiocarcinoma Because the development of an in vitro model of malignant transformation can provide a powerful new tool for establishing critical events governing the molecular pathogenesis of cholangiocarcinoma, we investigated the potential of achieving malignant tran 16344070 Human
neu prostatic intraepithelial neoplasia (pin) To begin addressing such open questions in an animal model, we have developed a transgenic line in which an oncogenic Neu cDNA (Neu*) driven by the probasin gene promoter is overexpressed in the mouse prostate and causes development of prostatic intraepit 16401639 Mouse
neu granulosa cell tumours METHODS AND RESULTS: Two TMAs containing 173 invasive carcinomas, 36 borderline tumours, 20 granulosa cell tumours, 14 carcinosarcomas, 11 benign cystadenoms and eight other pelvic tumours were constructed to assess HER-2/neu gene amplification by fluores 16405663 Human
neu acinic cell adenocarcinoma Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. 16470840 Mouse
neu salivary gland adenocarcinoma We developed and characterized a HER2/neu and Fas overexpressing cell line (BNT.888 ACA2) from a salivary gland adenocarcinoma that arose in a HER2/neu transgenic mouse. 16470840 Mouse
neu esophageal tumors Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively. 16490596 Human
neu gastric tumors Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively. 16490596 Human
neu metaplasia Tissue microarrays contained primary cancer, normal stomach, intestinal metaplasia, and gastric epithelial dysplasia and were probed with antibodies against nine potential markers that were either identified in a database of genes overexpressed in gastric 16492916 Human
neu schwannomas A point mutation of the neu/erbB-2 gene diagnostic of N-ethyl-N-nitrosourea-induced rat schwannomas is an early marker of Schwann precursor cells at high risk of subsequent malignant transformation. 16651423 Rat
neu acute myelogenous leukemia Monoclonal antibodies targeting non-Hodgkin's lymphoma (NHL), Her-2/neu highly expressing metastatic breast cancer, colorectal cancer, acute myelogenous leukemia, and B-cell chronic lymphocytic leukemia (CLL) have received FDA approval. 16730262 Human
neu parotid carcinomas Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. 16751417 Mouse
neu parotid tumors Double transgenic mice overexpressing the transforming rat HER-2/neu oncogene and the mutated p53, with both dominant-negative and a gain-of-function properties, display early aggressive and metastasizing parotid tumors. 16751417 Mouse
neu parotid carcinomas In conclusion, anti-HER-2/neu vaccination combined with systemic IL-12 control parotid carcinomas as far as p53 mutation makes their growth independent of HER-2/neu expression. 16751417 Mouse
neu metastatic endometrial cancers Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu. 16803532 Human
her-2 neuroendocrine carcinomas A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. 16158183 Human
her-2 large-cell neuroendocrine carcinomas (lcnec) Less is known on beta-catenin transactivation in high-grade pulmonary neuroendocrine tumors and on the status of beta-catenin activating EGFR and human epidermal growth factor receptor 2 (HER-2) or beta-catenin target genes cyclin D1 and matrix metallopro 16158183 Human
her-2 pulmonary neuroendocrine tumors Less is known on beta-catenin transactivation in high-grade pulmonary neuroendocrine tumors and on the status of beta-catenin activating EGFR and human epidermal growth factor receptor 2 (HER-2) or beta-catenin target genes cyclin D1 and matrix metallopro 16158183 Human
her-2 neuroendocrine tumors Nineteen cases were assessed for beta-catenin gene exon 3 mutations, expression of MMP-7, and expression/gene amplification of EGFR, HER-2, and cyclin D1. beta-catenin was expressed in all 96 high-grade neuroendocrine tumors, the vast majority (94%) showi 16158183 Human
her-2 adenoid cystic carcinoma of the breast Our study shows that adenoid cystic carcinoma of the breast is a special, estrogen receptor, progesterone receptor, HER-2 negative and highly KIT-positive, basal-like breast carcinoma, associated with an excellent prognosis. 16258515 Human
her-2 undifferentiated thyroid carcinoma Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: Implication for a new therapeutic approach. 16287490 Human
her-2 undifferentiated thyroid carcinoma (utc) To clarify the significance of KIT, EGFR, and HER-2 in undifferentiated thyroid carcinoma (UTC), the expression of these receptors and tyrosine phosphorylation was examined immunohistochemically in resected cases of UTC and papillary thyroid carcinoma (PT 16287490 Human
her-2 granulosa cell tumours METHODS AND RESULTS: Two TMAs containing 173 invasive carcinomas, 36 borderline tumours, 20 granulosa cell tumours, 14 carcinosarcomas, 11 benign cystadenoms and eight other pelvic tumours were constructed to assess HER-2/neu gene amplification by fluores 16405663 Human
her-2 squamous intraepithelial lesions There was no statistical difference in the frequencies of HER-2 Ile/Ile, Ile/Val, and Val/Val genotypes between squamous intraepithelial lesions (SILs) and controls. 16445653 Human
her-2 esophageal tumors Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively. 16490596 Human
her-2 gastric tumors Overexpression of cyclin D1 protein was identified in 37.5% of the specimens of esophageal tumors and 35% of gastric tumors, and overexpression of Her-2/neu protein in 12.5 and 7.5%, respectively. 16490596 Human
her-2 metaplasia Tissue microarrays contained primary cancer, normal stomach, intestinal metaplasia, and gastric epithelial dysplasia and were probed with antibodies against nine potential markers that were either identified in a database of genes overexpressed in gastric 16492916 Human
her-2 papillary carcinoma METHODS: The aim of our study was to assess, by Methylation-Specific Polymerase Chain Reaction (MSP), the methylation pattern of the CDH1 gene and its possible correlation with the expression of E-cadherin and other standard immunohistochemical parameters 16512896 Human
her-2 serous carcinoma The highest rate of HER-2 expression and amplification was seen in serous carcinoma (43% and 29%), while grade 1 endometrioid adenocarcinoma showed the lowest levels (3% and 1%). 16710036 Human
her-2 intestinal type carcinomas Positive membranous HER-2 immunoreactivity, on the other hand, accounted for 24% within the Turkish gastric carcinoma group and none from chronic gastritis cases; further, it was correlated with intestinal type carcinomas (P=0.007), and stage III-IV carci 16718853 Human
her-2 acute myelogenous leukemia Monoclonal antibodies targeting non-Hodgkin's lymphoma (NHL), Her-2/neu highly expressing metastatic breast cancer, colorectal cancer, acute myelogenous leukemia, and B-cell chronic lymphocytic leukemia (CLL) have received FDA approval. 16730262 Human
her-2 parotid carcinomas Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. 16751417 Mouse
her-2 parotid tumors Double transgenic mice overexpressing the transforming rat HER-2/neu oncogene and the mutated p53, with both dominant-negative and a gain-of-function properties, display early aggressive and metastasizing parotid tumors. 16751417 Mouse
her-2 parotid carcinomas In conclusion, anti-HER-2/neu vaccination combined with systemic IL-12 control parotid carcinomas as far as p53 mutation makes their growth independent of HER-2/neu expression. 16751417 Mouse
her-2 tubular carcinoma of the breast HER-2 Amplification in Tubular Carcinoma of the Breast. 16753605 Human
her-2 tubular carcinomas To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases. 16753605 Human
her-2 tubular carcinomas HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors. 16753605 Human
her-2 metastatic endometrial cancers Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu. 16803532 Human
her-2 metastatic prostate cancer CONCLUSIONS: We consider that HER-2 overexpression, as measured by immunohistochemistry, may be useful as a marker of an unfavorable prognosis by predicting the interval until relapse and outcome after endocrine therapy in patients with bone metastatic pr 16806433 Human
erbb-2 endometrial polyps Conclusions: Estrogen may have a role in the development of postmenopausal endometrial polyps, either by direct stimulation of localized proliferation or by stimulation of proliferation via other pathways, such as activation of Ki67 or through inhibition 16141722 Human
erbb-2 cholangiocarcinoma Because the development of an in vitro model of malignant transformation can provide a powerful new tool for establishing critical events governing the molecular pathogenesis of cholangiocarcinoma, we investigated the potential of achieving malignant tran 16344070 Human
erbb-2 schwannomas A point mutation of the neu/erbB-2 gene diagnostic of N-ethyl-N-nitrosourea-induced rat schwannomas is an early marker of Schwann precursor cells at high risk of subsequent malignant transformation. 16651423 Rat
erbb2 lung squamous cell carcinoma ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 16029927 Human
erbb2 lung squamous cell carcinomas This study demonstrated that in addition to lung adenocarcinoma ERBB2 kinase domain mutation could occur in lung squamous cell carcinomas, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations may occasionally contribute to 16029927 Human
her2 metastatic peritoneal carcinomatosis These results show that, although the pattern of protection is tumor model dependent, treatments with AbFPs can effectively generate high levels of protection against peritoneal tumors expressing HER2/neu, which may be relevant in patients with primary or 16648575 Human
her2 glassy cell carcinoma Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein. 16901007 Human
her2 glassy cell carcinoma (gcc) OBJECTIVE: To analyze the cytologic features, estrogen and progesterone receptors, and Her2/neu protein in glassy cell carcinoma (GCC) of the cervix. 16901007 Human
neu uterine serous carcinoma Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. 16182348 Human
neu metastatic peritoneal carcinomatosis These results show that, although the pattern of protection is tumor model dependent, treatments with AbFPs can effectively generate high levels of protection against peritoneal tumors expressing HER2/neu, which may be relevant in patients with primary or 16648575 Human
neu glassy cell carcinoma Glassy cell carcinoma of the cervix: cytologic features and expression of estrogen receptor, progesterone receptor and Her2/neu protein. 16901007 Human
neu glassy cell carcinoma (gcc) OBJECTIVE: To analyze the cytologic features, estrogen and progesterone receptors, and Her2/neu protein in glassy cell carcinoma (GCC) of the cervix. 16901007 Human
her-2 primary osteosarcoma We previously demonstrated that primary osteosarcoma cells express cell-surface EGFR and Her-2, with the p80 isoform of Her-4 localized to the nucleus. 16007579 Human
her-2 uterine serous carcinoma Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. 16182348 Human
her-2 biliary cancer In 72 biliary cancer (28 gallbladder and 44 bile duct cancer), HER-1 and HER-2 were stained immunohistochemically in formalin-fixed, paraffin-embedded specimens. 16739351 Human
her-2 cell carcinoma of the skin [Immunohistochemical analysis of EGFR and HER-2 in patients with metastasizing melanoma, Merkel carcinoma and squamous cell carcinoma of the skin] 16800183 Human
her-2 merkel carcinoma [Immunohistochemical analysis of EGFR and HER-2 in patients with metastasizing melanoma, Merkel carcinoma and squamous cell carcinoma of the skin] 16800183 Human
erbb2 malignant glial tumors These data reiterate the problem of the molecular heterogeneity of human gliomas and indicate that gp185c-erbB2 may have a role in at least a subset of malignant glial tumors. 7542696 Human
erbb2 precancerous lesion Multiple genetic abnormalities including hypomethylation of H-ras gene, amplification and overexpression of met and erbB2, deletion of APC, mts1/p16, p53 and nm23 gene and point mutation of p53 gene were noted in HGC and precancerous lesion of human gastr 8697090 Human
her2 murine sarcomas A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. 9699670 Mouse
her2 fibrosarcoma CHM-HER2 and CHP-HER2 were able to induce CD3+/CD8+ CTLs against HER2-transfected syngeneic fibrosarcoma cell lines. 9699670 Human
neu neuroblastoma Anchorage-independent growth of cells from the ethylnitrosourea-induced rat neuroblastoma line in which neu was originally detected by DNA transfection is also inhibited in the presence of anti-p185 monoclonal antibodies. 2860972 Rat
neu stage ii breast cancer Of 189 tumors from patients with Stage II breast cancer, 27 (14 percent) had neu-membrane staining. 2903446 Human
neu ductal carcinomas in situ Of 45 ductal carcinomas in situ, 19 (42 percent) had neu-membrane staining. 2903446 Human
neu fibrosarcoma We have examined the genomic organisation of c-myc, N-myc, L-myc, neu and N-ras in tissue from 41 breast carcinomas, lymph node metastases from 10 of these carcinomas, one fibrosarcoma, 10 cases of benign fibrocystic breast and six fibroadenomas. 3330785 Human
neu tumour antigen The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. 6095109 Rat
neu tumour antigen A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185). 6095109 Rat
neu tumour antigen The neu oncogene bears homology to erb-B and the tumour antigen, p185, is serologically related to the epidermal growth factor (EGF) receptor. 6095109 Human
neu hepatic tumors Furthermore, cells from three of the five neu-transduced cell lines, when injected into the liver of Fischer F344 rats through the portal vein, were highly tumorigenic (multiple focal hepatic tumors developed within 2 weeks). 7859363 Rat
neu lung squamous cell carcinomas We have also found that expression of c-erbB-2/neu-encoded p185neu was correlated with lymph node metastasis in lung squamous cell carcinomas. 7911396 Human
neu hepatocarcinogenesis To investigate the potential role of neu oncogene expression in hepatocarcinogenesis, a nested case-control study was conducted within a cohort of 9691 male adults in Taiwan. 7923126 Human
neu hepatocarcinogenesis The results suggest that both HBsAg carrier status and cigarette smoking are related to the increased expression of neu oncogene, and cigarette smoking seems to play a significant role in the latter stages of hepatocarcinogenesis. 7923126 Human
neu apl This is supported by the following findings: (i) PML suppressed anchorage-independent growth of APL-derived NB4 cells on soft agar and tumorigenicity in nude mice, (ii) PML suppressed the oncogenic transformation of rat embryo fibroblasts by cooperative o 7935403 Human
neu malignant astrocytomas Individual astrocytoma cells expressing a cytoplasmic form of p185c-neu migrated along basement membrane lined surfaces after xenografing fresh low or high grade human malignant astrocytomas into host rat brain. 7964977 Rat
neu malignant astrocytoma These data indicate that fresh human malignant astrocytoma cells that contain GFAP and express cytoplasmic p185c-neu have a high degree of migratory capacity and could be the cell in the tumor involved in intraparenchymal metastasis and poor patient survi 7964977 Human
neu malignant astrocytoma Simultaneous expression of human p185c-neu, HLA-DR, and glial fibrillary acidic protein was observed in a class of human malignant astrocytoma cells in both tumor tissue and xenografted cells that migrated into rat brain. 8093625 Human
neu malignant astrocytoma Brains were investigated periodically over 30 postoperative days and the migration of the human glioblastoma cells was traced with anti-PHAL immunofluorescence or the overexpression of human specific p185c-neu a specific marker of a class of human maligna 8116480 Human
neu bone tumors 5) When neu-transfected cell subclones from N35-induced primary and metastatic lymph node, kidney, and bone tumors were analyzed for cytoskeletal, extracellular matrix, and cell adhesion protein expression, the bone metastatic subclone exhibited increased 8604395 Mouse
neu apl We also found that PML suppresses the clonogenicity and tumorigenicity of APL-derived NB4 cells, as well as the transformation of rat embryo fibroblasts by cooperative oncogenes and NIH/3T3 by neu. 9031108 Human
neu pancreatic tumors Repeated stimulation of HLA-A2+ PBL from pancreatic cancer patients using the HER2/neu-derived peptide resulted in specific recognition of this peptide and, more importantly, HER2/neu+ pancreatic tumors in an HLA-A2-restricted fashion. 9174600 Human
neu ovarian adenocarcinoma In this communication, the authors summarize their characterization of eight ovarian adenocarcinoma-derived cell lines for level of neu gene amplification, expression of neu transcripts and protein, and intraperitoneal tumorigenicity in nude mice. 1346236 Human
neu mammary paget's disease Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. 1701961 Human
neu extramammary paget's disease Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. 1701961 Human
neu papilloma Malignant progression of papilloma-derived keratinocytes: differential effects of the ras, neu, and p53 oncogenes. 2471536 Mouse
erbb-2 pulmonary adenocarcinoma We evaluated the prognostic significance of p185c-erbB-2 expression and ras gene mutations in all patients diagnosed with a pulmonary adenocarcinoma between 1982 and 1985 at the University of Iowa. p185c-erbB-2 expression was detected in 15 cases (34%). 7906694 Human
erbb-2 bowen's disease These findings are helpful for differentiating Paget's disease from other lesions of the nipple, namely Bowen's disease and eczema which do not react with both antibodies, and from nipple adenoma which exhibits a positive staining with anti-EMA 8391688 Human
erbb-2 nipple adenoma These findings are helpful for differentiating Paget's disease from other lesions of the nipple, namely Bowen's disease and eczema which do not react with both antibodies, and from nipple adenoma which exhibits a positive staining with anti-EMA 8391688 Human
erbb2 squamous lung carcinomas In squamous carcinomas, pS2 positivity was associated with lower EGFR (p:0.02270) levels and higher erbB2 protein (p:0,00563) concentrations.Conclusions: Our results led us to suggest the following: 1) cytosolic pS2 concentrations are higher in tumoral th 11879619 Human
her2 organ metastases METHODS AND MATERIALS: Patients with adenocarcinoma of the esophagus without distant organ metastases and 2+/3+ HER2 overexpression by immunohistochemistry (IHC) were eligible. 17097832 Human
her2 tumourbearing Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. 17211467 Mouse
neu tumorinfiltrating lymphocytes Tumor-infiltrating lymphocytes and CD8(+) CTL killed T2 cells when loaded with specific HLA-A2(+) restricted TAA, or gliomas that were both HLA-A2(+) and also positive for specific TAA (Mart-1, GP100, Her2/neu, and tyrosinase) but not those cells negative 17255279 Human
her-2 high-risk breast cancers CONCLUSIONS: Protein expression profiling in high-risk breast cancers identified five subtypes, which differed with respect to survival and response to chemotherapy: In contrast to luminal-A and luminal-B subtypes, HER-2 and basal-like subgroups had a sig 17255270 Human
her-2 hydatidiform mole METHODS: Sections prepared from 33 consecutive formalin-fixed paraffin-embedded archival reconfirmed hydatidiform mole tissue blocks were immunohistochemically stained for Her-2/neu. 17126893 Human
her2 tumorinfiltrating lymphocytes Tumor-infiltrating lymphocytes and CD8(+) CTL killed T2 cells when loaded with specific HLA-A2(+) restricted TAA, or gliomas that were both HLA-A2(+) and also positive for specific TAA (Mart-1, GP100, Her2/neu, and tyrosinase) but not those cells negative 17255279 Human
erbb2 cin Focal staining of ERBB2 was found in one CIN lesion, two invasive carcinomas, and four metastases. 10534770 Human
erbb2 choriocarcinoma ERB-B2 was moderately positive in the secondary non-germ cell malignancy, in one mature teratoma component of a mixed nonseminoma, and together with EGFR in the syncytiotrophoblastic cells of a pure choriocarcinoma. 12124830 Human
erbb2 mature teratoma ERB-B2 was moderately positive in the secondary non-germ cell malignancy, in one mature teratoma component of a mixed nonseminoma, and together with EGFR in the syncytiotrophoblastic cells of a pure choriocarcinoma. 12124830 Human
erbb2 synovial sarcomas Statistical analysis showed a distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue sarcomas, which included variably high expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas. 12414507 Human
erbb2 soft tissue sarcomas Statistical analysis showed a distinct expression profile for the group of synovial sarcomas as compared to the other soft tissue sarcomas, which included variably high expression of ERBB2, IGFBP2, and IGF2 in the synovial sarcomas. 12414507 Human
erbb2 synovial sarcoma Our high-throughput studies of gene expression patterns, complemented by tissue microarray studies, confirm the distinctive expression profile of synovial sarcoma, provide leads for the study of glandular morphogenesis in this tumor, and identify a new po 12414507 Human
erbb2 cancerous lesions Thus, signal transduction via EGFR and erbB2 could be related to the estrogen-induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF-like growth factors, leading to ERalpha activation that may result in cancerous lesi 14647453 Mouse
erbb2 invasive cervical carcinoma The aim of this study was to investigate HER-2/neu (c-erbB2) overexpression/amplification in carcinoma of the uterine cervix using immunohistochemistry and fluorescent in situ hybridization (FISH) to assess whether anti-p185c-erbB2 therapy might have pote 14668544 Human
erbb2 invasive cervical carcinoma Overexpression/amplification of HER-2/neu is uncommon in invasive cervical carcinoma, suggesting that there is little indication for using anti-p185c-erbB2 therapy in the treatment of these patients. 14668544 Human
erbb2 small cell carcinomas To test this hypothesis, we examined four cell lines derived from human non-small cell carcinomas for: (1) ErbB2 and ErbB3 expression and endogenous activation; (2) NRG-1 expression and secretion/shedding; and (3) the effect of receptor blockade on autocr 14739033 Human
erbb2 oncogene For example, amplification and overexpression of the ERBB2 oncogene is associated with poor prognosis in breast cancer and ERBB2 serves as a target for antibody-based therapy. 15300811 Human
erbb2 bcc In both SCC and KA the subcellular distribution of ERBIN and Erb-B2 remained unchanged, whereas both proteins were redistributed from the plasma membrane into cytosolic aggregates in BCC. 15948989 Human
erbb2 bcc Based on our findings and on the biological activities of Erb-B2, it is conceivable that disturbed expression or functioning of ERBIN and Erb-B2 is implicated in the development of the malignant phenotype of BCC. 15948989 Human
erbb2 intestinal cancers E-cadherin expression, however, was significantly higher among intestinal cancers from the two countries: 56.3 per cent of cells from intestinal or mixed cancers from Japan (n = 32) expressed E-cadherin compared with 22.2 per cent of American specimens (n 16676859 Human
erbb2 tumorigenesis ErbB2 makes beta 4 integrin an accomplice in tumorigenesis. 16901776 Mouse
erbb2 tumorigenesis Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. 16901783 Mouse
erbb2 tumorigenesis To examine the role of the signaling and cell-adhesion receptor beta 4 integrin during ErbB2-mediated tumorigenesis, we introduced a targeted deletion of the beta 4 signaling domain into a mouse model of ErbB2-induced mammary carcinoma. 16901783 Human
erbb2 human malignant mesothelioma In this study, we have examined the effect of a species of p185 that contains the transmembrane domain and the extracellular domain of p185(c-neu), on growth properties of a human malignant mesothelioma cell line that coexpresses EGFR and erbB2. 16989576 Human
erbb2 invasive carcinoma In the latter, abnormalities in the expression and/or copy number of the ERBB2 gene are present in 10% to 30% of invasive carcinoma and behave as poor prognostic markers. 17001161 Human
erbb2 skin cancer These results reveal the influence of Erbb2 on the UV response and suggest a role for Erbb2 in UV-induced pathologies such as skin cancer. 17003495 Human
erbb2 ovarian tumor Hyaluronan-CD44 Interaction with Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promotes Actin Polymerization and ErbB2 Activation Leading to beta-Catenin Nuclear Translocation, Transcriptional Up-regulation, and Cell Migration in Ovarian Tumor Cells. 17092940 Human
erbb2 ovarian tumor In this study we have investigated the interaction of hyaluronan (HA) and CD44 with the neuronal Wiskott-Aldrich syndrome protein (N-WASP) in regulating actin polymerization and ErbB2/beta-catenin signaling in human ovarian tumor cells (SK-OV-3.ipl cells) 17092940 Human
erbb2 biliary cancers In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers. 17150109 Human
erbb2 biliary cancers RESULTS: We found 11% of hepatoma, but no biliary cancers, harbored a novel ERBB2 H878Y mutation in the activating domain. 17150109 Human
erbb2 colon carcinoma Using the suppression subtractive hybridization (SSH) method, we identified ERBB2/HER2-interacting protein (Erbin), Tumor rejection gp96 (Tr-gp96), 12S ribosomal RNA (12S rRNA), ATP synthase, Kruppel-like transcription factor 5 (KLF5), transcription facto 17164780 Human
her2 gastric tumours Finally, in RT-PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours. 11360194 Human
her2 carcinogenesis The results suggest overexpression of bFGF, PDGF, and HER2/Neu and the presence of K-ras mutation are important for carcinogenesis of bile duct cancers, and detection of the above abnormalities in bile is helpful for early diagnosis. 11478488 Human
her2 adh Two hypotheses may explain the progression to two tumor types: (1) atypical ductal hyperplasia (ADH) is a precursor of ductal carcinoma in situ (DCIS), which is a precursor of invasive ductal carcinoma (IDC); or (2) ADH is a precursor of HER2-negative IDC 11694790 Human
her2 npc Interphase FISH and immunohistochemical (IHC) staining were used to analyze the gene copy number and protein expression of HER2 in 45 cases of NPC from Guangzhou, Southern China, an area with the highest incidence of NPC in the world. 11850071 Human
her2 npc Our results, however, found no significant alterations in gene copy number for HER2, although IHC staining detected expression of HER2 oncoprotein in 33% of the 45 NPC tumors. 11850071 Human
her2 npc These results cast doubt on the value of HER2 as a prognostic factor for NPC. 11850071 Human
her2 male breast carcinoma In the Veterans Administration hospital setting, the clinical stage and the expressions of p53 and Her2-neu in male breast carcinoma may be prognostically useful markers in guiding future treatment in prospective studies, whereas ER, PR, and MiB1 expressi 12181271 Human
her2 carcinogenesis METHODOLOGY: We studied 410 patients (166 African Americans and 244 Caucasians) with a histologic diagnosis of pancreatic ductal adenocarcinoma of the usual type and analyzed (a) the clinicopathologic characteristics of the tumors, (b) the immunohistochem 12499914 Human
her2 lymphoma To test this strategy, we transduced human lymphoma Jurkat cells with a chimeric immunocasp-3 gene expression vector and showed that they not only expressed and secreted the fusion protein but also selectively killed tumor cells overexpressing HER2 in vit 12810656 Mouse
her2 leukemia Trastuzumab, against HER2/neu, is useful in breast cancer; rituximab, against CD20 in B lymphocytes is useful in lymphoma; alemtuzumah, against CD52 is used in lymphoma and leukemia; daclizumab and basiliximab block the IL-2 receptor interaction and reduc 15022409 Human
her2 osteosarcoma In conclusion, as our study showed amplification of HER2/neu oncogene in low-grade osteosarcoma, we assume that expression of HER2/neu is not a poor prognostic factor in low-grade osteosarcoma. 15201972 Human
her2 oncogenes Promising approaches and molecular markers include gene expression profiles, DNA ploidy, loss of heterozygosity and chromosomal aberrations as detected by CGH and FISH (1q, 17p, 17q), as well as oncogenes/ tumor suppressor genes and their proteins (TP53, 15624758 Human
her2 tcc OBJECTIVES: To investigate HER2 (c-erbB-2) protein overexpression and HER2 gene amplification in upper urinary tract transitional cell carcinoma (TCC) with respect to its association with tumor grade and stage, as well as the prognostic significance. 15667899 Human
her2 primary tumors Genomic analysis of primary tumors revealed HER2 gene amplification and overexpression in breast and ovarian adenocarcinomas and demonstrated strong correlation with poor prognosis. 15687589 Human
her2 solid tumors [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
her2 metaplastic carcinomas METHODS: 10 epithelial-only, 14 biphasic and 10 monophasic metaplastic carcinomas were assessed for nuclear grade, hormone receptor status, HER2/neu (cerbB2) oncogene expression, Ki-67 and p53, lymph node status and recurrence on follow-up. 16467167 Human
her2 meningeal carcinomatosis Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. 16596213 Human
her2 stage iii breast cancer The patient was diagnosed with HER2-overexpressing stage III breast cancer in December 2003. 16596213 Human
her2 serous ovarian cancer In our selected set of tumors, the Val allele was overrepresented in the subset of HER2-positive breast cancers and the Ile allele in serous ovarian cancer. 16682283 Human
her2 phyllodes tumors None of the phyllodes tumors was positive for HER2/neu or CD117/c-kit. 16889904 Human
her2 vulvar squamous carcinoma PURPOSE: The aims of this study were twofold: (1) to examine the effects of dual inhibition of 2 members of the HER family, the epidermoid growth factor receptor (EGFR) and HER2/neu, by gefitinib (ZD1839) and trastuzumab on radiosensitivity; and (2) to ex 16965995 Human
her2 low-grade tumors Broadly speaking, breast cancer can be divided into those that are HER2-positive, containing cancers that are both ER-positive and negative, cancers that are ER-positive and divided into high-grade and low-grade tumors, and the remaining but important cla 17001676 Human
her2 bronchoalveolar carcinomas METHODS: Using Path Vysion kit and LSI EGFR SpectrumOrange/CEP7 Spectrum Green probes, EGFR gene and HER2 gene status were evaluated by fluorescence insitu hybridization (FISH) using formalin-fixed, paraffin-embedded samples from 31 patients with non-smal 17069674 Human
her2 adenosquamous carcinomas METHODS: Using Path Vysion kit and LSI EGFR SpectrumOrange/CEP7 Spectrum Green probes, EGFR gene and HER2 gene status were evaluated by fluorescence insitu hybridization (FISH) using formalin-fixed, paraffin-embedded samples from 31 patients with non-smal 17069674 Human
her2 acinic cell carcinoma of the salivary gland In addition, the immunohistochemical profile of this tumor was identical to that of the acinic cell carcinoma of the salivary gland: estrogen receptor, progesterone receptor, HER2 and cytokeratin (CK)20 were negative and amylase and CK7 were positive. 17199742 Human
neu oncogene Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. 10502729 Human
neu precancerous lesion The precancerous lesion in the pancreas may be atypical papillary hyperplasia, which is similar to intraductal carcinoma with respect to the proliferative activity of cells and HER-2/neu, bcl-2 and p53 expression. 10909469 Human
neu oncoprotein The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. 11416960 Human
neu oncogene In breast cancer amplification of the HER-2/neu oncogene and over-expression of the protein product is associated with poor prognosis, predicts response to some chemotherapeutic regimens and is the target for Herceptin treatment. 11455000 Human
neu carcinogenesis The results suggest overexpression of bFGF, PDGF, and HER2/Neu and the presence of K-ras mutation are important for carcinogenesis of bile duct cancers, and detection of the above abnormalities in bile is helpful for early diagnosis. 11478488 Human
neu leukemia Clinically effective cancer immunotherapy has been sought for more than 100 years and has been recently applied most successfully in strategies that passively deliver immune effectors such as monoclonal antibodies (anti-CD20 for lymphoma and anti-HER2/neu 11727526 Human
neu oncogene BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. 11893034 Human
neu oncogene Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. 12653946 Human
neu hnscc In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. 12673202 Human
neu oncogene The amplification and/or overexpression of the HER-2/neu oncogene and its encoded receptor protein are increasingly used for prognostication and prediction of therapeutic response to Herceptin in breast cancer. 12733117 Human
neu pulmonary metastasis Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. 12808151 Human
neu lung metastases Conversely, expression of the dominant negative type II receptor decreased the latency of Neu-induced mammary tumor formation while significantly reducing the incidence of extravascular lung metastases. 12808151 Human
neu lung metastases These observations argue that TGF-beta can promote the formation of lung metastases while impairing Neu-induced tumor growth and suggest that extravasation of breast cancer cells from pulmonary vessels is a point of action of TGF-beta in the metastatic pr 12808151 Human
neu fibrosarcomas In contrast, we report here that transformation of VEGF-deficient adult fibroblasts (MDF528) with ras or neu oncogenes gives rise to highly tumorigenic and angiogenic fibrosarcomas. 12912908 Human
neu panin Moreover, these PanIN-like lesions also contain mutations in K-ras and overexpress HER-2/neu, which are genetic mutations found early in the progression of human pancreatic cancer. 14520413 Mouse
neu leukemia Trastuzumab, against HER2/neu, is useful in breast cancer; rituximab, against CD20 in B lymphocytes is useful in lymphoma; alemtuzumah, against CD52 is used in lymphoma and leukemia; daclizumab and basiliximab block the IL-2 receptor interaction and reduc 15022409 Human
neu escc By using immunohistochemistry, we measured expressions of DDH, GST, COX-2, nm23-H1, HER-2/neu and mdr-1 in 145 patients with ESCC. 15197778 Human
neu escc For patients with ESCC, DDH overexpression was positively correlated with smoking habit, tumor stage, number of metastatic lymph nodes, lymphovascular invasion and COX-2 expression, and inversely correlated with GST and nm23-H1 expressions, but not relate 15197778 Human
neu osteosarcoma In conclusion, as our study showed amplification of HER2/neu oncogene in low-grade osteosarcoma, we assume that expression of HER2/neu is not a poor prognostic factor in low-grade osteosarcoma. 15201972 Human
neu mouse tumor Depletion of CD4+ T cells or fusion to the IL-2 gene can thus further enhance the therapeutic effects of N'-neu DNA immunization on mouse tumor expressing endogenous p185neu. 15294176 Mouse
neu colon adenocarcinoma Intravenously administered Her2Bi-armed ATCs localized to PC-3 xenografts mediated cytotoxicity toward tumor cells and produced significant tumor growth delay of PC-3 tumors, but not Her2/neu-negative LS174T colon adenocarcinoma xenografts. 15479495 Mouse
neu solid tumors [Molecular diagnosis of solid tumors] This review highlights three examples of novel targeted therapeutics for solid tumors that are currently approved in Japan: 1) Trastuzumab (Herceptin) for patients with metastatic breast cancer that demonstrates overe 15773342 Human
neu oncogene Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of 15901136 Human
neu peritoneal carcinomatosis In a prospective study, 8 patients with malignant ascites due to peritoneal carcinomatosis were treated with intraperitoneal application of trAb, which bound either the EpCAM- or Her2/neu-antigen on tumor cells. 15906359 Human
neu prostatic intraepithelial neoplasia Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. 16401639 Mouse
neu metaplastic carcinomas METHODS: 10 epithelial-only, 14 biphasic and 10 monophasic metaplastic carcinomas were assessed for nuclear grade, hormone receptor status, HER2/neu (cerbB2) oncogene expression, Ki-67 and p53, lymph node status and recurrence on follow-up. 16467167 Human
neu malignant transformation A point mutation of the neu/erbB-2 gene diagnostic of N-ethyl-N-nitrosourea-induced rat schwannomas is an early marker of Schwann precursor cells at high risk of subsequent malignant transformation. 16651423 Rat
neu cystic endometrial hyperplasia Steroid receptor expression and HER-2/neu (c-erbB-2) oncoprotein in the uterus of cats with cystic endometrial hyperplasia-pyometra complex. 16737511 Human
neu cystic endometrial hyperplasia The presence of oestrogen-alpha receptor (ER), progesterone receptor (PR), and HER-2/neu (c-erbB-2) oncoprotein in the uterine walls of 10 healthy cats and 20 subjects with cystic endometrial hyperplasia-pyometra (CEH-P) were evaluated. 16737511 Human
neu phyllodes tumors None of the phyllodes tumors was positive for HER2/neu or CD117/c-kit. 16889904 Human
neu vulvar squamous carcinoma PURPOSE: The aims of this study were twofold: (1) to examine the effects of dual inhibition of 2 members of the HER family, the epidermoid growth factor receptor (EGFR) and HER2/neu, by gefitinib (ZD1839) and trastuzumab on radiosensitivity; and (2) to ex 16965995 Human
neu uterine papillary serous cancers HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. 17009989 Human
neu oncoprotein Another molecular marker that is being increasingly examined in breast cancer is the oncoprotein Her-2/neu, whose expression/amplification predicts the response to anti-Her-2/neu immunotherapy. 17049840 Human
neu breast cancer Another molecular marker that is being increasingly examined in breast cancer is the oncoprotein Her-2/neu, whose expression/amplification predicts the response to anti-Her-2/neu immunotherapy. 17049840 Human
neu sebaceous hyperplasia A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
neu sebaceous carcinomas A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
neu sebaceous adenomas A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
neu sebaceous carcinomas In addition, we found little or no Her-2/neu and CD117 staining, indicating that immunotherapy with Herceptin or Gleevac would likely not be useful for sebaceous carcinomas. 17122489 Human
neu basal cell carcinoma Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. 17142577 Human
neu b-cell acute lymphoblastic leukemia (b-all) Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant t 17168718 Human
neu axillary metastasis Our results show that HER-2/neu signal ratio increases with lymphovascular invasion, an extensive intraductal component, irregular growth pattern and axillary metastasis in clinically T1-2N0M0 invasive ductal carcinoma of the breast. 17189983 Human
neu basal cell carcinoma Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. 17201959 Human
neu advanced cancer Lapatinib, a reversible inhibitor of both EGFR and HER-2/neu, has shown some success in achieving clinical responses in heavily pretreated advanced cancer patients. 17203189 Human
her-2 oncogene Amplification of the c-erbB-2 (HER-2/neu) oncogene and over-expression of the corresponding p185erbB-2 protein have been linked to prognosis and response to therapy in breast cancer. 10502729 Human
her-2 precancerous lesion The precancerous lesion in the pancreas may be atypical papillary hyperplasia, which is similar to intraductal carcinoma with respect to the proliferative activity of cells and HER-2/neu, bcl-2 and p53 expression. 10909469 Human
her-2 oncoprotein The HER-2/neu proto-oncogene amplification or oncoprotein overexpression is an important prognostic factor and a predictive factor for resistance to endocrine therapy and adjuvant chemotherapy in breast cancers. 11416960 Human
her-2 oncogene In breast cancer amplification of the HER-2/neu oncogene and over-expression of the protein product is associated with poor prognosis, predicts response to some chemotherapeutic regimens and is the target for Herceptin treatment. 11455000 Human
her-2 oncogene BACKGROUND: Abnormal expression of the HER-2/neu oncogene, a tyrosine kinase-type transmembrane growth factor receptor localized to chromosome 17q, has been associated with poor prognosis and the prediction of therapy response in invasive breast cancer. 11893034 Human
her-2 oncogene Amplification of HER-2/neu oncogene and over-expression of its gene product have both prognostic and therapeutic implications in breast cancer. 12653946 Human
her-2 oncogene The amplification and/or overexpression of the HER-2/neu oncogene and its encoded receptor protein are increasingly used for prognostication and prediction of therapeutic response to Herceptin in breast cancer. 12733117 Human
her-2 panin Moreover, these PanIN-like lesions also contain mutations in K-ras and overexpress HER-2/neu, which are genetic mutations found early in the progression of human pancreatic cancer. 14520413 Mouse
her-2 solid tumors The overexpression and/or mutation of the epidermal growth factor receptor family of tyrosine kinases, namely EGFR and HER-2, have been implicated in poor prognosis of human solid tumors and are under investigation as molecular targets for cancer therapy. 14561085 Human
her-2 escc By using immunohistochemistry, we measured expressions of DDH, GST, COX-2, nm23-H1, HER-2/neu and mdr-1 in 145 patients with ESCC. 15197778 Human
her-2 comedo carcinoma Elevated HER-2 ECD concentration was related only to pT (p=0.0008), histological grade (p=0.0465), presence of comedonecrosis (p=0.0123) or comedo-type carcinoma (p=0.041) and was unrelated to the presence of an intraductal component. 15865102 Human
her-2 oncogene Our observation of the her-2/neu oncogene amplification does not shed light on the prognostic impact of uterine carcinosarcoma following tamoxifen therapy, but it may indicate the need for further studies of HER-2/neu overexpression in a larger series of 15901136 Human
her-2 cns metastases Recently, patients with Her-2-positive breast tumors who were treated with trastuzumab have been reported to develop CNS metastases at higher rates, often while responding favorably to treatment. 16192626 Human
her-2 oral carcinoma At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-induced oral carcinoma. 16265350 others
her-2 human oral cancer These findings suggest that DNA vaccination may have a future in the prevention of HER-2-positive human oral cancer. 16265350 others
her-2 cystic endometrial hyperplasia Steroid receptor expression and HER-2/neu (c-erbB-2) oncoprotein in the uterus of cats with cystic endometrial hyperplasia-pyometra complex. 16737511 Human
her-2 cystic endometrial hyperplasia The presence of oestrogen-alpha receptor (ER), progesterone receptor (PR), and HER-2/neu (c-erbB-2) oncoprotein in the uterine walls of 10 healthy cats and 20 subjects with cystic endometrial hyperplasia-pyometra (CEH-P) were evaluated. 16737511 Human
her-2 biliary cancer The clinicopathological significance of HER-1- and HER-2-overexpressions (OE) (HercepTest score 2+ or 3+) in biliary cancer and their relationship to the efficacy of adjuvant chemotherapy (ACT) were assessed. 16739351 Human
her-2 biliary cancer In conclusion, neither HER-1-OE or HER-2-OE were prognostic factors of the biliary cancer. 16739351 Human
her-2 squamous cell carcinoma of the skin [Immunohistochemical analysis of EGFR and HER-2 in patients with metastasizing melanoma, Merkel carcinoma and squamous cell carcinoma of the skin] 16800183 Human
her-2 uterine papillary serous cancers HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. 17009989 Human
her-2 oncoprotein Another molecular marker that is being increasingly examined in breast cancer is the oncoprotein Her-2/neu, whose expression/amplification predicts the response to anti-Her-2/neu immunotherapy. 17049840 Human
her-2 breast cancer Another molecular marker that is being increasingly examined in breast cancer is the oncoprotein Her-2/neu, whose expression/amplification predicts the response to anti-Her-2/neu immunotherapy. 17049840 Human
her-2 sebaceous hyperplasia A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
her-2 sebaceous carcinomas A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
her-2 sebaceous adenomas A total of 27 cases, including 9 sebaceous adenomas, 4 sebaceomas, 8 sebaceous carcinomas, and 6 cases of sebaceous hyperplasia, were examined by immunohistochemistry, with antibodies directed against Ki-67 (MIB-1), bcl-2, p53, p21WAF1, p27Kip1, c-erbB-2 17122489 Human
her-2 sebaceous carcinomas In addition, we found little or no Her-2/neu and CD117 staining, indicating that immunotherapy with Herceptin or Gleevac would likely not be useful for sebaceous carcinomas. 17122489 Human
her-2 basal cell carcinoma Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. 17142577 Human
her-2 metastatic adenocarcinoma of the esophagus Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. 17143264 Human
her-2 esophageal cancers In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus. 17143264 Human
her-2 metastatic cancers In order to evaluate the potential role of such a treatment in esophageal cancers, HER-2 amplification and overexpression was investigated in primary and metastatic cancers of the esophagus. 17143264 Human
her-2 b-cell acute lymphoblastic leukemia (b-all) Clinical studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant t 17168718 Human
her-2 axillary metastasis Our results show that HER-2/neu signal ratio increases with lymphovascular invasion, an extensive intraductal component, irregular growth pattern and axillary metastasis in clinically T1-2N0M0 invasive ductal carcinoma of the breast. 17189983 Human
her-2 basal cell carcinoma Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. 17201959 Human
her-2 advanced cancer Lapatinib, a reversible inhibitor of both EGFR and HER-2/neu, has shown some success in achieving clinical responses in heavily pretreated advanced cancer patients. 17203189 Human
erbb-2 human breast cancers Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
erbb-2 cancer Amplification of the c-erbB-2 (HER-2/neu) proto-oncogene is detected in 10-30% of human breast cancers and has been shown to be accompanied by the overexpression of its protein in the cancer cell membrane. c-erbB-2 gene amplification is one of the first g 11180764 Human
erbb-2 precancerous lesions RESULTS AND CONCLUSIONS: The expression of EGF-r, erbB-2, and TGF-alpha were significantly higher in SCC and associated precancerous lesions than in the normal bronchial epithelium and hyperplastic lesions of noncancer specimens. 11895903 Human
erbb-2 adenocarcinoma of the uterine cervix METHODS: Thirty-seven cases of FIGO clinical stage I and II adenocarcinoma of the uterine cervix were examined by immunohistochemical studies with anti-VEGF, anti-CD34, anti-p53, and anti-c-erbB-2 antibodies. 12051876 Human
erbb-2 hnscc Furthermore, the type I tyrosine kinase receptor ErbB-2 is overexpressed in at least 30% of HNSCC and CxCa. 15229656 Human
erbb-2 oncogenes Promising approaches and molecular markers include gene expression profiles, DNA ploidy, loss of heterozygosity and chromosomal aberrations as detected by CGH and FISH (1q, 17p, 17q), as well as oncogenes/ tumor suppressor genes and their proteins (TP53, 15624758 Human
erbb-2 malignant transformation A point mutation of the neu/erbB-2 gene diagnostic of N-ethyl-N-nitrosourea-induced rat schwannomas is an early marker of Schwann precursor cells at high risk of subsequent malignant transformation. 16651423 Rat

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.